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have made it possible to profile proteins associated with disease in a comprehensive manner. Within this thesis
current LC-MS methodology was applied to the problem of pancreatic cancer.
A comprehensive list of proteins secreted by the tumor microenvironment was compiled in the first aim.
Culture of pancreatic cell lines was used to simulate the tumor microenvironment in vitro and produce a
proteome rich in biomarkers. The proteins identified demonstrate the complex signals tumor cells use to
communicate with their environment and encompass therapeutic targets and biomarkers.
To assay these proteins in serum, a relative quantitative LC-MS method was developed in the second aim.
Traditional bioanalytical techniques were incorporated to enhance the utility of the method. Multiple reaction
monitoring (MRM)/MS provided sensitivity and specificity to the method and stable isotope dilution (SID)
provided correction for losses during sample analysis, enabling precise quantitation and efficient
determination of the concentration of over 70 proteins simultaneously.
In the third aim, the LC-MS method was used to compare a panel of putative protein biomarkers in pancreatic
cancer and control serum. This analysis identified 15 differential proteins with the ability to discriminate
pancreatic cancer subjects from their age-matched controls with sensitivity and specificity superior to any
other reported pancreatic cancer biomarkers. Future validation of this panel could change the way we
diagnose pancreatic cancer.
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ABSTRACT 
LC-MS FOR PROTEIN BIOMARKER DISCOVERY IN PANCREATIC 
ADENOCARCINOMA 
Angela Y. Wehr 
Ian A. Blair, PhD 
Pancreatic cancer is a devastating disease with one of the lowest survival 
rates of all cancers, partly due to the difficulty of detection in its early stages.  
Recent developments in liquid chromatography – mass spectrometry (LC-MS) 
technology have made it possible to profile proteins associated with disease 
in a comprehensive manner.  This work sought to apply current LC-MS 
methodology to the problem of pancreatic cancer.   
A comprehensive list of proteins secreted by the tumor microenvironment 
was compiled in the first aim.  Culture of human pancreatic cell lines, both 
cancerous and stromal, was used to simulate the tumor microenvironment in 
vitro and produce a proteome rich in potential biomarkers.  The proteins 
identified in this analysis demonstrated the complex signals pancreatic tumor 
cells use to communicate with their environment and might encompass 
therapeutic targets and biomarkers.   
To measure the levels of these proteins in human serum, a relative 
quantitative LC-MS method was developed in the second aim.  Traditional 
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bioanalytical techniques were incorporated to enhance the utility of the 
method.  Multiple reaction monitoring (MRM)/MS provided sensitivity and 
specificity to the method and stable isotope dilution (SID) provided correction 
for losses during sample preparation and analysis that enabled precise 
quantitation.  The multiplexed method efficiently determined the 
concentration of over 70 proteins in a single analysis. 
In the third aim, the relative quantitative method was used to compare a 
panel of putative protein biomarkers in human pancreatic cancer and control 
serum.  This analysis identified 15 differential proteins with the ability to 
discriminate pancreatic cancer subjects from their age-matched controls with 
sensitivity and specificity superior to any other reported pancreatic cancer 
biomarkers.  Future validation of this panel could change the way we 
diagnose pancreatic cancer. 
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1 Chapter 1 – General Introduction 
1.1 Pancreatic cancer 
Pancreatic cancer is the 4th leading cause of cancer death in the United 
States even though it accounts for only 3% of new cancer diagnoses1.  One 
reason for the high mortality rate is the late stage of progression at 
presentation due to the asymptomatic nature of early disease.  Early stage 
pancreatic cancer can be treated with surgical resection which can improve 
the 5-year survival rate to 15-40%2, but few treatment options exist for the 
majority of patients that present with locally advanced or metastatic 
disease3.  Currently there are no screening measures for the detection of 
pancreatic cancer4.  The advent of such a diagnostic tool could dramatically 
impact the way we treat this devastating disease.  
Over 95% of pancreatic malignancies originate in the exocrine pancreatic 
ducts and are adenocarcinoma by histology2.  These cancers are thought to 
evolve from pancreatic intraepithelial neoplasms (PanINs) that develop 
through three stages5.  Each stage is associated with different genetic 
changes.  Oncogenic mutation in K-ras is common in stage 1, followed by 
p16 inactivation in stage 2, and finally p53 and Smad4 are inactivated in 
stage 35,6.  The role of K-ras mutation in the development of PanIN and 
pancreatic ductal adenocarcinoma (PDAC) is supported by the finding in 
mouse models of pancreatic cancer7. 
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Pancreatic adenocarcinoma is characterized by a highly desmoplastic region, 
with only a low percentage of cancer cells (<40%)6.  The rest of the tumor is 
composed of stromal cells, such as pancreatic stellate cells (PSCs), and 
extracellular matrix (ECM)8.  Pancreatic desmoplasia is a well-described but 
poorly understood process that occurs in response to organ damage or tumor 
development.  The pancreatic desmoplastic response contributes significantly 
to the morbidity of pancreatic cancer, limiting the rate of resection9. 
Since their initial description in 199810,11, PSCs have become increasingly 
recognized as important players in pancreatic fibrosis as seen in pancreatitis 
and PDAC. An excessive stromal response is a defining feature of PDAC and 
mounting evidence supports PSCs as a major contributor to the ECM proteins 
observed with this stromal response8,12. 
Under normal conditions, PSCs reside in the exocrine pancreas in a quiescent 
state, characterized by the expression of desmin, vimentin, and glial fibrillary 
acidic protein (GFAP) and the ability to store vitamin A8. PSCs become 
activated in vivo in response to pancreatic injury10,11. Upon activation, PSCs 
proliferate, lose the ability to store vitamin A, and express α-smooth muscle 
actin (α-SMA) and collagen I11,12. It has been reported that activated PSCs 
produce autocrine factors such as platelet derived growth factor (PDGF), 
transforming growth factor (TGF)-β, cytokines, and cyclooxygenase-2 to 
perpetuate the activated phenotype13-17.  
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Pancreatic cancer cells (PCCs) are known to secrete a number of proteins 
that enable them to interact with and modify their environment.  PCCs may 
enhance cell motility and extracellular matrix remodeling through the 
secretion of myosin, vimentin, and matrix metalloproteinases, and evade the 
immune response via CD59 glycoprotein and complement decay accelerating 
factor18.  PCCs may also induce the activation of PSCs via paracrine signaling 
in vivo, a phenomenon shown to occur in vitro.  For example, TGF- and 
PDGF, activators of PSCs, are commonly upregulated in pancreatic 
adenocarcinoma19,20 and PSC activation can be achieved in culture following 
the application of conditioned media supernatant taken from PCCs in 
culture12,21.
It is clear that the pancreatic tumor microenvironment is a complex tissue 
composed of a variety of cell types, each shedding an array of proteins into 
the extracellular matrix.  This secretome provides a unique signature and 
also a unique opportunity to detect pancreatic cancer in biological tissues or 
fluids.  
1.2 Biomarkers 
Biomarkers have been defined by the National Cancer Institute as “cellular, 
biochemical, and molecular (including genetic and epigenetic) characteristics 
by which normal and/or abnormal processes can be recognized and/or 
monitored”22.  Disease biomarkers may take the form of cell types, genetic 
markers, lipids, proteins, or small molecules such as hormones, and may be 
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detected in tissue or biological fluids.  For clinical utility as a diagnostic tool, 
a biomarker must possess sufficient sensitivity and specificity to discriminate 
between afflicted and unafflicted individuals.  Sensitivity refers to the ability 
of the biomarker to detect the disease and is a measure of the rate of false-
negatives.  Specificity refers to the ability of the biomarker to discriminate 
the disease state from other causes of a positive result and thus is a measure 
of the false-positive rate.  It has been estimated that for clinical utility, a 
screening biomarker should possess sensitivity and specificity rates of at 
least 90%23. 
1.2.1 Previous studies 
Unfortunately, despite years of research, pancreatic cancer biomarkers have 
yet to be found that meet such stringent criteria24,25.  Endoscopic procedures 
for the sampling of pancreatic juice have been described, but are expensive, 
carry significant risk of complications, and have shown only limited success 
26,27.  Proteomic analysis of pancreatic cyst fluid has identified potential 
biomarkers, but again relies on invasive testing that is not feasible for 
general screening28.  A method to detect a biomarker or panel of biomarkers 
in the serum would provide a minimally invasive technique that could be 
readily applied to the general population. 
The carbohydrate CA19-9 is the only pancreatic cancer biomarker currently 
in use and lacks sufficient sensitivity and specificity for screening24,25 and as 
such is currently only used to monitor response to therapy29-31. 
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Genetic markers such as K-ras have been studied and detected in the blood 
of patients with advanced disease.  However, it can be difficult to detect 
against a background of normal DNA32,33.  DNA methylation profiling of 
leukocytes has been conducted as a cancer biomarker in bladder34, breast35, 
lung36, and pancreatic cancer37, although the reasons for why there could be 
differences in leukocyte methylation are not clear. 
Proteins have been a popular subject of biomarker research.  Many serum 
markers of pancreatic cancer have been reported, such as MIC-1, PAM4, 
OPN, HSP27, TPS, TSGF, CAM17.1, PF4, CEACAM1, annexin A8, Claudin 18, 
lactose binding protein, and plectin -1, yet all lack the necessary levels of 
sensitivity and specificity26,38-42. 
1.2.2 Development  
It has been suggested that the development of biomarkers be conducted in    
phases similar to drug development in the pharmaceutical industry43.  Just as 
new drug trials start in model organisms for toxicity studies, move into small 
human studies in Phase I, and ultimately grow into larger and more 
significant trials the further and more successful the drug is in the process, 
biomarker studies should also expand as the marker gains significance.  
Biomarker studies can be broken down into 5 phases: preclinical exploratory 
studies aimed at the discovery of candidates, clinical assay development and 
validation in a training set of samples, retrospective longitudinal studies to 
detect disease immediately prior to diagnosis, prospective screening studies 
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for diagnosis, and cancer control studies to determine whether screening 
reduced cancer burden43.   
Historically, early biomarker discovery studies can be broken down into two 
methods: the hypothesis driven targeted approach and the pattern based 
discovery approach.  The hypothesis driven approach sought to an 
understanding of the cell and molecular biology of the disease to identify 
molecules hypothesized to vary in a disease state.  While well founded 
scientifically, these studies were lengthy and produced few results.  The 
pattern recognition approach, based largely on surface-enhanced laser 
desorption ionization (SELDI)/MS, operated on the theory that the identity of 
the biomarkers was irrelevant and their relationship to the disease could 
remain unknown as long as a successfully predictive pattern was found.  This 
approach, which was lacking in bioanalytical rigor and did not consider the 
potential for inter-individual differences in ionization efficiency led to 
numerous studies that could not be validated including a highly-cited study of 
ovarian cancer44, which had serious methodological flaws45-47.  Since those 
early studies, a new approach that employs more rigorous systems has 
emerged.  MS-based proteomic approaches that survey the proteome are 
first used to identify differential proteins in a sample set.  The identity of the 
proteins can then be verified by immunological or other methods.  Once the 
identity of the candidate protein is confirmed, targeted methods capable of 
quantitating the protein are used in biological samples to validate the 
biomarker in the second phase of development. 
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The discovery approach used in my studies have relied on the simulation of 
the tumor microenvironment based on the culture of human cell lines.  Since 
the ultimate goal is to identify proteins secreted by pancreatic cancer and 
stromal cells in vivo, it is important to select cell lines that exhibit expression 
and mutations similar to those seen in vivo.  As discussed above, during 
pancreatic cancer development, activating mutations in K-ras commonly 
occur early on, while inactivating mutations in tumor suppressors, such as 
p16, p53, and Smad4, follow as PanIN progresses.  A number of cancerous 
and normal pancreatic cell lines that share a variety of these mutations, 
listed in Table 1, are commonly used and commercially available.   
Table 1. Pancreatic Cell Line Characteristics 
Cell Line Site of origin Tumor 
grade 
K-ras p16 p53 Smad4 
CAPAN-1 Liver Metastasis 1 Mut Mut Mut Mut 
CAPAN-2 Primary Tumor 1 Mut Mut WT ND 
ASPC-1 Ascites 2/3 Mut Mut Mut WT 
BXPC-3 Primary Tumor 2/3 WT Mut Mut Mut 
MiaPaCa-2 Primary Tumor 3 Mut Mut Mut WT 
HPDE6E6E7 Pancreatic Duct N/A WT WT Mut WT 
 
The methods used to validate candidate biomarkers have evolved as well.  
Discovery studies generated vast lists of candidate biomarker proteins 
awaiting quantitation in human samples for validation48-55. Enzyme-linked 
immunosorbent assay (ELISA) is the most common method used for the 
quantitation of proteins in serum due to its high sensitivity and specificity.  
However, ELISA becomes expensive and labor intensive when applied to a 
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large number of proteins and samples, which is why most biomarker 
validation studies are limited to a few proteins56-59.  LC-MS analysis of 
proteins provides a more robust and high-throughput alternative to 
immunological methods since it does not require the generation of specific 
antibodies for each protein.  Also, since many methods utilize MS for the 
identification of biomarkers in the discovery phase, it is a logical progression 
to use the same methodology for their quantitation during validation. 
1.3 LC-MS for protein analysis 
1.3.1 Qualitative analysis 
MS-based proteomic profiling is a technique used to survey a spectrum of 
proteins in a sample.  Both top-down and bottom-up strategies have been 
used effectively60-62.  Top-down strategies rely on high-resolution mass 
spectrometers to analyze and fragment intact proteins.  Bottom-up, also 
called shotgun, proteomics uses the mass spectrum of the products of tryptic 
peptide fragmentation to determine the peptide sequence.  These sequences 
are then searched against protein databases to determine their identity.  It is 
this method that was used for the research presented in this dissertation. 
The tryptic digests produced by shotgun analysis are complex in the array of 
peptides that are formed and the concentration range at which each peptide 
is present.  Sample complexity can be reduced by separation using 
conventional reversed phase (RP) chromatography with elution online to the 
mass spectrometer.  However, to further reduce the sample complexity 
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during MS analysis, multidimensional protein identification technology 
(MudPIT) has been developed63.  Such methods depend on orthogonal 
separation techniques to fractionate the samples prior to LC-MS analysis.  
This work has relied on the use of strong cation (SCX) exchange as the first 
dimension of separation, followed by RP chromatography as the second 
dimension64.   
Discovery MS is achieved through data dependent analysis.  In the first stage 
of this analysis intact peptides are scanned to produce a mass spectrum.  
Instrument software analyzes this spectrum in real-time to identify the most 
intense ions.  The most intense precursor ions are then selected for 
fragmentation.  After acquiring product ion spectra for each of the selected 
precursor ions, the process is repeated beginning with a scan of intact 
peptides.  The time it takes to complete the process of precursor selection 
and fragmentation is termed cycle time.  Care must be taken to select an 
appropriate cycle time.  By selecting more precursors for fragmentation, the 
proteome can be searched in greater depth, though this increases the cycle 
time and reduces the number cycles that can be completed during a 
chromatographic run.  An excessively long cycle time will result in the 
omission of significant peptides that elute while other analytes are 
undergoing fragmentation.   
Once precursor and product ion spectra have been obtained, raw MS/MS files 
are batch searched against a reference sequence database using search 
10 
 
software such as SEQUEST or Mascot.  The search output files are then 
analyzed and validated by PeptideProphet, an automated method to assign 
peptides to MS/MS spectra. 
1.3.2 Relative quantitation analysis 
In the search for biomarkers, proteomic analysis is used not only to identify 
the proteins present in a system, but to assess differences in the proteome 
that are the result of disease status or response to therapy.  To quantitate 
relative proteome changes in the model both label-free and isotope/mass tag 
labeling approaches have been used.  Label-free methods use either external 
protein standards or spectral counts, the number of times an analyte was 
detected, to approximate the abundance of the analyte in each sample55,65.  
Isotope labeling strategies, such as isotope-coded affinity tags (ICAT)66, 
iTRAQ™67, and stable isotope labeling by amino acids in cell culture (SILAC)68 
rely on the use of stable isotope or isobaric tag labeling of one or more sets 
of samples.  The differentially labeled samples are then pooled and analyzed 
simultaneously; after co-eluting from the LC column, they ionize 
simultaneously, and are discriminated by the mass spectrometer based on 
their mass-to-charge (m/z) ratio.  The ratio of the differentially labeled 
analytes can then be used to approximate their relative abundance.  The 
ICAT and iTRAQ™ methods rely on chemical modification of the proteins or 
peptides; a small molecule tag reacts with a functional moiety of the analyte.  
These analyses are based on the assumption that both protease digestion 
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and subsequent chemical reaction of the protease-derived peptides with the 
relevant reagent is consistent for all samples, a presumption that may be 
false and hence is a potential pitfall of these methods.  However, these 
analyses are useful for samples that cannot be cultured for metabolic labeling 
such as primary cell lines and human tissues or fluid.  
SILAC is a metabolic labeling system amenable to cell culture models.  This 
methodology uses heavy labeled essential amino acids, such as leucine and 
lysine (13C6, 
15N2 L-Lysine dihydrochloride and 
13C6, 
15N L-Leucine), in the 
culture of cells.  All of the proteins produced by these cells are thus labeled 
with stable (or heavy) isotopes and can then be compared with those 
produced by unlabeled cells.  SILAC requires the use of cells that can be 
passaged many times to guarantee a high percentage of labeling and care 
must be taken to ensure any contamination by unlabeled protein is low.  
However, labeling efficiency can easily be measured to rule out this problem. 
1.3.3 Targeted quantitative analysis – Multiple Reaction Monitoring 
MRM is an experiment conducted on tandem mass spectrometers and is 
commonly used for bioanalytical analyses69-71.  During an MRM experiment on 
a triple quadrupole mass spectrometer, the precursor m/z of the analyte is 
selected in the first quadrupole.  The precursor ion is then fragmented via 
collision induced dissociation (CID) in the second quadrupole.  A 
characteristic product ion is then selected in the third quadrupole and 
ultimately recorded by the detector.  The goal during MRM/MS development 
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is to select a transition, a pair of precursor and product ions, that is specific 
to the analyte of interest.  The specificity of this process, the transition from 
precursor to product, is what makes it the tool of choice to analyze low 
abundance molecules within a complex matrix, such as serum or plasma.  
With developments in MS technology, this system has rapidly become even 
faster and more sensitive, making the detection of low abundance proteins in 
serum feasible72,73.  Within the course of the research presented in this 
dissertation, a method to quantitate potential biomarker proteins in human 
serum using LC-MRM/MS technology has been developed. 
While intact proteins are difficult to analyze by traditional LC columns, 
peptides that result from tryptic digestion can be readily separated by RP 
chromatography.  Tryptic peptides have an additional advantage during LC-
MS analysis; when subjected to electrospray ionization (ESI) they readily 
form multiply charged ions due to the presence of lysine and arginine in 
every peptide.  Multiply charged precursor ions generally produce product 
ions with a lower charge state than the precursor, some of which possess a 
higher m/z ratio than the precursor ion.  This effect improves the sensitivity 
of MRM/MS analysis by reducing the background as fewer serum matrix ions 
are capable of multiple charging.  The targeted approach reported here uses 
the response of tryptic peptides to estimate the abundance of their 
respective proteins present in the serum. 
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Human serum is rich in proteins, however this too poses a challenge for 
analysis as the proteins in human serum span over 10 orders of magnitude in 
concentration74.  Low abundance proteins that are typically of interest in 
biomarker analyses comprise less than 1 percent of the serum proteins by 
weight75.  Immunoaffinity methods have been used to resolve this problem.  
Stable isotope standards and capture by anti-peptide antibodies (SISCAPA) 
uses antibodies raised against the protein of interest to extract the analyte 
prior to MS analysis76.  While this method has been effective, like ELISA, it 
requires the development of specific antibodies for each protein.  An 
alternative approach is to use antibodies raised against the most highly 
abundant proteins (HAP) in serum to deplete the serum of these interfering 
proteins77-79. 
While digestion and depletion aid in enhancing the sensitivity and specificity 
of the method, they are also a potential source of variability in the analysis.  
A stable isotope labeled internal standard is commonly used in bioanalytical 
methods to track analyte losses during sample preparation or analysis72,80.  
Similarly, a stable isotope labeled proteome (SILAP) standard can be used to 
normalize proteomic profiling and correct for protein losses during extraction 
and analysis50,73,81.   
The SILAP method is based on SILAC methodology, using heavy isotopically-
labeled essential amino acids, such as leucine and lysine (13C6, 
15N2 L-lysine 
dihydrochloride and 13C6, 
15N L-leucine), to produce fully labeled, correctly 
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folded, fully functional human proteins in cell culture.  These proteins can 
then be harvested and used as an internal standard during protein 
preparation and LC-MS analysis (Figure 1). 
 
Figure 1. SILAP diagram 
1.4 Conclusions 
The following chapters of this dissertation describe the development of 
potential biomarkers of pancreatic cancer.  My approach began with the 
identification of potential protein biomarkers through the application of 
shotgun proteomics to study the secretome of the tumor microenvironment 
in vitro.  Chapter 2 details the cell culture models used to simulate the tumor 
microenvironment and the mass spectrometric and bioinformatic techniques 
used to analyze the secreted proteins.   
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The mass spectral data acquired in the discovery phase was then used to 
direct the development of a targeted analytical LC-MS method for the 
quantitation of these candidate biomarkers in human serum.  Chapter 3 
serves as a template for the development of targeted methods and details 
potential pitfalls in such analyses.   
Finally, the targeted method is applied to the analysis of a training set of 
human serum samples, comparing pancreatic cancer patients and controls.  
Chapter 4 is the reward of years of development work, as differential 
proteins with the potential to diagnose pancreatic cancer were discovered.  
By analyzing a panel of protein biomarkers in parallel, as afforded by LC-MS 
analysis, we were able to establish a diagnostic panel with levels of 
sensitivity and specificity not previously reported. 
While this work provides a set of detailed methods that may direct LC-MS 
analyses, it also serves to provide proof of principle for cell-based LC-MS 
cancer biomarker discovery.  By using a cell culture model of disease we are 
able to rapidly identify a list of potential biomarkers, the data of which is 
easily translated to the development of a targeted method, which is made 
more robust by the internal standard generated in the cell culture model that 
started it all.  Ultimately it is the robustness of the method that permits us to 
discriminate the differences observed in protein concentration in human 
samples.  Thus, this dissertation provides a strategy for biomarker discovery 
and stands to impact the way we detect cancer and many other diseases.  
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2 Chapter 2 – Proteomic Profiling of the Pancreatic Cancer 
Microenvironment 
Published as: 
Wehr AY, Furth EE, Sangar V, Blair IA, Yu KH. Analysis of the human 
pancreatic stellate cell secreted proteome. Pancreas. 2011 May;40(4):557-
66. PubMed PMID:21499210; PubMed Central PMCID: PMC3086313. 
2.1 Abstract 
Objective: PSCs are important players in pancreatic fibrosis and are major 
contributors to the extracellular matrix proteins observed with the stromal 
response characteristic of PDAC. PSCs are also believed to secrete soluble 
factors that promote tumor progression; however no comprehensive analysis 
of the PSC proteome in either the quiescent or activated state has been 
reported.  
Methods: Using two-dimensional MS/MS and the RLT-PSC cell line, we 
present the first comprehensive study describing and comparing the 
quiescent and activated human PSC secreted proteomes. 
Results: Very few proteins are secreted in the quiescent state. In stark 
contrast, activated PSCs secreted a vast array of proteins. Many of these 
proteins differed from those secreted by PDAC derived cell lines. Proteins 
associated with wound healing, proliferation, apoptosis, fibrosis and invasion 
were characterized. Selected proteins were verified in human tissue samples 
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from PDAC, dysplastic pancreas, and normal pancreas using Western blot 
analysis and immunohistochemical staining. 
Conclusions: Our study represents the first comprehensive analysis of 
proteins secreted by PSCs. These findings lay the foundation for 
characterizing PSC derived proteins involved in stroma-tumor interactions 
and the promotion of pancreatitis and PDAC. 
2.2 Introduction 
Since their initial description in 199810,11, PSCs have become increasingly 
recognized as important players in pancreatic fibrosis as seen in pancreatitis 
and PDAC. An exuberant stromal response is a defining feature of PDAC. 
Indeed, cancer cells compose on average less than 40% of PDAC tumors6 
and accumulating evidence supports PSCs as a major contributor to the ECM 
proteins observed with this stromal response8,12. 
Under normal conditions, PSCs reside in the exocrine pancreas in a quiescent 
state, characterized by the expression of desmin, vimentin, and GFAP and 
the ability to store vitamin A8. PSCs become activated in vivo in response to 
pancreatic injury10,11. Upon activation, PSCs proliferate, lose the ability to 
store vitamin A, and express -SMA and collagen I11,12. It has been reported 
that activated PSCs produce autocrine factors such as PDGF, TGF-β, 
cytokines, and cyclooxygenase-2 to perpetuate the activated phenotype 13-17; 
however, no comprehensive analysis of the PSC proteome in either the 
quiescent or activated state has been reported. 
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While knowledge of the intracellular proteome is important, it is the secreted 
proteome, or secretome, that is of particular interest with regards to 
understanding intercellular interactions, for example with tumor cells. It 
remains difficult to characterize proteins secreted by a single cell type to the 
exclusion of all others in vivo. One solution to this problem is studying cell 
lines derived from the cell type of interest in vitro, an approach we have 
already used to study the secretome of PDAC cells50. 
In the current study, the RLT-PSC cell line, an immortalized cell line derived 
from human PSCs, was exploited in order to characterize the secretome of 
both the quiescent and activated PSC.  The RLT-PSC cell line can be 
maintained in a quiescent state when grown on a soft substrate, or in an 
activated state when grown on untreated culture plates82. The first 
comparative proteomic study was conducted, which demonstrated a 
remarkable differential secretome upon PSC activation and highlighted the 
potential biological functions of these proteins. Expression of selected 
proteins were verified in human pancreatic tissue samples. 
2.3 MATERIALS AND METHODS 
2.3.1 Cell Culture 
The human PDAC cell lines MiaPaCa-2 and CAPAN-2, and the immortalized 
human PSC line RLT-PSC82 were cultured according to standard practice 
using Dulbecco's Modified Eagle Medium (DMEM, Sigma, St. Louis, MO) 
supplemented with 10 % fetal bovine serum (Sigma) and 1 % antibiotic 
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(penicillin/streptomycin, Invitrogen, Grand Island, NY).  Secreted proteins 
were harvested by allowing cells to grow to 80 % confluence, washing with 
phosphate buffered saline (Invitrogen), and incubating the cells with serum-
free media at 37 °C for 48 h. This media was collected, passed through a 
0.22 µm filter, and stored at -80 °C until used. To induce a quiescent 
phenotype, 80 % confluent RLT-PSCs were treated with trypsin (Invitrogen), 
resuspended in serum-free DMEM supplemented with 1 % antibiotic and 2.5 
mM N-acetyl cysteine (Sigma), then plated at a concentration of 20,000 
cells/cm2 on collagen I coated cover-slips or plates (BD Biosciences, San 
Jose, CA) and incubated at 37 °C for 24 h. RLT-PSCs were plated on 
uncoated tissue culture plates to achieve an activated state. 
2.3.2 Cell culture immunocytochemistry 
RLT-PSCs were plated on either uncoated (activated cells) or collagen I 
coated (quiescent cells) coverslips and incubated at 37 °C for at least 24 h to 
allow attachment.  Cells were formalin fixed, washed with propylene glycol 
(PolyScientific, Bay Shore, NY) and incubated with oil red O (0.5 % in 
propylene glycol, PolyScientific) for 1 hr at RT. Cells were then washed with 
85 % propylene glycol, blocked with 1 % bovine serum albumin/PBS 
(Sigma), and labeled overnight at 4 °C with antibodies against either α-SMA 
(mouse, Sigma) or GFAP (rabbit, Sigma) diluted 1:1,600 and 1:600, 
respectively, in blocking solution. Cells were incubated with a Cy2 conjugated 
secondary antibody (donkey anti-mouse or anti-rabbit, Jackson 
ImmunoResearch, West Grove, PA) diluted 1:600 in blocking solution for 1 hr 
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at RT. Finally, cells were incubated with DAPI (Sigma), diluted 1:10,000 in 
water, for 45 sec. Fluorescence was visualized using a Nikon (Melville, NY) 
E600 fluorescent microscope equipped with a CCD camera and IPLab image 
analysis software (BD Biosciences). 
2.3.3 2D LC-MS/MS  
Two biological replicates were analyzed for each cell line. Secreted proteins 
were concentrated using 3 kDa MW cutoff spin-filters (Millipore, Billerica, 
MA), and then precipitated using methanol-chloroform extraction. 100 µg of 
protein from each cell line was digested and separated by SCX 
chromatography using standard methods as previously described83. SCX 
fractions were subjected to reversed phase chromatography using a C18 
column (0.3 x 150 mm, 4 µ, 90 Å Jupiter Proteo, Phenomenex, Torrence, CA) 
on a microflow high pressure liquid chromatography system (Eksigent, 
Dublin, CA). A chromatographic gradient increasing mobile phase B (95 % 
acetonitrile, 0.1 % formic acid) from 0 to 60 % over 30 min at a flow rate of 
12 µl/min was used to elute peptides online to a linear ion trap mass 
spectrometer (LTQ, ThermoFisher, San Jose, CA) with positive ESI.  Data 
dependent scanning was used to identify the 5 most intense precursor 
masses, which were then subjected to collision-induced dissociation to 
produce product ion spectra. 
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2.3.4 Protein identification 
Raw data were submitted to Bioworks Browser version 3.2 (ThermoFisher) 
and batch searched through SEQUEST™ against the NCBI RefSeq human 
reference sequence database (version updated 03/17/09) containing 75,484 
sequences consisting of 37,742 proteins and 37,742 decoy entries (1 reverse 
sequence for each real entry).  The database was indexed using the following 
criteria: precursor and fragment mass tolerance of 1 amu, strict trypsin 
cleavage rules with up to two internal cleavage sites; differential 
modifications of methionine oxidation and carboxyamidomethylation on 
cysteine. Sequences were further processed using the Trans-Proteomic 
Pipeline software (version 2.8, Institute for Systems Biology, Seattle, WA) for 
analysis and validation of peptides and proteins using Peptide Prophet™ 
(version 3.0) and ProteinProphet™ (version 2.0), respectively. 
ProteinProphet™ results were filtered using a minimum probability score of 
0.6, translating to a false discovery rate of 5 %.  Proteins identified by fewer 
than two unique peptide sequences were discarded.  Proteins that contained 
similar peptides and could not be differentiated based on MS/MS analysis 
alone were grouped to satisfy the principles of parsimony.  The remaining 
proteins in each replicate were recombined to generate a complete list of 
secretome proteins for each cell line. 
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2.3.5 Bioinformatics  
Pathway analysis was performed on proteins using the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) database 84 as a reference using methods 
previously described50.  Gene ontology (GO) analysis was also conducted 
using the functional annotation tool available through the DAVID 
Bioinformatics Database85,86. 
2.3.6 Western blot analysis 
The following primary polyclonal rabbit anti-human antibodies were obtained: 
pyruvate dehydrogenase kinase (PKM2) (GenWay, San Diego, CA), urokinase 
plasminogen activator preproprotein (PLAU) (Abgent, San Diego, CA) and 
transforming growth factor, beta-induced, 68kDa (TGFBI) (Proteintech 
Group, Inc., Chicago, IL).  Primary goat anti-human serpin peptidase 
inhibitor, clade I (pancpin), member 2 (SERPINI2) antibody was obtained 
(Everest, Oxfordshire, UK). The following mouse monoclonal antibodies were 
obtained: ubiquitin carboxyl-terminal esterase L1 (UCHL1), matrix 
metallopeptidase 2 (MMP2), plasminogen activator inhibitor-1 (SERPINE1), 
non-metastatic cells 1, protein (NM23A) (NME1), ezrin (EZR), annexin A2 
(ANXA2), and galectin-3-binding protein (LGALS3BP) (Santa Cruz 
Biotechnology, Santa Cruz, CA). Alexa Fluor 680 conjugated secondary 
donkey anti-mouse, anti-rabbit, and anti-goat antibodies were obtained 
(Invitrogen).  Cells were lysed in either 25 % sample loading buffer (LDS, 
Invitrogen) or 6 M urea/2 M thiourea containing HALT™ Protease Inhibitor 
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Cocktail (Pierce, Rockford, IL).  Secreted proteins were concentrated using 3 
kDa MW cutoff spin filters, precipitated using methanol-chloroform, then 
resuspended in 6 M urea/2M thiourea.  Protein concentration of reconstituted 
whole cell lysates and secreted proteins was determined according to the 
Bradford method. 8 µg of protein was loaded per well on NuPAGE® 4-12 % 
Bis-Tris gels (Invitrogen) then separated in MOPS buffer (Invitrogen). 
Proteins were transferred to a PVDF membrane (Millipore, Billerica, MA), 
blocked with 5 % powdered milk in TBST (Teknova, Hollister, CA), then 
incubated with primary antibody overnight at 4 °C at a dilution of 1:200.  
After washing with TBST, membranes were incubated with secondary 
antibody for 30 min at RT at a dilution of 1:10,000 in the dark, and then 
washed again with TBST.  Fluorescence was measured used the Odyssey® 
Imaging System (LI-COR Biosciences, Lincoln, NE). 
2.3.7 Tissue immunohistochemistry 
The following primary polyclonal rabbit anti-human antibodies were obtained: 
PKM2 (GenWay, San Diego, CA), and TGFBI (Proteintech Group, Inc., 
Chicago, IL).  Primary goat anti-human SERPINI2 antibody was obtained 
(Everest, Oxfordshire, UK).  The following mouse monoclonal antibodies were 
obtained: MMP2 (Calbiochem, San Diego, CA), NME1, EZR, ANXA2, and 
LGALS3BP (Santa Cruz Biotechnology, Santa Cruz, CA), -SMA, vimentin, 
CD31, and UCHL1 (Dako, Glostrup, Denmark).  Biotinylated secondary 
donkey anti-mouse, -rabbit, or -goat antibodies were obtained (Vector, 
Burlingame, CA).  Formalin-fixed paraffin embedded human pancreatic tissue 
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was obtained from patients treated at the Hospital of the University of 
Pennsylvania through Institutional Review Board approved protocols.  In 
total, 5 tissue samples of normal human pancreas, 5 tissue samples of 
human PDAC, and 2 tissue samples of PDAC metastasis to lymph node were 
analyzed. 4 µm serial sections were dewaxed, slides were microwaved in 10 
mM citric acid pH 6 solution to achieve antigen retrieval, then endogenous 
peroxidases were quenched using 30 % hydrogen peroxide solution. Slides 
were incubated with successive solutions of avidin and biotin blocking 
solutions (Vector) and StartingBlock blocking buffer (Pierce, Rockford, IL) for 
15 min each at RT and primary antibody overnight at 4 °C.  Slides were 
incubated with biotin conjugated secondary antibody followed by the 
VECTSTAIN® HRP-ABC reagent (Vector, Burlingame, CA), each for 30 min at 
37 °C. After developing the signal with diaminobenzadine (Vector), slides 
were washed with water and counterstained with hematoxylin.  Images were 
captured using a Nikon (Melville, NY) E600 fluorescent microscope equipped 
with a CCD camera and IPLab image analysis software (BD Biosciences).  
2.4 RESULTS  
2.4.1 RLT-PSCs recapitulate primary human PSCs 
RLT-PSC is a human PSC line immortalized via transfection with SV40 large T 
antigen82. When cultured on Matrigel plus N-acetyl cysteine treatment, RLT-
PSCs exhibit a quiescent phenotype82.  RLT-PSCs cultured on collagen I 
coated cover slips or plates also maintained a quiescent phenotype denoted 
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by morphology (Figure 2a), expression of GFAP (Figure 2d), presence of lipid 
droplets and absence of α-SMA (Figure 2e).  The quiescent PSCs could then 
be activated by application of conditioned media harvested from MiaPaCa-2 
pancreatic cancer cell lines.  This activation is illustrated by morphology 
(Figure 2b), loss of oil red O staining, and expression of -SMA (Figure 2f). 
PSCs cultured on uncoated tissue culture plates yielded an activated 
phenotype as well (Figure 2c).  These results show that RLT-PSCs 
recapitulate features typical of primary human PSCs.  
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Figure 2. Brightfield and fluorescence microscopy demonstrating morphology of 
PSCs. RLT-PSCs are shown in (A) the quiescent state, and activated by (B) exposure to 
PCC CM, or (C) growth on a tissue-culture treated plate.  Fluorescent microscopy 
demonstrating (D) quiescent PSC lipid droplets (red), GFAP Expression (green), and 
nucleus (blue); (E) quiescent PSC lipid droplets (red), -SMA (green), and nucleus 
(blue); and (F) activated PSC loss of lipid droplets (red), -SMA Expression (green), and 
nucleus (blue). 
2.4.2 PSC secretion is altered upon activation 
Proteomic profiling of the media harvested from cells in culture was 
undertaken to assess changes in the secretome of PSCs upon activation.  
Proteins identified by fewer than two different unique peptide sequences 
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within a replicate were excluded. Reverse database analysis revealed a false 
discovery rate of less than 4 %.  A list of all quiescent and activated PSC 
proteins and pancreatic cancer cell proteins is provided in Appendix 1.   
Duplicate analyses were used in an effort to include as many potential 
biomarkers and therapeutic targets as possible, a reasonable approach given 
that any leads would be subject to further validation.  A total of 641 unique 
proteins were identified in the secretome from activated PSCs.  This is 
significantly higher than the 46 unique proteins indentified in the secretome 
from quiescent PSCs.  The secretomes from CAPAN-2 and MiaPaCa-2 cancer 
cell lines contained 432 and 529 unique proteins, respectively.  Proteins 
identified in the quiescent PSCs, activated PSCs, and cancer cell lines were 
compared to identify unique and shared proteins (Figure 3).  
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Figure 3. Venn diagram of secreted proteins identified from PSCs and cancer cells 
in cell culture.  All identifications were made in the conditioned media derived from cells 
in culture. 
The activated PSC data set was sorted by total number of spectra per protein 
to estimate relative abundance.  A literature search was conducted on the 
most abundant proteins to identify those previously linked to cancer 
progression, including roles in angiogenesis, invasion, and apoptosis.  These 
proteins (Table 2) were then chosen for further validation studies. 
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Table 2. PSC secreted proteins selected for immunologic validation 
GI no Abbreviation Protein Name 
gi|5453886 SERPINI2 
serpin peptidase inhibitor, clade I (pancpin), 
member 2 
gi|4505863 PLAU urokinase plasminogen activator preprotein 
gi|10835159 SERPINE1 plasminogen activator inhibitor 1 
gi|11342666 MMP2 matrix metallopeptidase 2 
gi|4507467 TGFBI transforming growth factor, beta-induced, 68kDa 
gi|5031863 LGALS3BP galectin-3-binding protein 
gi|33286418 PKM2 pyruvate kinase, muscle isoform 1 
gi|66392203 NME1 nucleotide diphosphate kinase 1 
gi|161702986 EZR ezrin 
gi|50845386 ANXA2 annexin A2 
gi|21361091 UCHL1 ubiquitin carboxyl-terminal esterase L1 
 
2.4.3 Western blot analysis confirms MS results 
Expression of proteins secreted by activated RLT-PSCs (Table 2) was verified 
by Western blot analysis (Figure 4).  Protein expression was also assessed in 
RLT-PSC whole cell lysate.  Relative protein levels varied greatly. SERPINI2, 
PLAU, SERPINE1, MMP2, TGFBI, and EZR were undetected and LGALS3BP, 
PKM2, and UCHL1 showed faint bands in the activated RLT-PSC whole cell 
lysate. ANXA2 showed similar levels in the whole cell lysate and secretome.  
NME1 was expressed at higher abundance in the whole cell lysate than the 
secretome.  All proteins were undetected in the quiescent RLT-PSC 
secretome. All proteins observed in the activated RLT-PSC whole cell lysate 
were also seen in the quiescent whole cell lysate. 
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Figure 4. Western blot demonstrating expression of PSC proteins in cell culture.  
Conditioned media (S) and lysate (L) from activated or quiescent PSCs were analyzed.  
Equal amounts of protein were added to each well. 
2.4.4 IHC analysis confirms in vitro results 
IHC analysis conducted on human tissue samples from patients with PDAC or 
normal controls was used to confirm and localize expression of selected 
proteins in relation to PSCs. PSCs were visualized by staining serial sections 
of tissue using PSC markers α-SMA and vimentin (Figure 5).  To differentiate 
PSCs from endothelial cells, which also express α-SMA and vimentin, the 
endothelial cell marker, CD-31, was used.87 Therefore PSCs could be readily 
identified by the presence of α-SMA and vimentin and the absence of CD-31.  
Staining of serial sections was organized such that IHC staining of proteins of 
interest were performed in a tissue section immediately adjacent to a set of 
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PSC markers (Table 3).  
 
Table 3. Serial pancreatic tissue section staining scheme for 
immunohistochemistry 
Slide # Protein 
1 SERPINI2 
2 -SMA 
3 CD-31 
4 vimentin 
5 PKM2 
6 TGFBI 
7 -SMA 
8 CD-31 
9 vimentin 
10 EZR 
11 LGALS3BP 
12 -SMA 
13 CD-31 
14 Vimentin 
15 UCHL1 
16 NME1 
17 -SMA 
18 CD-31 
19 vimentin 
20 ANXA2 
 
In PDAC tissue sections, SERPINI2, PKM2 (Figure 5), LGALS3BP, and NME1 
(Figure 6), were detected in the cytosol of cancer cells and PSCs (Figure 5). 
In the dysplastic human pancreas, SERPINI2, PKM2 (Figure 5), LGALS3BP, 
and NME1 (Figure 6) were detected in ductal cells and PSCs.  These proteins 
were also detected within the cytosolic region of acinar and ductal cells in 
normal human pancreas. UCHL1 was detected distinctly in the nuclei of PSCs 
in PDAC tissue sections and at low levels in the nuclei of some ductal cells 
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and PSCs in the dysplastic pancreas and some acinar and ductal cells in 
normal pancreas (Figure 6).  TGFBI was the only protein detected distinctly 
in stromal regions, to the exclusion of cancer cells in PDAC tissue (Figure 5).  
In the dysplastic pancreas, TGFBI was found in the fibrotic region containing 
PSCs (Figure 5).  Interestingly, TGFBI was also observed in vesicles in 
normal pancreatic tissue. In PDAC tissue, EZR was detected in the cytosol of 
cancer cells, but also was distinctly present at the luminal membrane of 
ductal cells and the nuclei of PSCs (Figure 6).  EZR was also detected in the 
cytosol of ductal cells with strong localization to the luminal surface of ductal 
cells in dysplastic pancreas.  In normal pancreas, EZR was detected in the 
centroacinar space and within a few acinar cells in the cytosolic region 
bordering the centroacinar space. In PDAC tissue, ANXA2 was detected in the 
cytosol of cancer cells and PSCs.  Similar to EZR, ANXA2 was detected along 
the luminal membrane of ductal cells.  ANXA2 was also detected in the 
cytosol of ductal cells and PSCs in the dysplastic pancreas.  ANXA2 
localization in normal pancreas was similar to that of EZR with strong 
staining observed in the centroacinar space and the bordering cytosol of 
acinar cells. 
33 
 
 
Figure 5. IHC staining of serial sections of pancreatic tissue.  Normal human 
pancreas tissue (first column), dysplastic human pancreas tissue (middle column), and 
human pancreatic ductal adenocarcinoma (last column) are stained.  Positive stain is in 
brown.  PSCs were visualized by the expression of markers -SMA and vimentin and 
the absence of CD31. 
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Figure 6. IHC staining of serial sections of pancreatic tissue.  Normal human 
pancreas tissue (first column), dysplastic human pancreas tissue (middle column), and 
human pancreatic ductal adenocarcinoma (last column) are stained.  Positive stain is in 
brown. 
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2.4.5 Bioinformatics analysis 
Of the 641 proteins identified in the RLT-PSC secretome 174 (27%) were 
implicated in at least one biological pathway according to analysis against the 
KEGG database (Table 4).  Most classifiable proteins were involved in 
metabolism.  As expected for secreted proteins, none were classified as 
involved with transcription pathways.  The most highly populated pathway 
was cell communication followed closely by the immune system.  Many 
proteins were also identified within the cell motility pathway.  17 proteins 
have been implicated in various cancers, of which 14 were implicated in 
pancreatic cancer.  
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Table 4. Activated PSC proteins identified within KEGG pathways 
 
GO analysis was conducted to elucidate biological function (data not shown). 
As was seen with the KEGG analysis, the majority of proteins were related to 
cellular metabolic processes; however, a significant number of proteins were 
involved in fibrosis, invasion, inflammation, cell division, and apoptosis. PSCs 
are believed to play important roles in wound healing, inflammation, fibrosis, 
tumor progression and invasion through matrix remodeling (Figure 7).  To 
identify activated PSC proteins that effect these changes, GO terms that 
Pathways Number of Gis 
Metabolism 48 
Genetic Information Processing 
 Transcription  0 
Translation 7 
Folding, Sorting and Degradation 18 
                                   Proteasome 11 
Replication and Repair 10 
Environmental Information Processing 
 Membrane Transport 0 
Signal Transduction 15 
                                  MAPK Signaling pathway 7 
Signaling Molecules and Interaction 14 
Cellular Processes 
 Cell Motility 22 
Cell Growth and Death 12 
Cell Communication 31 
                                  Focal adhesion 21 
                                 Insulin signaling pathway 10 
Immune System 30 
                                 Leukocyte transendothelial migration 5 
Nervous System 6 
Sensory System 2 
Development 5 
Behavior 0 
Human Diseases 
 Cancers 17 
Immune Disorders 8 
Neurodegenerative Diseases 9 
Metabolic Disorders 2 
Infectious Diseases 14 
 
37 
 
relate to these functions were probed and the resulting list of proteins is 
presented in Appendix 2.  Some functions, such as wound healing, 
inflammation, and apoptosis relate readily to the GO terms available. Other 
important pathways, such as fibrosis, cannot be studied using GO terms 
currently available.  Fibrotic tissue consists largely of ECM proteins and 
proteases control the remodeling of these proteins.  For this reason, proteins 
relating to the ECM or protease inhibitors are listed under the category of 
fibrosis in Appendix 2. To identify proteins associated with proliferation, all 
proteins classified as relating to the cell cycle, mitogens, or cell proliferation 
were grouped together (Appendix 2). Finally, to identify proteins that play a 
role in invasion, proteins relating to cell motility and vasculature 
development were compiled and are presented in Appendix 2.  
 
Figure 7.  Diagram illustrating proposed activated stellate cell functions.  The 
number of proteins identified within a function is given in parentheses.  Proteins selected 
for validation are listed below the function. 
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2.5 DISCUSSION 
The crucial role of PSC activation in the pathobiology of PDAC has only 
recently begun to be appreciated.  PSCs potentiate pancreatic tumors 
implanted in vivo21,88, and conditioned media from activated PSCs enhances 
proliferation and invasion of PCCs in vitro89,90.  These observations support 
the hypothesis that PSCs secrete soluble factors that promote tumor 
progression.  Therefore, this first characterization of the secretome from 
activated PSCs could provide insight into mechanisms of tumor progression.  
While PSCs secrete few proteins in the quiescent state, activation results in a 
rich and complex mixture of secreted proteins.  It is likely that the secretome 
of immortalized PSCs differ in some ways from freshly isolated PSCs.  A 
comparison of gene expression profiles demonstrated few differences 
following immortalization, involving extracellular matrix proteins, integrins, 
intermediate filament proteins and cytokines21.  In our study the protein 
MMP2, which has previously been described as expressed at low levels in the 
quiescent PSC,22 was not identified in the quiescent RLT-PSC secretome.  A 
number of factors are likely at play, such as differences resulting from 
immortalization and across species.  Most importantly, previous studies have 
used cell lines which are only transiently quiescent, whereas the RLT-PSC cell 
line can be stably maintained in a quiescent state indefinitely.  It is possible 
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that the low level of MMP2 expression previously observed reflects low level 
PSC activation.  
It is likely that the proteins secreted by activated PSCs are dependent upon 
the activating stimulus.  Future studies could examine proteins secreted by 
PSCs activated in response to other stimuli, such as PDAC cells, to study 
these differences.  Interestingly, many proteins secreted by activated PSCs 
are also secreted by the cancer cell lines studied.  Approximately 60% of the 
proteins identified in the activated PSC secretome and one half to three-
quarters of the cancer cell line secretomes were found common to both cell 
types (Figure 3). 
Many proteins secreted by activated PSCs play important roles in 
proliferation, invasion, inflammation and fibrosis, pathways important for the 
proposed role of PSCs in supporting tumor growth and metastasis. The 
potential roles of individual proteins present within the identified PSC 
secretome are discussed below. 
2.5.1 Wound healing 
Wound healing is a primary function of PSCs. It has been hypothesized that 
cancer cells exploit this PSC function to support tumor growth. Thus, 21 
proteins associated with wound healing were identified, including PLAU and 
SERPINE1. SERPINE1 inhibits tissue plasminogen activator (tPA) and 
urokinase (uPA), the activators of PLAU, a key enzyme in fibrinolysis. High 
levels of SERPINE1 have been correlated with a poor outcome in PDAC91. 
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Expression of PLAU and SERPINE1 have been previously reported in 
desmoplastic regions of PDAC tissue92-95. 
2.5.2 Inflammation 
Some 33 proteins associated with inflammation were identified.  
Inflammation is one of the primary activators of PSCs in the pancreas.  
Chronic pancreatitis, a condition of prolonged inflammation, is one of the risk 
factors for PDAC.  Inflammatory processes are thought to potentiate PDAC 
through classical mechanisms, such as oxidative-stress induced DNA 
damage.  Another recently proposed mechanism implicates recruitment of 
immunosuppressive cells as a key pathway for evasion of immune 
surveillance early in pancreatic carcinogenesis96.  Our findings support the 
hypothesis that PSCs play a role in perpetuating a state of inflammation in 
the tumor microenvironment. 
2.5.3 Proliferation 
Accumulating evidence supports the presence of factors secreted by 
activated PSCs that enhance cancer cell proliferation.  Among the 68 
secreted PSC proteins involved in proliferation, NME1 and UCHL1 expression 
was verified in the current study. NME1, a nucleoside diphosphate kinase, 
was observed at higher levels in cervical, thyroid97,98, and metastatic ovarian 
tumors99, suggesting a role in enhancing cancer cell proliferation.  
UCHL1 is an enzyme whose function varies with dimerization and post-
translational modifications100.  In some cancers, the gene for UCHL1 is 
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methylated, and restoration of UCHL1 expression inhibited proliferation in 
hepatocellular carcinoma101.  Other studies have shown that UCHL1 is 
upregulated in lung cancer, invasive colorectal cancer, and PDAC102-104.  
2.5.4 Apoptosis 
Inhibition of apoptosis is a key mechanism in tumor growth.  Some 49 
proteins associated with apoptosis were identified, including NME1.  NME1 
has shown the ability to limit the expression of the apoptotic protein Bcl-2105.  
Thus, in addition to promoting PCC proliferation, NME1 may support PDAC 
progression through inhibition of apoptosis. 
2.5.5 Fibrosis and invasion 
Activated PSCs are known to secrete ECM proteins such as collagens I, III, 
and IV, and fibronectin10,11.  This matrix then serves to promote cell proliferation 
and migration to heal wounded areas.  Chronic activation, as seen in chronic 
pancreatitis or PDAC, results in the accumulation of fibrotic tissue.  PSCs are 
also known to produce factors that break down ECM, which may play a role 
in promoting invasion.  Indeed, PDAC lymph node metastases were observed 
to contain stroma and PSCs (Figure 8).  In addition, 24 ECM proteins and 
proteases and 40 proteins associated with cell motility and vasculature 
development were identified. 
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Figure 8. IHC staining of PDAC lymph node metastasis.  PSCs are visualized by the 
expression of markers -SMA (A) and vimentin (B) and the absence of CD31(C).  
Positive staining is in brown. 
ANXA2, a phospholipid binding protein, is believed to play a role in 
angiogenesis, invasion, and metastasis, and its expression has been best 
described in colon cancer106,107, ANXA2 has also been reported to serve as a 
receptor for plasminogen108 and as such may play a role in the plasminogen 
activator pathway The urokinase plasminogen activator pathway is believed 
to play a role in cancer cell invasion in the pancreas92,94 and includes the 
proteins MMP2 and SERPINE1, along with PLAU. SERPINI2 is a protein 
specific to the pancreas and to breast cancer stroma109,110.  The function of 
SERPINI2 is poorly understood, however its sequence identifies it as a serine 
protease inhibitor in the same family as SERPINE1, suggesting a role in the 
plasminogen activator pathway, as well.  LGALS3BP, a protein expressed in 
advanced gastric cancer111, binds the receptor galectin-3, a protein highly 
expressed in PDAC metastases112.  LGALS3BP modulates cell-integrin 
interactions to either promote or inhibit cell attachment113.  NME1 has been 
implicated as a suppressor of tumor metastasis in melanoma and breast 
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cancer114,115.  In vitro studies have shown that NME1 suppresses tumor 
metastatic potential and negatively regulates cell migration, possibly via 
regulation of integrin expression or trafficking116-118.  TGFBI is a secreted 
RGD-containing protein and has anti-adhesive properties119,120.  TGFBI is 
upregulated in renal cell carcinoma and esophageal adenocarcinoma121,122, 
and has been reported to inhibit cell attachment in vitro119. 
Finally, UCHL1 and EZR are believed to enhance invasion. UCHL1 is thought 
to modify cell morphology through modulation of the Akt-signaling 
pathway123.  EZR is a mediator of cell-integrin interactions and high 
expression of EZR has been associated with prostate and pancreatic cancer 
progression124,125.  By organizing the interaction between the cytoskeleton 
and the cell membrane EZR regulates cell adhesion, migration and 
invasion126.  Furthermore, EZR has been found to be essential to the 
metastatic potential of some cell lines127,128.  Taken together, our results 
demonstrate PSCs are an important source of proteins that regulate ECM 
remodeling, cell motility and invasion. 
The proteins discussed here are a sampling of the many secreted proteins 
identified from the activated PSC secretome.  It is clear that the PSC 
secretome is an important source of proteins that regulate proliferation, 
inflammation, and ECM remodeling as well as cell motility and invasion.  
Characterization of the activated PSC secretome is an important first step in 
elucidating the complex role of PSCs in PDAC progression. These results lay 
the foundation for future studies, for example, characterizing the proteins 
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involved in paracrine signaling with PDAC cells.  Further studies would 
determine whether secreted PSC proteins identified here can serve as 
biomarkers of PDAC progression or potential new therapeutic targets. 
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3 Chapter 3 – Development of an LC-MS method for the relative 
quantitation of potential biomarker proteins 
For submission as: 
Wehr AY, Blair IA, Yu KH. Relative quantitation of serum pancreatic cancer 
biomarker proteins by stable isotope dilution liquid chromatography-mass 
spectrometry. JPR 2011  
3.1 Abstract 
An innovative multiplexed LC-MRM/MS-based assay for rapidly measuring a 
large number of disease specific protein biomarkers in human serum has 
been developed.  This approach is based on stable isotope dilution 
methodology in order to reliably quantitate candidate protein biomarkers.  
Human serum was diluted using a SILAP standard prepared from the 
secretome of pancreatic cell lines, subjected to immunoaffinity removal of 
the most highly abundant proteins, trypsin digested, and analyzed by LC-
MRM/MS.  The method was found to be precise, linear, and specific for 
relative quantitation of 72 proteins when analyte response was normalized to 
the relevant internal standard (IS) from the SILAP.  The method made it 
possible to determine statistically different concentrations for 3 proteins in 
control and PDAC patient samples. This method proves the feasibility of using 
SILAP dilution with MRM analysis of tryptic peptides as a means to compare 
changes in the concentration of candidate protein biomarkers in human 
serum. 
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3.2 Introduction 
Many methods have been developed to characterize differential proteomes, 
resulting in vast lists of candidate biomarker proteins which await 
quantitation in human samples for validation48-55.  ELISA is the most common 
method used for the quantitation of proteins in serum due to its high 
sensitivity and specificity.  However, this method becomes expensive and 
labor intensive when applied to a large number of proteins and samples.  
Furthermore, high quality monoclonal antibodies are not available for the 
vast majority of candidate biomarkers identified.  As a result, most 
biomarker validation studies are limited to single or several proteins56-59.  
Stable isotope dilution with detection by MS has been the mainstay of 
bioanalytical analyses for the past two decades69-71, due to both the 
specificity and sensitivity with which this methodology can measure the 
concentration of small molecules.  With developments in MS technology, such 
an approach has provided the speed and sensitivity to allow for detection of 
low abundance proteins in serum72,73. 
Compared with small molecule LC-MS, the analysis of proteins has some 
specific challenges.  Intact proteins can be difficult to separate on traditional 
LC columns, especially those designed to work at the decreased flow rates 
required to achieve high sensitivity microflow electrospray.  However, the 
peptides that result from tryptic digestion behave much more like small 
molecules and are easier to separate by RP LC with MS-compatible mobile 
phases.  Tryptic peptides terminating in lysine and arginine are also 
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amenable to multiple charging by ESI.  This makes it possible to generate 
products ions of a lower charge state and higher m/z than their 
corresponding precursor ions, which helps to minimize background noise, a 
key concern when working in a complex matrix like human serum. 
The protein load in human serum poses another concern.  The LC columns 
used with microflow ESI/MS are limited in the amount of protein that can be 
loaded onto the column.  The concentration range of proteins in human 
serum spans over 10 orders of magnitude74 and 99% of the protein by mass 
in serum is made up of 22 highly abundant proteins such as albumin and 
immunoglobulins75.  SISCAPA has been developed as a system to purify 
proteins of interest from the biological matrix76.  However, antibodies specific 
to each protein of interest must first be developed, and thus is limiting in a 
similar fashion to ELISA. Commercially available immunoaffinity columns can 
be used to remove these proteins from the serum, reducing the protein 
concentration and effectively increasing the loading capacity of the LC 
column77-79.  
The processes of digestion and immunoaffinity removal of abundant proteins 
are not without drawbacks and both have been associated with high 
variability which can confound studies intended to compare the concentration 
of an analyte across different samples83,129.  Dilution with a stable isotope 
labeled IS is commonly used in bioanalytical assays to correct for losses 
during sample preparation or variability in chromatographic separation or 
ionization72,80.  The Blair group has previously reported the use of SILAC as a 
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means to normalize proteomic profiling, a methodology that was termed 
SILAP50,73,81.  The current study represents a novel implementation of SILAP 
for the relative quantitation of a panel of potential serum protein biomarkers.  
Stable isotope labeled secreted proteins from human pancreatic cell lines in 
culture were used as the SILAP standard.  The development and validation of 
a quantitative method, using relevant IS from the SILAP to normalize the 
analyte response in human serum has now been completed. 
3.3 Experimental Procedures 
3.3.1 Cell culture 
The human PDAC cell lines MiaPaCa-2 and CAPAN-2, and the immortalized 
human PSC line RLT-PSC82 were cultured according to standard practice 
using DMEM (Sigma, St. Louis, MO) supplemented with 10 % fetal bovine 
serum (Sigma) and 1 % antibiotic (penicillin/streptomycin, Invitrogen, Grand 
Island, NY). SILAC labeling was achieved using leucine and lysine free DMEM 
supplemented with 13C,15N-labeled leucine and lysine (Cambridge Isotopes, 
Andover, MA), 10 % dialyzed fetal bovine serum (Sigma), and 1% antibiotic 
(penicillin/streptomycin, Invitrogen).  Cells were passaged a minimum of 7 
times to achieve amino acid labeling exceeding 99 %.  Secreted proteins 
were harvested by allowing cells to grow to 80 % confluence, washing with 
phosphate buffered saline (Invitrogen), and incubating the cells with serum-
free SILAC media at 37 °C for 48 h. This media was collected, passed 
through a 0.22 µm filter, and stored at -80 °C. 
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3.3.2 Immunoaffinity removal of abundant proteins 
Human serum was first diluted with SILAP internal standard prior to 
processing with either the IgY-14 LC2 column (Seppro®, Sigma) alone, or in 
tandem with the SuperMix column (Seppro®, Sigma), according to 
manufacturer instructions.  Briefly, the serum and internal standard mixture 
was diluted 1:4 with dilution buffer (Seppro®, Sigma) centrifuged through a 
0.45 m filter, then injected onto the immunoaffinity column(s).  Dilution 
buffer was used to elute the flowthrough, or low-abundance, fraction which 
was monitored at 280nm, collected, and stored on ice.  The bound, or high-
abundance, fraction was eluted with stripping buffer (Seppro®, Sigma), 
collected, and stored on ice.  The columns were regenerated with 
neutralization buffer (Seppro®, Sigma).  The protein was then concentrated 
using 3 kDa molecular weight cutoff spin-filters (Millipore, Billerica, MA), and 
precipitated using methanol-chloroform extraction. 
3.3.3 Tryptic digestion 
The precipitated protein mixture was dissolved in 10 % 6 M urea, 2 M 
thiourea in 25 mM ammonium bicarbonate, reduced in 5 mM dithiothreitol for 
45 min at 60°C, alkylated in 15 mM iodoacetamide for 30 min at room 
temperature in the dark, and digested using sequencing grade trypsin 
(Promega, Madison, WI) at a ratio of 1:20 by weight at 37 °C overnight. 
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3.3.4 LC-MS/MS analysis 
Peptides were acidified to 0.1 % formic acid and desalted with disposable 
C18 spin filters (Nest Group, Southborough, MA).  Peptides were separated 
by reversed phase chromatography using a C18 column (0.3 x 150 mm, 3 
µm, 200 Å C18AQ, Michrom Bioresources, Auburn, CA) on a microflow HPLC 
system (Eksigent, Dublin, CA).  After a 5 min isocratic hold at 95 % mobile 
phase A (2 % acetonitrile, 0.1 % formic acid), a linear gradient increasing 
mobile phase B (95 % acetonitrile, 0.1 % formic acid) from 5 to 60 % over 
55 min at a flow rate of 5 µl/min was used to elute peptides online to a triple 
quadrupole mass spectrometer (Vantage, ThermoFisher, San Jose, CA) with 
positive ESI and MRM.  Raw files were imported to Skyline 130,131 and 
integration was manually verified by retention time of all six transitions per 
peptide. 
3.3.5 Sample Analysis 
Human serum samples were collected in accordance with an IRB approved 
protocol.  Samples were matched for age, race, and gender.  Samples were 
classified as PDAC if the patient was determined to have cytopathological or 
surgical pathological confirmation of pancreatic adenocarcinoma as 
performed by gastrointestinal pathologists as the Hospital of the University of 
Pennsylvania.  With the exception of one patient, whose tumor was removed 
4 months prior to blood collection, control samples were taken from patients 
with a distant history of solid tumor malignancy deemed cured based upon 
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greater than five year interval free of disease based on CT scans.  
Furthermore, greater than 2 year follow up with CT scans following collection 
of blood sample confirmed no measurable recurrence of disease.  Samples 
were analyzed in batches, each batch contained a mixture of PDAC and 
control samples.  Samples were assigned a unique identifier to blind the 
analyst during processing.  Statistical analysis was conducted using Prism 5 
(GraphPad Software, Inc., La Jolla, CA).  A two-tailed, unpaired t-test with 
Welch’s correction for unequal variances, and a confidence interval of 95% 
was used to determine statistical significance. 
3.4 Results  
3.4.1 Transition List Development 
Peptide sequences were selected from a spectral library generated in 
house50,132.  The peptide list was filtered to remove those redundant to more 
than one protein, lacking lysine and leucine, singly charged, possessing an 
Xcorr score less than 2, or a precursor m/z below 450 or above 1900.  The 
spectral library was then used to generate a transition list for a selected 
number of filtered peptides.  Three transitions were selected per peptide 
using the 3 most intense y-ions with m/z greater than the precursor m/z.  
Based on this list of transitions, an IS transition list was created using the 
calculated mass of each peptide assuming 13C,15N labeling of all lysines and 
leucines.  The final transition list is provided in Appendix 3. 
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3.4.2 Scheduling Development 
The IS transition list was split into smaller lists, each composed of no more 
than 90 transitions.  Each list was then used to analyze the IS, monitoring all 
transitions for the duration of the chromatographic run.  Using a dwell time 
of 10 ms, the cycle time was maintained under 1 sec.  SkyLine software was 
then used to identify the correct peak and retention time for each peptide 
based on the co-elution of all three transitions as well as predicted elution 
time.  SkyLine software was then used to generate a scheduled method, 
encompassing the entire list of transitions, both analyte and IS, using a 4 
min window for each peptide.  A four min window provided a maximal 
overlap of 180 transitions, corresponding to a cycle time of 1.8 sec (Figure 
9A).  Analysis of the effect of dwell time on peak area revealed that no 
further gain is achieved beyond a dwell time of 20 ms, yet the dwell time can 
be reduced to 10 ms without significant loss of signal (Figure 9B).  At a dwell 
time of 10 ms, no difference in peak area was seen when varying the number 
of points across the peak from 10 to 50 (Figure 9C).  Thus a scheduled 
method utilizing a dwell time of 10ms and 10 points per peak, as provided by 
the scheduled method resulting in a 1.8 sec cycle time with a 
chromatographic method producing 18 sec wide peaks, was deemed 
acceptable. 
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Figure 9. Transition list development of window size, dwell time and points per 
peak. 
3.4.3 Depletion Development 
Two immunoaffinity methods were compared for removal of abundant 
proteins, both based on the Seppro system.  The IgY-14 LC column alone, 
designed to remove the 14 HAP present in human plasma, was compared 
with the IgY-14 LC column used in tandem with the SuperMix LC column, 
designed to remove a large subset of moderately abundant proteins (MAP) 
present in human plasma.  To test the ability of the immunoaffinity 
column(s) to selectively remove only the highly and moderately abundant 
proteins from serum, the enzyme MMP2 was used as a surrogate.  MMP2 was 
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added to human serum and processed by each LC removal method.  MMP2 
was only detected in the unbound flowthrough fraction of each method as 
demonstrated by both western blot and LC-MRM/MS analysis (Figure 10).  
MMP2 was not detected by LC-MRM/MS in the any of the bound, high 
abundance fractions.  Although some interference is observed in the 
chromatogram of peptide VDA when using the IgY-14 column alone, this 
method was chosen for subsequent analyses.   
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Figure 10. MMP2 is only detected in the unbound fraction following 
immunoaffinity depletion as evidences by western blot and mass spectrometry.  
(A) Western blot of MMP2 in human serum.  Lanes 1 and 2 display the unbound and 
bound fractions, respectively derived from the LC IgY-14 column alone. Lanes 3, 4, and 
5 contain the unbound, IgY-14 bound, and SuperMix bound fractions from the tandem 
LC. 
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Based on the results of the development, a final workflow (Figure 11) was 
adopted.  Elements of the process were validated with respect to precision, 
linearity, sensitivity, and specificity. 
 
Figure 11. The final workflow consisted of dilution of the serum sample with 
SILAP standard, followed by depletion of highly abundant proteins, trypsin 
digestion, and LC-MRM/MS analysis. 
3.4.4 LC-MS validation 
A tryptic digest of both light and heavy proteins derived from the cell culture 
secreted proteome was analyzed by LC-MRM/MS in triplicate.  The precision 
of the peak area response was plotted as a function of several factors 
including retention time, peak area, peak width, and precursor m/z.  Peak 
area and precursor m/z had the most striking effects (Figure 12).  When 
precision was plotted as a function of peak area it became clear that below a 
peak area of 10,000, the percent relative standard deviation (%RSD) was 
consistently above 15%.  Similarly, when plotting precision as a function of 
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parent m/z, the % RSD was above 15 % for parent m/z below 500, and with 
the exception of one analyte, below 15 % when the precursor m/z was above 
600.  These data were used to drive the selection of peptides for further 
analysis.   
 
Figure 12. LC-MS precision, linearity, and sensitivity. The impact of peak area (A) 
and precursor m/z (B) on precision are demonstrated.  The response is linear over the 
range 10 to 100 fmol protein(C) and both peptides are easily detected at 10 fmol by LC-
MRM/MS (D). 
The linearity of the response was assessed by preparing a tryptic digest of 
MMP2, which was then diluted over a range of 2 to 100 fmol and spiked with 
digested SILAP internal standard.  The peptide response is measureable at 
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10 fmol and the response is linear over the range of 10 to 100 fmol (Figure 
12).   
3.4.5 Digestion validation 
The SILAP internal standard was spiked into a light protein sample, derived 
from the cell culture secreted proteome, to test the precision of the trypsin 
digestion.  From this pool, 5 replicates were trypsin digested and analyzed by 
LC-MRM/MS.  Using analyte peak area alone, the %RSD was less than 20% 
for all proteins.  When normalized using the IS peak area, the %RSD of the 
analysis was below 15% for all proteins (Figure 13) which conforms to 
commonly observed acceptance criteria for bioanalytical methods.  Linearity 
of the digestion was tested by spiking a fixed amount of the SILAP standard 
into increasing amounts of MMP2 in the range 10 to 250 fmol.  Samples were 
then trypsin digested and analyzed by LC-MRM/MS.  The response was found 
to be linear across the range of 10 to 250 fmol (Figure 13).  Replicate 
analysis at the lower limit of quantitation (LLOQ) of 10 fmol resulted in a % 
RSD less than 20 % for both peptides which conforms to bioanalytical 
acceptance criteria.   
 
0
0.5
1
1.5
2
0 100 200 300
P
e
a
k
 A
re
a
 R
a
ti
o
fmol protein
0%
20%
40%
60%
80%
100%
%
R
S
D
Protein
Peak Area
Area Ratio
A B C
Time (min)
0
7.38E3
0
1.51E3
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
0
4.42E3
0
2.03E3
VDA
VDA IS
AFQ
AFQ IS
25 26 27 28 29 30 31 32 33
100
100
100
100
519 → 681,752,823
524 → 691,762,833
710 → 385,
974,1073
715 → 395,
984,1080
59 
 
Figure 13. Digestion precision, linearity, and sensitivity. The precision of digestion is 
improved when normalized to the internal standard response (A).  The response after 
digestion remains linear over the range of 10 to 250 fmol (B). And both peptides remain 
easily detected at 10 fmol by LC-MRM/MS (C). 
3.4.6 Validation of immunoaffinity removal of abundant proteins 
Five replicates of serum mixed with SILAP internal standard were processed 
by LC immunoaffinity removal of the HAP (IgY-14), trypsin digested, and 
analyzed by LC/MS.  The precision of the peak areas and peak area ratios for 
26 endogenous proteins present in the serum is plotted in Figure 14A.  The 
precision of the analyte area alone is unacceptable for many proteins, with 
%RSD over 20%.  However, when the peak areas are normalized to the 
internal standard, the %RSD of the ratio is below 20% for all proteins.  
Linearity of the analysis was determined by spiking SILAP internal standard 
into a 10 – 60 L serum curve.  The curve was then processed by LC 
immunoaffinity removal of the HAP (IgY-14), trypsin digested, and analyzed 
by LC-MS.  The area ratio response for one protein is given as an example 
(Figure 14B).  The curves for all proteins were linear with R squared values 
all above 0.8.  To determine the specificity of the analyte response, the 
response of the endogenous protein in serum was compared to the response 
in the SILAP internal standard.  Similarly, the specificity of the IS response  
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was determined by comparing the response of the heavy protein in the IS to 
the response in blank serum lacking IS.  Representative chromatograms are 
given in Figures 14C and 14D.  The IS does not interfere with the analyte 
signal, nor does the blank serum possess any compounds interfering with the 
IS.  This finding was consistent for all proteins.  The interference, if any, is 
less than 20% for all proteins.   
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Figure 14. Depletion precision, linearity, and specificity.  The precision of depletion 
is dramatically improved when normalized to the internal standard response (A).  The 
response after depletion is linear over the range of 10 to 60 mL serum (B). To test the 
specificity of the response, blank serum lacking internal standard (top chromatograms), 
and the SILAP internal standard lacking serum (bottom chromatograms), were 
independently analyzed. The results for insulin-like growth factor binding protein 7 are 
shown as an example.  The specificity of the analyte response is demonstrated by the 
lack of response in the analyte channel of an LC-MRM/MS chromatogram from the 
internal standard sample (C).  Similarly, the specificity of the internal standard response 
is demonstrated by the lack of response in the internal standard channel in the LC-
MRM/MS chromatogram from the blank serum sample (D). 
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3.4.7 Sample Analysis 
Prior to the start of any LC-MRM/MS sample analysis, a test injection was 
used to verify peptide retention times.  During the test injection, 10 peptides 
were monitored for the duration of the LC gradient.  Any retention time shifts 
seen in these peptides were used to correct the MRM windows for all other 
peptides.  The method was used to quantitate 72 proteins in 40 serum 
samples, 20 samples taken from patients with PDAC, and 20 samples taken 
from control patients.  Comparison of the scatter plots as prepared from the 
analyte peak area alone versus the peak area ratio after normalization with 
the SILAP IS, revealed tighter clustering than observed without 
normalization(Figure 15). A t-test was used to look for differences in the two 
cohorts.  Statistical analysis was also improved when using normalized data.  
The difference in the average response of 3 proteins was discernable when 
using the normalized response (Table 5).  Cystatin M, IGF binding protein 7, 
and villin 2 were all significantly lower in the PDAC patients, with p values < 
0.04 when compared with relevant control subjects. 
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Figure 15. Scatter plots of cystatin M, IGF binding protein 7, and villin 2.  Statistical 
analysis of the peak area ratios using a t-test revealed differences between cancer 
(PDAC) and control patients when response was normalized to the internal standard (top 
row) but not when comparing analyte area alone (bottom row). 
Table 5. Statistical analysis of cystatin M, IGF binding protein 7, and villin 2 
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Cystatin M Peak area 17190 ± 2498 19680 ± 2292 -2487 ± 3390 -9360 to 4386 0.01433 0.4679
Area ratio 0.124 ± 0.0102 0.186 ± 0.0156 -0.0620 ± 0.0187 -0.100 to -0.0240 0.2562 0.0023
IGF binding Peak area 32110 ± 3565 26670 ± 3871 5440 ± 5263 -5230 to 16110 0.02806 0.308
protein 7 Area ratio 0.0762 ± 0.00365 0.106 ± 0.0126 -0.0303 ± 0.0131 -0.0574 to -0.00308 0.1951 0.0307
Villin2 Peak area 7164 ± 912.1 10800 ± 1393 -3635 ± 1665 -7027 to -242.2 0.1297 0.0365
Area ratio 0.243 ± 0.0173 0.347 ± 0.0317 -0.104 ± 0.0361 -0.178 to -0.0302 0.2226 0.0074
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3.5 Discussion 
A method for the relative quantitation of 72 endogenous proteins in human 
serum has been developed.  The method was validated with respect to 
precision, linearity, and specificity. 
3.5.1 Development 
Development studies resulted in a workflow consisting of depletion, 
digestion, chromatographic separation and stable isotope dilution LC-
MRM/MS analysis.  Certain elements of this approach to the development 
enhanced chances for success.  First, a spectral library developed in house 
for the derivation of our transition list.  All of the peptides we sought to 
monitor had previously been identified by LC-MS in our laboratory. This 
approach made it possible to pursue peptides known to endure the processes 
of digestion, chromatographic separation, and ionization well, which may 
have conferred an advantage during the validation of these processes.  
Second, three MRM/MS transitions were monitored per isotopic peptide.  
Comparison of quantitation using either the single best transition, or the sum 
of all three, gave comparable results with respect to precision, linearity, and 
specificity (results not shown).  However, the use of six transitions per 
peptide (three for the labeled, three for unlabeled), enabled the accurate 
identification of chromatographic retention time.  This step was critical to 
MRM/MS window scheduling, and peak integration.  Scheduling reduced the 
number of concurrent transitions enabling a shorter cycle time and thus a 
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sufficient number of points per peak for proper peak integration.  Finally, we 
chose to use our SILAP standard to refine the transition list prior to analysis 
of analytes.  This enabled us to ensure that each analyte would possess a 
solidly performing IS. 
A limitation in the development of the depletion method was the lack of 
authentic proteins standards.  We selected MMP2 as surrogate for all other 
proteins of interest based on its presence in the SILAP internal standard, as 
well as its enzymatic activity and the availability of sensitive and specific 
antibodies.  By selecting an enzymatically active protein, the chances of 
acquiring a recombinant protein with the correct primary sequence and 
structure were enhanced.  The commercially available recombinant MMP2 
that we obtained was efficiently separated from the HAP and recovered from 
the unbound fraction during depletion.  However, it cannot be reasonably 
expected that all proteins selected for our analysis would behave analogously 
to MMP2.  The apparent MS response may be reduced by either loss of 
signal, or an excess of noise.  For example, a reduction in signal may occur if 
a protein were lost during depletion, due to either nonspecific binding to the 
column or association with highly or moderately abundant plasma 
proteins133,134.  Conversely, the apparent signal of some lower abundance 
proteins may benefit from the reduction in noise resulting from tandem 
depletion of the MAP and HAP.  Thus, a balance between analyte loss and 
background reduction has to be made, which can only properly be 
determined by analyzing each protein individually.  This analysis would be 
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excessively costly given the preliminary nature of the study.  Therefore a 
surrogate protein was used during development, in the anticipation that it 
would approximate the behavior of the average analyte.  
3.5.2 LC-MS validation 
When studying the sources of imprecision in the LC-MS analysis, the 
determination that retention time had little effect on precision could be 
expected due to the well crafted scheduled method developed with dwell 
time and cycle time in mind.  The poor precision below 10,000 area counts 
can be expected as well since low intensity analytes often suffer from poor 
precision.  These data established 10,000 area counts as the lower limit of 
detection for the Thermo Vantage triple quadrupole mass spectrometer.  
However, the observation that precision was improved above precursor m/z 
600 was somewhat surprising and may reflect either the performance of our 
instrument or the impact of background noise as fewer small molecules 
might interfere at this elevated m/z.  Overall, the LC-MS analysis performed 
well with respect to precision and linearity.  While the establishment of a 
linear range of only one order of magnitude might seem small, it was 
expected that the concentration of endogenous proteins would vary by far 
less than this amount and so the range was suitable for our application. 
3.5.3 Digestion validation 
The reproducibility and linearity of the digestion was unexpectedly good.  
Trypsin digestion can vary in the degree of completion, confounding the use 
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of peptide internal standards 129.  Normalization using the intact protein 
SILAP internal standard clearly improved the precision and is responsible for 
bringing the analysis into conformance with the commonly accepted criteria 
of %RSD less than 15%.  However, even without normalization, the digestion 
was remarkably reproducible.  This may be due to use of the spectral library 
in forming the peptide list, as only stable and easily digested proteins were 
included in the library. 
3.5.4 Depletion validation 
Validation of the depletion method was anticipated to be the most 
problematic and drove home the importance of the SILAP internal standard.  
Without normalization, the precision of the analyte area is unacceptable for 
many proteins.  However, this is corrected when normalized to the internal 
standard.  This can be attributed to the ability of the intact protein SILAP 
internal standard to mimic the endogenous analyte.  Since the proteins in the 
SILAP standard are all native proteins produced in nontransduced  human 
cells, they all possess the correct primary sequence and are properly folded 
and post-translationally modified, enabling them to properly track each 
analyte during depletion and digestion, a feat not possible with recombinant 
or synthetic proteins or peptides.  Again, the linear range as determined by 
this analysis is small, spanning less than an order of magnitude.  However, 
we expect endogenous protein levels to vary by less than 4-fold, so this 
range was considered to be suitable for our analyses. 
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The specificity of the analysis was excellent and most likely due to the use of 
precursor ions with m/z above 600 and product ions with m/z greater than 
the relevant precursor ion.  It is important to note the importance of 
ensuring the purity of the SILAP standard.  If the cells are not passaged 
sufficiently in the heavy media, contamination with unlabeled protein could 
lead to high background in the analyte channel, reducing the ability to detect 
changes in abundance. 
A limitation of this study has been the lack of protein standards with known 
concentrations, preventing the assessment of accuracy and a definitive lower 
limit of quantitation.  However, by studying the endogenous proteins present 
in our serum, we were able to determine the precision, linearity, and 
specificity of the method, which is sufficient for the relative quantitation of 
proteins necessary to evaluate potential biomarkers. 
3.5.5 Sample Analysis 
The method performed well for the duration of sample analysis.  Of the 72 
proteins quantitated in 40 serum samples, 3 showed a significant difference 
in average response when comparing PDAC and control samples.  The 
simultaneous analysis of 72 proteins enabled us to quickly evaluate our list of 
potential biomarkers to identify those appropriate for further analysis.  The 
method is sufficiently fast and inexpensive to permit the analysis of many 
proteins, while retaining the rigor required to achieve statistical significance. 
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3.6  Conclusion 
This method proves the feasibility of using stable isotope dilution LC-MRM/MS 
analysis of tryptic peptides as a means to compare difference in the 
concentration of endogenous proteins in human serum for the selection of 
potential biomarkers for further validation.  Moreover, the thorough 
investigation of the method illustrates the power of the SILAP standard to 
enhance method performance.  A major limitation in the use of stable isotope 
labeled tryptic peptides ISs or AQUA peptides135,136 is that they are not 
affected by differences in extraction and digestion efficiency in the same way 
as the intact proteins.  This can lead to inaccurate quantitation even though 
excellent standard curves can be generated from the unlabeled peptides.  
Our method could easily be expanded to cover a larger set of proteins or 
validated for the absolute quantitation of multiple proteins simply through 
the addition of a standard curve derived from an authentic protein standard.  
This precise, linear, and specific method could have far reaching implications 
in the study of many human disease biomarkers. 
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4 Chapter 4 - Identification of a panel of protein biomarkers for 
the detection of pancreatic cancer in serum 
For submission as: 
Wehr AY, Hwang W, Blair IA, and Yu KH. Multiplexed serum biomarker 
analysis for the detection of pancreatic cancer in human serum. Cancer 
Epidemiology and Biomarkers, 2011 
4.1 Abstract 
Current biomarkers for the detection of pancreatic cancer lack the specificity 
and sensitivity needed for use as a screening diagnostic.  We used a targeted 
multiplexed LC-MS method to quantitate 72 proteins in human serum.  The 
method relies on a SILAP internal standard to normalize the response and 
correct for losses during sample preparation.  By comparing the response of 
these proteins in cancer serum (n=31) and control serum (n=20) samples 
we identified 15 differentially-secreted proteins:  anterior gradient 2 
homolog, cystatin C, cystatin M, heparan sulfate proteoglycan 2, IGF binding 
protein 7, kallikrein-related peptidase 10, lamin A/C, lipocalin 2, myosin, 
heavy polypeptide 9, non-muscle, SMT3A, profilin 1, S100 A6, transgelin 2, 
tropomyosin 3, and villin 2.  A receiver operating characteristics (ROC) curve 
based on this panel resulted in 95% sensitivity and 94% specificity in the 
ability to detect pancreatic cancer. 
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4.2 Introduction 
Pancreatic cancer is the 4th leading cause of cancer death in the United 
States even though it accounts for only 3% of new cancer diagnoses 1.  One 
reason for the high mortality rate is the late stage of progression at 
presentation due to the asymptomatic nature of early disease.  For the 
fortunate few who present with early stage disease, resection via the Whipple 
procedure is a highly effective treatment137,138.  Thus, a screening test for 
pancreatic cancer could dramatically impact the way that this devastating 
disease is treated. 
Endoscopic procedures are expensive, carry significant risk of complications 
and have shown only limited success 26,27.  Proteomic analysis of pancreatic 
cyst fluid has identified potential biomarkers, but again relies on invasive 
testing that is not feasible for general screening28.  A method to detect a 
biomarker or panel of biomarkers in the serum would provide a minimally 
invasive technique that could be easily applied to the population. 
The carbohydrate CA19-9 is the only serum biomarker currently used for 
PDAC and lacks sufficient sensitivity and specificity for screening24,25.  As 
such it is currently used as a marker of response to therapy29-31.  Some 
protein biomarkers that have been reported include MIC-1, PAM4, OPN, 
HSP27, TPS, TSGF, CAM17.1, PF4, CEACAM1, annexin A8, Claudin 18, 
lactose binding protein, and plectin-1, yet all lack the necessary levels of 
sensitivity and specificity26,38-42.  Panel testing has been conducted as well on 
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up to four potential markers, but will little to no improvement in the 
specificity and sensitivity38. 
The Blair laboratory has previously identified over 1000 proteins secreted by 
pancreatic cancer and stromal cell lines50,132.  By using a mixture of cell types 
that constitute the tumor microenvironment, it was possible to identify a 
comprehensive set of candidate biomarkers with the potential to seep into 
the blood.  This set of candidate biomarkers was used to direct the 
development of a targeted method for their relative quantitation in human 
serum.  Subsequently, an LC-MRM/MS method capable of monitoring up to 
100 proteins simultaneously was developed (Chapter 3).  The method relies 
on a SILAP internal standard to track each protein through the process of 
depletion, digestion, chromatographic separation, ionization, and MRM 
analysis.  We used this method to test the ability of a set of candidate 
biomarkers to discern pancreatic cancer from control in a training set of 
serum samples.  By using a significantly larger panel of biomarkers in a large 
training set of human serum samples, as afforded by this unique LC-MRM/MS 
method, it was possible to identify a panel of biomarkers possessing a level 
of specificity and sensitivity previously unreported for this disease.  Analysis 
of 72 candidate biomarker proteins in PDAC serum and control serum 
samples has been conducted. 
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4.3 Materials and Methods 
4.3.1 Sample collection 
Human serum samples were collected in accordance with an IRB approved 
protocol.  Samples were matched for age, race, and gender.  Samples were 
classified as PDAC if the patient was determined to have cytopathological or 
surgical pathological confirmation of pancreatic adenocarcinoma as 
performed by gastrointestinal pathologists as the Hospital of the University of 
Pennsylvania.  With the exception of one patient, whose tumor was removed 
4 months prior to blood collection, control samples were taken from patients 
with a distant history of solid tumor malignancy deemed cured based upon 
greater than five year interval free of disease based on computerized axial 
tomography (CT) scans.  Furthermore, greater than 2 year follow up with CT 
scans following collection of blood sample confirmed no measurable 
recurrence of disease.   
Whole blood samples were collected preoperatively in glass tubes without 
additive (10 mL BD Vacutainer™ No Additive, BD, Franklin Lakes, NJ) and 
allowed to clot at room temperature for 40 min.  Serum was separated by 
centrifugation at 1500 rpm for 15 min.  1 mL aliquots of serum were taken 
and stored at -80 °C until ready for use.  The time from collection to frozen 
storage was no more than 60 min. Relevant clinical information was collected 
and linked to individual serum samples.  The study was conducted as part of 
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a protocol approved by the Institutional Review Board of the University of 
Pennsylvania. 
4.3.2 Internal Standard 
The SILAP internal standard was prepared as described in Chapter 3.      
4.3.3 Sample analysis 
Samples were prepared as previously described in Chapter 3.  Briefly, 45 
microliters of serum was mixed with SILAP internal standard and dilution 
buffer (Seppro, Sigma).  The sample was depleted of the most highly 
abundant proteins using the IgY-14 LC column (Seppro, Sigma).  The 
depleted fraction was concentrated by molecular weight filtration through a 
3kDa filter (Millipore, Billerica, MA) and methanol/chloroform extraction.  The 
protein was redissolved in 6M urea/2M thiourea and 25mM ammonium 
bicarbonate, reduced with dithiothreitol, alkylated with iodoacetamide, and 
digested with trypsin.  The peptides were desalted using C18 spin columns, 
separated by reverse phase (0.3 x 150 mm, 3 µm, 200 Å C18AQ, Michrom 
Bioresources, Auburn, CA) on a microflow LC system (Eksigent, Dublin, CA), 
and analyzed by positive ESI with scheduled MRM on a triple quadrupole 
mass spectrometer (Vantage, ThermoFisher, San Jose, CA).  A list of 
transitions is provided in Appendix 3.  Raw files were imported to 
Skyline130,131 and integration was manually verified by retention time of all six 
transitions per peptide.  Samples were analyzed in a series of batches 
containing roughly 10 samples per batch.  Each batch contained a mixture of 
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cancer and control samples and samples were assigned a unique identifier to 
blind the analyst during analysis.   
4.3.4 Statistical analysis 
Descriptive statistics including mean, standard deviation for continuous 
variable and proportions for categorical variables were produced. To 
determine the univariate association between the proteins level and the 
PDAC case status, we used two-sample t-test with unequal variances using 
Satterthwaite's approximation139 . Proteins that were found to have a 
significant univariate association at 0.05 level were included in a 
multivariable logistics regression model where binary PDAC case status were 
modeled as the outcome variable. Only proteins that retained their 
significance in the adjusted model remained in the final model.  
Discrimination of the model was evaluated by the mean of area under the 
ROC curve (AUC)140. Calibration was assessed by Hosmer-Lemeshow 
goodness-of-fit χ2 statistics141.  A two-tailed P-value of less than 0.05 was 
considered statistically significant. All statistical calculations were performed 
using STATA software version 11 (College Station, TX) 
4.4 Results and Discussion 
4.4.1 Training set statistics 
The demographics of the patients used in this study are presented.  Serum 
samples collected from cancer patients and controls were analyzed for sex, 
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age, and diagnosis (Table 6).  Subjects were well matched for age.  The 
demographics are representative of the patients treated at the University of 
Pennsylvania. 
We have used a larger sample size for our training set than is seen in other 
reports.  By using larger sample groups, we have reduced the likelihood of 
false positive and negative results.  We have also taken care to reduce the 
possibility of bias in sample collection, handling, and analysis.  Our sample 
groups are well matched with respect to age and gender and samples were 
stored concomitantly.  Samples were analyzed in batches containing samples 
from both groups and samples were assigned unique identifiers to blind the 
analyst to the grouping.  The classification of the samples was not revealed 
until all data processing was complete. 
Table 6. Training set patient demographics. 
 
  
Healthy control Cancer
No. of patients 20 31
Sex
Male 11 19
Female 9 12
Age, mean (SD) 63 (10) 64 (14)
Clinical stage
1 n/a 0
2 n/a 8
3 n/a 8
4 n/a 13
No info n/a 2
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4.4.2 LC-MS analysis 
Of the 72 proteins monitored by LC-MRM, 52 were successfully measured in 
the training set.  20 proteins were removed from the analysis post-
acquisition due to erratic detection or signal below the limit of quantitation 
for all samples.  The internal standard response was sufficient for all 52 
proteins in the training set.  The retention time was adjusted for all analytes 
at the beginning of each batch based on a test injection.  The retention time 
did not shift by more than 0.7 minutes in a given run and shifted by less than 
1.5 minutes over the course of all analyses.  The peak area of each analyte 
was normalized to the respective internal standard peak area.  
It is important to note the impact of the SILAP internal standard which 
permitted us to correct for variability in sample preparation.  The SILAP 
method uses culture of human cells in stable isotopically labeled media to 
produce full length, properly folded and modified proteins that may be used 
as an internal standard when coupled to mass spectrometric detection.  Since 
the isotopically labeled protein is identical to the analyte in sequence and 
structure, it is able to track the analyte through the potentially variable 
procedures of depletion, digestion, separation, and ionization.  We have 
previously shown (Wehr JPR 2011) that this internal standard dramatically 
improves the precision of the method.  The enhanced precision of our 
analytical method likely reduced the variability of the responses, amplifying 
the ability of the biomarkers to discern the disease state. 
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4.4.3 Statistical analysis 
The mean ratios were compared using a two-tailed t-test with Welch’s 
correction.  Statistical analysis revealed 15 proteins with differential means in 
the two data sets (Table 7).  The individual scatter plots and ROC curves are 
provided for each of the 3 most predictive proteins (Figure 16).  Anterior 
gradient homolog 2 is the best predictor of PDAC with 87.1% sensitivity, 
54.6% specificity, and an AUC of 0.789.  However, the power of the test to 
detect PDAC is seen when combining multiple proteins into one analysis.  By 
combining the top 3 performing proteins, cystatin M, anterior gradient 2 
homolog, and transgelin 2, the ROC results in 87.1% sensitivity, 70.0% 
specificity and an AUC of 0.879 (Figure 17A).  By combining the results of all 
15 differential proteins, the ROC achieves 93.6% sensitivity, 95.0% 
specificity, and the AUC is increased to 0.968(Figure 17B).   
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Table 7. Statistical analysis of the 15 differential proteins. 
 
The AUC for a given model is the probability that the predicted value for the 
PDAC subject is greater than that for the control subject.  AUC takes values 
between 0 to 1, with a value of 1 representing perfect prediction and a value 
of 0.5 representing chance prediction. AUC value between 0.70 and 0.80 is 
acceptable and a value greater than 0.80 is excellent141.  While external 
validation and statistical internal validation have not yet been conducted, 
given the limited sample size, such analysis is not warranted given the 
preliminary nature of the current study. 
Protein Name
  PDAC Mean ± 
SEM
  Control Mean ± 
SEM
  Difference between 
means
  95% confidence 
interval   R squared   P value
anterior gradient 2 
homolog 0.124 ± 0.0160 0.342 ± 0.0813 -0.218 ± 0.0828 -0.389 to -0.0459 0.239 0.0154
cystatin C 2.34 ± 0.108 2.84 ± 0.197 -0.506 ± 0.225 -0.964 to -0.0481 0.137 0.0313
cystatin M 0.130 ± 0.00853 0.193 ± 0.0155 -0.0636 ± 0.0177 -0.0998 to -0.0275 0.294 0.0011
heparan sulfate 
proteoglycan 2 0.283 ± 0.0314 0.390 ± 0.0393 -0.107 ± 0.0502 -0.208 to -0.00557 0.0975 0.0391
insulin-like growth 
factor binding 
protein 7 0.0847 ± 0.00471 0.119 ± 0.00962 -0.0347 ± 0.0107 -0.0566 to -0.0128 0.266 0.003
kallikrein-related 
peptidase 10 0.110 ± 0.0167 0.0544 ± 0.0124 0.0559 ± 0.0208 0.0140 to 0.0978 0.128 0.0099
lamin A/C isoform 2 0.0604 ± 0.00446 0.0451 ± 0.00384 0.0153 ± 0.00589 0.00347 to 0.0272 0.121 0.0123
lipocalin 2 0.0334 ± 0.00363 0.0489 ± 0.00642 -0.0155 ± 0.00738 -0.0306 to -0.000487 0.122 0.0433
myosin, heavy 
polypeptide 9, non-
muscle 0.272 ± 0.0443 0.497 ± 0.0623 -0.225 ± 0.0764 -0.380 to -0.0699 0.185 0.0056
SMT3A 0.0235 ± 0.00142 0.0311 ± 0.00266 -0.00756 ± 0.00302 -0.0137 to -0.00141 0.169 0.0176
profilin 1 0.234 ± 0.0305 0.350 ± 0.0470 -0.116 ± 0.0561 -0.230 to -0.00231 0.106 0.0456
S100 calcium 
binding protein A6 0.152 ± 0.0131 0.226 ± 0.0328 -0.0739 ± 0.0354 -0.147 to -0.00115 0.144 0.0467
transgelin 2 0.261 ± 0.0530 0.460 ± 0.0715 -0.199 ± 0.0890 -0.379 to -0.0186 0.113 0.0314
tropomyosin 3 
isoform 4 0.0706 ± 0.0104 0.117 ± 0.0179 -0.0459 ± 0.0207 -0.0880 to -0.00378 0.13 0.0335
villin 2 0.188 ± 0.0140 0.251 ± 0.0235 -0.0634 ± 0.0274 -0.119 to -0.00761 0.14 0.0271
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Figure 16. Scatter plots and ROCs  of the 3 most predictive proteins. 
  
anterior gradient 2 homolog
P
D
A
C
C
on
tr
ol
0.0
0.5
1.0
1.5
2.0
p
e
a
k
 a
re
a
 r
a
ti
o
transgelin 2
P
D
A
C
C
on
tr
ol
0.0
0.5
1.0
1.5
2.0
p
e
a
k
 a
re
a
 r
a
ti
o
cystatin M
P
D
A
C
C
on
tr
ol
0.0
0.1
0.2
0.3
0.4
p
e
a
k
 a
re
a
 r
a
ti
o
0
0
.2
5
0
.5
0
.7
5
1
.0
S
e
n
s
it
iv
it
y
0 0.25 0.5 0.75 1.0
1 - Specificity
Area under ROC curve = 0.7896
0
0
.2
5
0
.5
0
.7
5
1
.0
S
e
n
s
it
iv
it
y
0 0.25 0.5 0.75 1.0
1 - Specificity
Area under ROC curve = 0.7788
0
0
.2
5
0
.5
0
.7
5
1
.0
S
e
n
s
it
iv
it
y
0 0.25 0.5 0.75 1.0
1 - Specificity
Area under ROC curve = 0.7957
82 
 
 
 
Figure 17. Combined ROC curves. The combined 3 most predictive proteins, AUC = 
0.88 (A),  and 15 proteins, AUC = 0.97 (B), are shown. 
4.4.4 Differential proteins   
The result that many of the differential proteins had a lower response in 
PDAC than in control might be surprising upon initial inspection.  The original 
hypothesis had been the opposite, given that the candidate biomarker 
proteins were derived from PDAC and pancreatitis cell lines and selected 
based on their high abundance in the culture media.  Only two of the 
differential proteins were elevated in PDAC serum, lamin A/C and kallikrein-
related peptidase 10, and study of their functions suggests this is to be 
expected.  Lamins A and C are splice variants of the LMNA gene.  They are 
intermediate filament proteins localized to the nucleus and most commonly 
associated with nuclear structure, however studies have shown it plays a role 
in TGF-, Erk, and Wnt signaling142-146.  Disregulation of lamin A/C is 
associated with an imbalance in differentiation and proliferation and has 
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previously been reported to be upregulated in lung cancer cells and 
progressive tumor cells 147-149.  Kallikrein-related peptidase 10 is a secreted 
serine protease and as such may be expected to play a role in invasion and 
angiogenesis 150.  It has previously been associated with colorectal, renal, 
and ovarian cancer 151-153.  
Further inspection of the lower abundance proteins in our study reveals that 
a decreased level of some of these proteins may not be unexpected.  
Previous studies show a decrease in the cystatins is to be expected.  
Cystatins are secreted non-specific inhibitors of cysteine proteases and are 
involved in extracellular matrix degradation, a process crucial to invasion and 
angiogenesis.  Therefore a decrease in cystatins C and M might be expected 
in metastatic disease and has been seen in association with breast cancer 154.  
Cystatins are epigenetically silenced via methylation in various cancers and 
suitably, immunohistochemical staining of pancreatic tissue shows low 
expression of cystatin C in PDAC as compared to other pancreatic tissue 
155,156. 
The expected levels of some proteins in the serum are less easy to predict.  
Heparan sulfate proteoglycan 2 is thought to be a pro-angiogenic factor; 
however, studies have found conflicting impact on cancer cell lines; while 
silencing decreased the angiogenic potential of some tumor cell lines157, it 
enhanced the aggressiveness of others158.  Insulin like growth factor (IGF) 
binding protein 7 is similarly nuanced.  The IGFs are secreted proteins that 
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circulate in the blood and help to regulate cellular proliferation.  The effects 
of their binding proteins, such as IGF binding protein 7, are complex.  While 
the binding proteins prolong the half life of the IGFs in circulation, they also 
compete with cellular receptors for free IGF159.  IGF binding protein 7 has 
been described as a tumor suppressor160 and as such has been suggested as 
a cancer therapy161, yet its upregulation has been associated with colorectal 
cancer162. 
An explanation for the reduced serum levels of the remaining proteins in the 
panel is not obvious.  Anterior gradient homolog 2 has previously been 
described as a relevant factor in many cancers including breast, prostate, 
colorectal, and esophageal, in addition to pancreatic.  It serves as an 
inhibitor of the tumor suppressor p53 and is involved in drug resistance163.  
The finding that the level of anterior gradient 2 homolog is lower in the 
serum of PDAC patients is in contrast with reports that found it to be 
elevated or unchanged in the plasma of PDAC patients as measured by ELISA 
methods 164,165.  However both of the ELISA studies used much smaller 
sample sets that were poorly matched for age and thus may have had less 
power to assess the true level of this protein.  Lipocalin 2 is a circulatory 
protein binding protein.  It serves to scavenge and deliver iron to cells, but 
also promotes the activity of matrix metalloproteinase 9166, an enzyme 
responsible for matrix remodeling in association with invasion and 
angiogenesis.  Multiple biomarker discovery studies have identified lipocalin 2 
as upregulated in pancreatic cancer167-169, so it is surprising to find its serum 
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levels suppressed in our study.  Myosin, heavy polypeptide 9, non-muscle is 
also reported to promote cancer cell migration and invasion170,171, yet was 
detected at a lower level in our cancer serum samples.  The binding proteins 
small ubiquitin-like modifier SMT3A and S100 A6 have been identified in 
other biomarker discovery studies as well.  SMT3A binds protein targets as a 
post-translational modification to direct various cellular processes.  Its 
expression has been identified in proteomic analysis of breast cancer172. The 
S100 proteins are calcium-binding proteins that interact with annexins and as 
such are thought to facilitate cellular interactions.  S100 A6 expression has 
been reported in melanoma 173. 
Profilin 1, transgelin 2, tropomyosin, and villin are all actin binding proteins 
and their association with cancer is complex174.  Profilin 1 was identified as 
overexpressed in biomarker studies of renal cell carcinoma175 and pancreatic 
cancer53.  However, lower profiling expression was found in breast cancer 
cells where it is thought to suppress tumorigenicity 176,177. While the function 
of transgelin 2 is unknown, it has been implicated in various cancers 
including colorectal, gastric, and pancreatic 52,178,179.  A decrease in the 
expression of tropomyosin 3 was observed previously in proteomic analysis 
of lung cancer tissue180.  Villin 2(ezrin) is thought to promote metastasis181 
and its expression has been associated with breast cancer, hepatocellular 
carcinoma, and lung cancer182-184. 
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4.5 Conclusion 
Great care was taken in this study to reduce the possibility of error in our 
analysis.  Other biomarkers have been proposed before only to fail during 
validation.  However, the results reported in the present study should be 
robust due to several factors.  The samples groups in the training set were 
larger and well matched in the age of the subjects compared with other 
studies.  Sample analysis was designed to reduce bias and the SILAP internal 
standard provided an extra measure of normalization to correct for sample 
loss. 
A panel of 15 proteins with statistically different mean concentrations in a 
training set of serum samples derived from cancer and control patients was 
identified.  By combining the results of these proteins, an ROC curve was 
obtained that achieved 93.6% sensitivity and 95.2% specificity, values 
greater than any other biomarkers of PDAC reported to date38.  This feat was 
made possible through the use of our multiplexed LC-MRM/MS method, 
which made it possible to routinely monitor 52 proteins.  Therefore, a wide 
net was cast in order to identify differential proteins.  The method may easily 
be expanded to study more proteins, and such a study may result in the 
identification of additional biomarker proteins.  This means that the discovery 
of additional differential proteins in the serum could enhance this biomarker 
panel further.  Validation of this panel will be an important step in the 
evolution of a screening assay for the detection of pancreatic cancer.   
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5 Chapter 5 – Conclusions and Future Directions 
5.1 Conclusions 
Pancreatic cancer is a devastating disease, however early detection has the 
ability to dramatically improve the survival rate.  While many biomarkers of 
pancreatic cancer have been proposed, none meet the specificity or 
sensitivity levels required for utility as a screening test. 
The research presented here seeks to change this.  As reported in Chapter 2, 
via in vitro simulation of the tumor microenvironment and LC-MS based 
proteomic analysis, a comprehensive list of candidate protein biomarkers was 
compiled.  The culture of a mixture of pancreatic cancer and stromal cell lines 
provided a rich source of proteins for proteomic profiling.  Qualitative 2D-LC-
MS was effective in producing high quality protein identifications which were 
validated in culture and human tissue by traditional immunologic methods.  
A subset of these candidate biomarker proteins were then validated in a 
training set of human serum samples by LC-MRM/MS.  Chapter 3 describes 
the development of an LC-MRM/MS method for the targeted quantitation of 
over 70 proteins in a single assay.  This work was facilitated by the LC-
MS/MS data acquired in the discovery phase and as such was a logical 
progression.  The probability of detecting the targeted proteins was enhanced 
since the peptides monitored in the experiment were those that were most 
easily detected by LC-MS/MS during discovery.  Spectral libraries generated 
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during discovery also provided insight into the best precursor and product 
ions for peptide monitoring. 
While immunologic methods have prevailed as the mechanism for validating 
protein biomarkers, Chapter 3 shows that LC-MS can efficiently quantitate a 
large panel of proteins in biological matrix. The application of the traditional 
bioanalytical techniques of correction using a stable isotope labeled internal 
standard and LC-MRM/MS analysis empowered this methodology.  The 
internal standard was critical to the precision of the assay since the depletion 
and digestion steps of sample processing have traditionally introduced 
significant variability to the analysis.  MRM/MS analysis provided sensitive 
and specific detection of a large set of peptide analytes despite the complex 
matrix.   
The full power of the quantitative LC-MRM/MS method was demonstrated in 
Chapter 4.  The evaluation of a large set of proteins in parallel enabled the 
identification of a panel of protein biomarkers with sensitivity and specificity 
superior to any single biomarker reported to date.  Precision of the 
quantitative LC-MS was critical to the statistical analysis of the data.  
Furthermore, the low variability in the cancer and control data sets made it 
easier to discern differences in these two groups.  
Based on this research the workflow provided in Figure 18 is proposed for 
biomarker development studies.  In the first stage of development, cell 
culture models of disease are used to identify candidate biomarker proteins.  
The spectral library produced during discovery is then used in the second 
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stage of development to direct a targeted MRM method for the quantitation 
of candidate proteins.  The cell culture model used in the first stage is 
employed again for the production of a stable isotope labeled proteome for 
use as an internal standard.  In stage 3 the quantitative method is used for 
the identification of differential proteins in a training set of human samples.  
Any differential proteins identified in stage 3 may then be validated in a 
subsequent set of human samples, using the same LC-MS method. 
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Figure 18. Biomarker development plan 
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5.2 Future directions 
The focus of this work has been on the development of a screening method 
for the early detection of pancreatic cancer.  However, this panel also has the 
potential for use in drug development as a means to measure response to 
therapy.  A training set of human serum samples used to identify differential 
proteins compared the serum taken from pancreatic cancer patients to that 
derived from survivors of gastrointestinal cancers in remission.  Thus, the 
panel might prove to serve well as an indicator of therapy response. 
The panel of protein biomarkers identified in this work requires additional 
validation prior to implementation as either a screening test or device to 
monitor response to therapy.  Several phases of biomarker development (as 
outlined by Pepe et al.) dictate that studies to prove the ability of the 
biomarker to detect disease prior to conventional diagnosis are required43.  
Furthermore, it is ultimately necessary to determine whether screening 
reduces cancer burden43.  Just as drug development is a lengthy and 
expensive process that takes many years to complete, so biomarker 
development is a significant process that requires years of study in large 
populations.  A panel of biomarkers presented here are still early in the 
development process but they show promise.  The next important step in 
their development is the validation of their predictive value in a second set of 
samples, the procurement of which is under way. 
To support such studies, an absolute quantitative assay would be beneficial.  
The current method relies on the relative response of the endogenous protein 
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to a custom SILAP internal standard produced in house.  This approach 
allows us to normalize samples to one another within a study, provided the 
same batch of IS is used.  However, each new batch of IS needs to be cross-
validated if comparisons are to be made between samples prepared using 
different batches of IS.  It would be preferable to develop an authentic 
external reference standard that could be used to back calculate the absolute 
concentration of each protein in serum.  Such an assay would be more easily 
applied to large multi-site studies.  
Another area for development lies in the list of candidate biomarkers 
identified in the discovery stage of this project.  Hundreds of proteins have 
yet to be explored for their differential potential in human serum samples.  
The relative quantitative method described in chapter 3 could easily be 
expanded to include more of these candidate biomarkers.  Expansion of the 
biomarker panel to include additional proteins may increase the sensitivity 
and specificity of the method further. 
Research presented in this dissertation on biomarkers for PDAC will stimulate 
many additional experiments.  Studies have yet to be done to validate the 
biomarkers proposed and develop a method for absolute quantitation and the 
biomarker panel itself is open to expansion.  However, studies presented in 
this dissertation represent a significant first step in the quest to develop 
cancer biomarkers.  Methodology that was developed not only identified a 
potential screening system for the early detection of pancreatic cancer, but 
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has also laid the foundation for future biomarker discovery and validation 
studies. 
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APPENDIX 1 
q
P
S
C 
c
a
P
S
C 
P
C
C 
Protein Description 
  X X 
gi|23308751|ref|NP_689953.1| 3-hydroxyisobutyrate dehydrogenase [Homo 
sapiens] 
    X 
gi|20127454|ref|NP_004035.2| 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase [Homo 
sapiens] 
  X   
gi|47132622|ref|NP_002442.2| 5'-methylthioadenosine phosphorylase [Homo 
sapiens] 
    X gi|6912586|ref|NP_036220.1| 6-phosphogluconolactonase [Homo sapiens] 
  X X 
gi|148539872|ref|NP_005882.2
| 
acetyl-Coenzyme A acetyltransferase 2 [Homo 
sapiens] 
  X X 
gi|119393891|ref|NP_000143.2
|,gi|119393893|ref|NP_001073
271.1|,gi|119393895|ref|NP_00
1073272.1| 
acid alpha-glucosidase preproprotein [Homo 
sapiens] 
  X   gi|4757714|ref|NP_004291.1| acid phosphatase 1 isoform c [Homo sapiens] 
  X X 
gi|5453880|ref|NP_006296.1| acidic (leucine-rich) nuclear phosphoprotein 32 
family, member A [Homo sapiens] 
  X X 
gi|5454088|ref|NP_006392.1| acidic (leucine-rich) nuclear phosphoprotein 32 
family, member B [Homo sapiens] 
  X   gi|8659555|ref|NP_002188.1| aconitase 1 [Homo sapiens] 
  X   gi|4501867|ref|NP_001089.1| aconitase 2 precursor [Homo sapiens] 
  X   
gi|23238211|ref|NP_690601.1|,
gi|5031599|ref|NP_005722.1| 
actin related protein 2/3 complex subunit 2 [Homo 
sapiens] 
    X 
gi|5031597|ref|NP_005710.1| actin related protein 2/3 complex subunit 3 [Homo 
sapiens] 
  X X gi|4501891|ref|NP_001093.1| actinin, alpha 1 [Homo sapiens] 
  X   gi|4557241|ref|NP_001095.1| actinin, alpha 3 [Homo sapiens] 
X X X gi|12025678|ref|NP_004915.2| actinin, alpha 4 [Homo sapiens] 
    X 
gi|30089997|ref|NP_817126.1|,
gi|30089999|ref|NP_829888.1|,
gi|4757718|ref|NP_004292.1| 
actin-like 6A isoform 2 [Homo sapiens],actin-like 6A 
isoform 1 [Homo sapiens] 
  X   
gi|5031571|ref|NP_005713.1|,g
i|53692187|ref|NP_001005386.
1| 
actin-related protein 2 isoform b [Homo 
sapiens],actin-related protein 2 isoform a [Homo 
sapiens] 
X X   
gi|68163411|ref|NP_001618.2| activated leukocyte cell adhesion molecule [Homo 
sapiens] 
  X X 
gi|19923784|ref|NP_006704.2| activated RNA polymerase II transcription cofactor 
4 [Homo sapiens] 
    X 
gi|40217847|ref|NP_054733.2| activating signal cointegrator 1 complex subunit 3-
like 1 [Homo sapiens] 
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q
P
S
C 
c
a
P
S
C 
P
C
C 
Protein Description 
    X 
gi|32528282|ref|NP_863654.1|,
gi|32528284|ref|NP_863655.1|,
gi|32528286|ref|NP_863656.1|,
gi|75709208|ref|NP_009205.3| 
acyl-CoA thioesterase 7 isoform hBACHb [Homo 
sapiens],acyl-CoA thioesterase 7 isoform hBACHc 
[Homo sapiens],acyl-CoA thioesterase 7 isoform 
hBACHd [Homo sapiens],acyl-CoA thioesterase 7 
isoform hBACHa [Homo sapiens] 
  X X 
gi|4501915|ref|NP_003807.1|,g
i|54292121|ref|NP_001005845.
1| 
ADAM metallopeptidase domain 9 isoform 1 
precursor [Homo sapiens],ADAM metallopeptidase 
domain 9 isoform 2 precursor [Homo sapiens] 
  X X 
gi|22027651|ref|NP_001118.2|,
gi|22027653|ref|NP_663782.1| 
adaptor-related protein complex 1 beta 1 subunit 
isoform a [Homo sapiens],adaptor-related protein 
complex 1 beta 1 subunit isoform b [Homo sapiens] 
  X   
gi|19913414|ref|NP_055018.2|,
gi|19913416|ref|NP_570603.2| 
adaptor-related protein complex 2, alpha 1 subunit 
isoform 1 [Homo sapiens],adaptor-related protein 
complex 2, alpha 1 subunit isoform 2 [Homo 
sapiens] 
    X 
gi|4557469|ref|NP_001273.1|,g
i|71773106|ref|NP_001025177.
1| 
adaptor-related protein complex 2, beta 1 subunit 
isoform b [Homo sapiens],adaptor-related protein 
complex 2, beta 1 subunit isoform a [Homo 
sapiens] 
  X   gi|47078295|ref|NP_000013.2| adenosine deaminase [Homo sapiens] 
  X X 
gi|4502013|ref|NP_001616.1|,g
i|7524346|ref|NP_037543.1| 
adenylate kinase 2 isoform a [Homo 
sapiens],adenylate kinase 2 isoform b [Homo 
sapiens] 
    X gi|34577063|ref|NP_001117.2| adenylosuccinate synthase [Homo sapiens] 
X X X 
gi|157649073|ref|NP_0010990
00.1|,gi|5453595|ref|NP_00635
8.1| 
adenylyl cyclase-associated protein [Homo 
sapiens] 
  X   gi|4557263|ref|NP_001116.1| ADP-ribosylarginine hydrolase [Homo sapiens] 
  X   gi|8923417|ref|NP_060295.1| ADP-ribosylhydrolase like 2 [Homo sapiens] 
  X X gi|54873613|ref|NP_940978.2| agrin [Homo sapiens] 
  X X 
gi|6912280|ref|NP_036243.1| AHA1, activator of heat shock 90kDa protein 
ATPase homolog 1 [Homo sapiens] 
  X X gi|61743954|ref|NP_001611.1| AHNAK nucleoprotein isoform 1 [Homo sapiens] 
    X 
gi|109148542|ref|NP_001596.2
| 
alanyl-tRNA synthetase [Homo sapiens] 
X X X gi|4502027|ref|NP_000468.1| albumin precursor [Homo sapiens] 
  X X gi|21361176|ref|NP_000680.2| aldehyde dehydrogenase 1A1 [Homo sapiens] 
  X   
gi|24497577|ref|NP_697021.1|,
gi|5174391|ref|NP_006057.1| 
aldo-keto reductase family 1, member A1 [Homo 
sapiens] 
X X X 
gi|34577110|ref|NP_908930.1|,
gi|34577112|ref|NP_908932.1|,
gi|4557305|ref|NP_000025.1| 
aldolase A [Homo sapiens] 
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Protein Description 
  X   
gi|4501881|ref|NP_001091.1|,g
i|4501883|ref|NP_001604.1|,gi|
4501889|ref|NP_001606.1|,gi|4
885049|ref|NP_005150.1| 
alpha 1 actin precursor [Homo sapiens],alpha 2 
actin [Homo sapiens],actin, gamma 2 propeptide 
[Homo sapiens],cardiac muscle alpha actin 1 
proprotein [Homo sapiens] 
  X X 
gi|4501881|ref|NP_001091.1|,g
i|4885049|ref|NP_005150.1| 
alpha 1 actin precursor [Homo sapiens],cardiac 
muscle alpha actin 1 proprotein [Homo sapiens] 
  X   
gi|89276751|ref|NP_000084.3| alpha 1 type V collagen preproprotein [Homo 
sapiens] 
  X   
gi|110611233|ref|NP_569712.2
|,gi|110611235|ref|NP_085059.
2| 
alpha 1 type XVIII collagen isoform 2 precursor 
[Homo sapiens],alpha 1 type XVIII collagen isoform 
1 precursor [Homo sapiens] 
    X 
gi|4504345|ref|NP_000508.1|,g
i|4504347|ref|NP_000549.1| 
alpha 2 globin [Homo sapiens],alpha 1 globin 
[Homo sapiens] 
    X gi|48762934|ref|NP_000080.2| alpha 2 type I collagen [Homo sapiens] 
  X X 
gi|89363017|ref|NP_000384.2| alpha 2 type V collagen preproprotein [Homo 
sapiens] 
  X   
gi|115527062|ref|NP_001840.3
|,gi|115527066|ref|NP_478054.
2|,gi|115527070|ref|NP_47805
5.2| 
alpha 2 type VI collagen isoform 2C2 precursor 
[Homo sapiens],alpha 2 type VI collagen isoform 
2C2a precursor [Homo sapiens],alpha 2 type VI 
collagen isoform 2C2a precursor [Homo sapiens] 
    X 
gi|38202257|ref|NP_938148.1|,
gi|88900491|ref|NP_938149.2| 
alpha glucosidase II alpha subunit isoform 2 [Homo 
sapiens],alpha glucosidase II alpha subunit isoform 
3 [Homo sapiens] 
  X X 
gi|21361399|ref|NP_055040.2| alpha isoform of regulatory subunit A, protein 
phosphatase 2 [Homo sapiens] 
    X 
gi|4506019|ref|NP_002708.1| alpha isoform of regulatory subunit B55, protein 
phosphatase 2 [Homo sapiens] 
  X X gi|66932947|ref|NP_000005.2| alpha-2-macroglobulin precursor [Homo sapiens] 
    X gi|4501989|ref|NP_001125.1| alpha-fetoprotein precursor [Homo sapiens] 
    X gi|4504009|ref|NP_000160.1| alpha-galactosidase A precursor [Homo sapiens] 
  X X 
gi|15451907|ref|NP_006301.2| aminopeptidase puromycin sensitive [Homo 
sapiens] 
    X 
gi|4502147|ref|NP_001633.1| amyloid beta (A4) precursor-like protein 2 [Homo 
sapiens] 
  X X 
gi|41406055|ref|NP_958816.1|,
gi|4502167|ref|NP_000475.1| 
amyloid beta A4 protein precursor, isoform b 
[Homo sapiens],amyloid beta A4 protein precursor, 
isoform a [Homo sapiens] 
  X   
gi|91206450|ref|NP_653309.2| ankyrin and armadillo repeat containing [Homo 
sapiens] 
  X   gi|4502107|ref|NP_001145.1| annexin 5 [Homo sapiens] 
    X 
gi|22165431|ref|NP_665875.1|,
gi|22165433|ref|NP_665876.1|,
gi|4557317|ref|NP_001148.1| 
annexin A11 [Homo sapiens] 
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P
C
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  X X 
gi|4757756|ref|NP_004030.1|,g
i|50845386|ref|NP_001002857.
1|,gi|50845388|ref|NP_001002
858.1| 
annexin A2 isoform 2 [Homo sapiens],annexin A2 
isoform 1 [Homo sapiens] 
  X X gi|4502101|ref|NP_000691.1| annexin I [Homo sapiens] 
  X   gi|4757804|ref|NP_004036.1| antioxidant protein 1 [Homo sapiens] 
  X X 
gi|18375501|ref|NP_001632.2|,
gi|18375503|ref|NP_542379.1|,
gi|18375505|ref|NP_542380.1| 
APEX nuclease [Homo sapiens] 
    X 
gi|91984773|ref|NP_658985.2| apolipoprotein A-I binding protein precursor [Homo 
sapiens] 
    X gi|4557321|ref|NP_000030.1| apolipoprotein A-I preproprotein [Homo sapiens] 
  X X gi|5729730|ref|NP_006586.1| apoptosis inhibitor 5 [Homo sapiens] 
  X   gi|11863154|ref|NP_001646.2| archain [Homo sapiens] 
  X   
gi|5031573|ref|NP_005712.1| ARP3 actin-related protein 3 homolog [Homo 
sapiens] 
  X X gi|4758762|ref|NP_004530.1| asparaginyl-tRNA synthetase [Homo sapiens] 
  X X gi|4504067|ref|NP_002070.1| aspartate aminotransferase 1 [Homo sapiens] 
X X X 
gi|73486658|ref|NP_002071.2| aspartate aminotransferase 2 precursor [Homo 
sapiens] 
    X 
gi|38569421|ref|NP_001087.2|,
gi|38569423|ref|NP_942127.1| 
ATP citrate lyase isoform 1 [Homo sapiens],ATP 
citrate lyase isoform 2 [Homo sapiens] 
  X   
gi|32189394|ref|NP_001677.2| ATP synthase, H+ transporting, mitochondrial F1 
complex, beta subunit precursor [Homo sapiens] 
  X X 
gi|17136148|ref|NP_001174.2| ATPase, H+ transporting, lysosomal accessory 
protein 1 precursor [Homo sapiens] 
  X X gi|10863945|ref|NP_066964.1| ATP-dependent DNA helicase II [Homo sapiens] 
  X   
gi|4503841|ref|NP_001460.1| ATP-dependent DNA helicase II, 70 kDa subunit 
[Homo sapiens] 
  X X gi|10835067|ref|NP_003133.1| autoantigen La [Homo sapiens] 
  X   
gi|21536466|ref|NP_068713.2|,
gi|21536468|ref|NP_001690.2| 
AXL receptor tyrosine kinase isoform 1 [Homo 
sapiens],AXL receptor tyrosine kinase isoform 2 
[Homo sapiens] 
  X X 
gi|41281429|ref|NP_055485.2| basic leucine zipper and W2 domains 1 [Homo 
sapiens] 
X X X 
gi|4501885|ref|NP_001092.1|,g
i|4501887|ref|NP_001605.1| 
beta actin [Homo sapiens],actin, gamma 1 
propeptide [Homo sapiens] 
  X X 
gi|4504349|ref|NP_000509.1|,g
i|4504351|ref|NP_000510.1| 
beta globin [Homo sapiens],delta globin [Homo 
sapiens] 
  X X gi|4757826|ref|NP_004039.1| beta-2-microglobulin precursor [Homo sapiens] 
  X X 
gi|4504981|ref|NP_002296.1| beta-galactoside-binding lectin precursor [Homo 
sapiens] 
  X   gi|4502403|ref|NP_001702.1| biglycan preproprotein [Homo sapiens] 
  X X gi|33589854|ref|NP_000703.2| biliverdin reductase A [Homo sapiens] 
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    X 
gi|4502419|ref|NP_000704.1| biliverdin reductase B (flavin reductase (NADPH)) 
[Homo sapiens] 
    X gi|4557373|ref|NP_000051.1| biotinidase precursor [Homo sapiens] 
X X   
gi|30795231|ref|NP_006308.3| brain abundant, membrane attached signal protein 
1 [Homo sapiens] 
    X gi|21361370|ref|NP_002853.2| brain glycogen phosphorylase [Homo sapiens] 
  X   gi|14589889|ref|NP_001783.2| cadherin 2, type 1 preproprotein [Homo sapiens] 
  X X 
gi|60218913|ref|NP_00100721
5.1|,gi|7656952|ref|NP_055227
.1| 
calcyclin binding protein isoform 2 [Homo 
sapiens],calcyclin binding protein isoform 1 [Homo 
sapiens] 
  X   
gi|15149463|ref|NP_149130.1|,
gi|15149465|ref|NP_149131.1|,
gi|15149467|ref|NP_149347.1|,
gi|44680105|ref|NP_149129.2|,
gi|4826657|ref|NP_004333.1| 
caldesmon 1 isoform 4 [Homo sapiens],caldesmon 
1 isoform 5 [Homo sapiens],caldesmon 1 isoform 3 
[Homo sapiens],caldesmon 1 isoform 1 [Homo 
sapiens],caldesmon 1 isoform 2 [Homo sapiens] 
X X X 
gi|4502549|ref|NP_001734.1|,g
i|58218968|ref|NP_005175.2|,g
i|5901912|ref|NP_008819.1| 
calmodulin 2 [Homo sapiens],calmodulin 3 [Homo 
sapiens],calmodulin 1 [Homo sapiens] 
    X 
gi|157389005|ref|NP_001739.2
| 
calpain 2, large subunit [Homo sapiens] 
  X X 
gi|4502565|ref|NP_001740.1|,g
i|51599151|ref|NP_001003962.
1| 
calpain, small subunit 1 [Homo sapiens] 
  X X 
gi|109637753|ref|NP_001741.4
|,gi|109637757|ref|NP_775086.
1|,gi|109637759|ref|NP_00103
5905.1|,gi|109637761|ref|NP_0
01035906.1|,gi|109637763|ref|
NP_001035907.1| 
calpastatin isoform a [Homo sapiens],calpastatin 
isoform e [Homo sapiens],calpastatin isoform f 
[Homo sapiens],calpastatin isoform g [Homo 
sapiens],calpastatin isoform h [Homo sapiens] 
  X   
gi|41327730|ref|NP_958434.1|,
gi|4758018|ref|NP_004359.1| 
calponin 2 isoform b [Homo sapiens],calponin 2 
isoform a [Homo sapiens] 
  X   gi|4502923|ref|NP_001830.1| calponin 3 [Homo sapiens] 
  X X gi|4757900|ref|NP_004334.1| calreticulin precursor [Homo sapiens] 
  X X 
gi|57242755|ref|NP_055759.3|,
gi|57242757|ref|NP_00100956
6.1| 
calsyntenin 1 isoform 2 [Homo sapiens],calsyntenin 
1 isoform 1 [Homo sapiens] 
  X   gi|11545861|ref|NP_071414.1| calsyntenin 2 [Homo sapiens] 
  X X gi|4502551|ref|NP_001210.1| calumenin precursor [Homo sapiens] 
  X X 
gi|5453599|ref|NP_006127.1| capping protein (actin filament) muscle Z-line, 
alpha 2 [Homo sapiens] 
    X gi|4502599|ref|NP_001748.1| carbonyl reductase 1 [Homo sapiens] 
  X   gi|61743916|ref|NP_057436.2| carboxypeptidase A4 preproprotein [Homo sapiens] 
  X   gi|4503009|ref|NP_001864.1| carboxypeptidase E preproprotein [Homo sapiens] 
  X   gi|62241003|ref|NP_705838.3| cardiomyopathy associated 5 [Homo sapiens] 
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    X 
gi|119395729|ref|NP_000299.2
| 
cathepsin A precursor [Homo sapiens] 
  X X 
gi|22538431|ref|NP_680090.1|,
gi|22538433|ref|NP_680091.1|,
gi|22538435|ref|NP_680092.1|,
gi|22538437|ref|NP_680093.1|,
gi|4503139|ref|NP_001899.1| 
cathepsin B preproprotein [Homo sapiens] 
    X 
gi|4503141|ref|NP_001805.1| cathepsin C isoform a preproprotein [Homo 
sapiens] 
  X X gi|4503143|ref|NP_001900.1| cathepsin D preproprotein [Homo sapiens] 
    X 
gi|22202619|ref|NP_666023.1|,
gi|4503155|ref|NP_001903.1| 
cathepsin L1 preproprotein [Homo sapiens] 
  X X gi|23110960|ref|NP_001324.2| cathepsin L2 preproprotein [Homo sapiens] 
  X X gi|22538442|ref|NP_001327.2| cathepsin Z preproprotein [Homo sapiens] 
    X 
gi|115529484|ref|NP_598000.2
| 
CD109 [Homo sapiens] 
  X X 
gi|48255935|ref|NP_000601.3|,
gi|48255937|ref|NP_00100138
9.1|,gi|48255939|ref|NP_00100
1390.1|,gi|48255941|ref|NP_00
1001391.1| 
CD44 antigen isoform 1 precursor [Homo 
sapiens],CD44 antigen isoform 2 precursor [Homo 
sapiens],CD44 antigen isoform 3 precursor [Homo 
sapiens],CD44 antigen isoform 4 precursor [Homo 
sapiens] 
    X gi|4502693|ref|NP_001760.1| CD9 antigen [Homo sapiens] 
  X   gi|11067747|ref|NP_001244.1| CDC5-like [Homo sapiens] 
  X X gi|8923710|ref|NP_060018.1| CDV3 homolog [Homo sapiens] 
  X X gi|5901922|ref|NP_008996.1| cell division cycle 37 protein [Homo sapiens] 
    X 
gi|33589824|ref|NP_006560.2| cell growth regulator with EF-hand domain 1 [Homo 
sapiens] 
  X   gi|87298937|ref|NP_008949.4| centrosomal protein 110kDa [Homo sapiens] 
  X X 
gi|31542947|ref|NP_002147.2|,
gi|41399285|ref|NP_955472.1| 
chaperonin [Homo sapiens],chaperonin [Homo 
sapiens] 
  X X 
gi|5453603|ref|NP_006422.1| chaperonin containing TCP1, subunit 2 [Homo 
sapiens] 
  X   
gi|58761484|ref|NP_00100880
0.1|,gi|58761486|ref|NP_00100
8883.1|,gi|63162572|ref|NP_00
5989.3| 
chaperonin containing TCP1, subunit 3 isoform c 
[Homo sapiens],chaperonin containing TCP1, 
subunit 3 isoform b [Homo sapiens],chaperonin 
containing TCP1, subunit 3 isoform a [Homo 
sapiens] 
  X X 
gi|38455427|ref|NP_006421.2| chaperonin containing TCP1, subunit 4 (delta) 
[Homo sapiens] 
    X 
gi|24307939|ref|NP_036205.1| chaperonin containing TCP1, subunit 5 (epsilon) 
[Homo sapiens] 
    X 
gi|4502643|ref|NP_001753.1| chaperonin containing TCP1, subunit 6A isoform a 
[Homo sapiens] 
  X X 
gi|5453607|ref|NP_006420.1| chaperonin containing TCP1, subunit 7 isoform a 
[Homo sapiens] 
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  X X 
gi|48762932|ref|NP_006576.2| chaperonin containing TCP1, subunit 8 (theta) 
[Homo sapiens] 
    X gi|4504153|ref|NP_001502.1| chemokine (C-X-C motif) ligand 1 [Homo sapiens] 
  X   
gi|10834988|ref|NP_000600.1|,
gi|40316924|ref|NP_954637.1|,
gi|76563933|ref|NP_00102905
8.1| 
chemokine (C-X-C motif) ligand 12 (stromal cell-
derived factor 1) isoform beta [Homo 
sapiens],chemokine (C-X-C motif) ligand 12 
(stromal cell-derived factor 1) isoform alpha [Homo 
sapiens],chemokine (C-X-C motif) ligand 12 
(stromal cell-derived factor 1)  
    X 
gi|4506849|ref|NP_002985.1| chemokine (C-X-C motif) ligand 5 precursor [Homo 
sapiens] 
  X X gi|14251209|ref|NP_001279.2| chloride intracellular channel 1 [Homo sapiens] 
  X   gi|7330335|ref|NP_039234.1| chloride intracellular channel 4 [Homo sapiens] 
  X   gi|31542306|ref|NP_065145.2| chromatin modifying protein 1B [Homo sapiens] 
  X   gi|28827795|ref|NP_789782.1| chromatin modifying protein 4B [Homo sapiens] 
  X   
gi|5803076|ref|NP_006798.1| chromobox homolog 1 (HP1 beta homolog 
Drosophila ) [Homo sapiens] 
  X X 
gi|15082258|ref|NP_009207.2|,
gi|20544151|ref|NP_057671.2|,
gi|89038889|ref|XP_943872.1| 
chromobox homolog 3 [Homo sapiens],chromobox 
homolog 3 [Homo sapiens],PREDICTED: similar to 
Chromobox homolog 3 (HP1 gamma homolog, 
Drosophila) [Homo sapiens] 
  X   
gi|6912292|ref|NP_036249.1| chromobox homolog 5 (HP1 alpha homolog, 
Drosophila) [Homo sapiens] 
  X   gi|4758012|ref|NP_004850.1| clathrin heavy chain 1 [Homo sapiens] 
  X   
gi|5901926|ref|NP_008937.1| cleavage and polyadenylation specific factor 5 
[Homo sapiens] 
    X gi|31563537|ref|NP_056097.1| CLIP-associating protein 1 [Homo sapiens] 
  X X 
gi|42716297|ref|NP_001822.2|,
gi|42740907|ref|NP_976084.1| 
clusterin isoform 1 [Homo sapiens],clusterin 
isoform 2 [Homo sapiens] 
  X X gi|8922699|ref|NP_060705.1| CNDP dipeptidase 2 [Homo sapiens] 
  X X gi|21624607|ref|NP_066972.1| coactosin-like 1 [Homo sapiens] 
  X   
gi|148536853|ref|NP_004362.2
|,gi|148536855|ref|NP_001091
868.1| 
coatomer protein complex, subunit alpha isoform 2 
[Homo sapiens],coatomer protein complex, subunit 
alpha isoform 1 [Homo sapiens] 
  X X gi|5031635|ref|NP_005498.1| cofilin 1 (non-muscle) [Homo sapiens] 
  X X 
gi|14719392|ref|NP_068733.1|,
gi|33946278|ref|NP_619579.1| 
cofilin 2 [Homo sapiens],cofilin 2 [Homo sapiens] 
  X   gi|19923969|ref|NP_612451.1| coiled-coil domain containing 124 [Homo sapiens] 
  X   
gi|39930511|ref|NP_597716.1| collagen and calcium binding EGF domains 1 
[Homo sapiens] 
  X X 
gi|87196339|ref|NP_001839.2| collagen, type VI, alpha 1 precursor [Homo 
sapiens] 
  X   
gi|93141047|ref|NP_004361.3| collagen, type XII, alpha 1 long isoform precursor 
[Homo sapiens] 
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    X 
gi|27262661|ref|NP_000748.3|,
gi|27262663|ref|NP_757349.1|,
gi|27262665|ref|NP_757350.1|,
gi|27262667|ref|NP_757351.1| 
colony stimulating factor 1 isoform a precursor 
[Homo sapiens],colony stimulating factor 1 isoform 
b precursor [Homo sapiens],colony stimulating 
factor 1 isoform c precursor [Homo sapiens],colony 
stimulating factor 1 isoform a precursor [Homo 
sapiens] 
  X X 
gi|4502491|ref|NP_001203.1| complement component 1, q subcomponent 
binding protein precursor [Homo sapiens] 
  X X 
gi|66347875|ref|NP_001724.3| complement component 1, r subcomponent [Homo 
sapiens] 
    X 
gi|41393602|ref|NP_958850.1|,
gi|4502495|ref|NP_001725.1| 
complement component 1, s subcomponent [Homo 
sapiens] 
    X 
gi|115298678|ref|NP_000055.2
| 
complement component 3 precursor [Homo 
sapiens] 
  X X gi|67782358|ref|NP_001701.2| complement factor B preproprotein [Homo sapiens] 
  X   gi|4503123|ref|NP_001892.1| connective tissue growth factor [Homo sapiens] 
  X   
gi|13124873|ref|NP_001746.1|,
gi|13124881|ref|NP_074036.1| 
core-binding factor, beta subunit isoform 2 [Homo 
sapiens],core-binding factor, beta subunit isoform 1 
[Homo sapiens] 
  X X 
gi|7656991|ref|NP_055140.1| coronin, actin binding protein, 1C isoform 1 [Homo 
sapiens] 
  X   
gi|20357552|ref|NP_005222.2|,
gi|20357556|ref|NP_612632.1| 
cortactin isoform a [Homo sapiens],cortactin 
isoform b [Homo sapiens] 
  X X 
gi|29029559|ref|NP_001307.2| CSE1 chromosome segregation 1-like protein 
[Homo sapiens] 
  X X 
gi|62198241|ref|NP_00101443
3.1|,gi|62526022|ref|NP_00101
4837.1|,gi|62526024|ref|NP_00
1014838.1|,gi|62526026|ref|NP
_001014840.1|,gi|7706244|ref|
NP_057005.1| 
cutA divalent cation tolerance homolog isoform 1 
[Homo sapiens],cutA divalent cation tolerance 
homolog isoform 2 [Homo sapiens],cutA divalent 
cation tolerance homolog isoform 3 [Homo sapiens] 
  X X gi|4503117|ref|NP_000091.1| cystatin B [Homo sapiens] 
  X X gi|4503107|ref|NP_000090.1| cystatin C precursor [Homo sapiens] 
  X   
gi|31542331|ref|NP_001545.2| cysteine-rich, angiogenic inducer, 61 [Homo 
sapiens] 
  X   
gi|10835051|ref|NP_001742.1|,
gi|21269877|ref|NP_644802.1|,
gi|62240992|ref|NP_00101443
7.1|,gi|62240994|ref|NP_00101
4438.1| 
cysteinyl-tRNA synthetase isoform b [Homo 
sapiens],cysteinyl-tRNA synthetase isoform a 
[Homo sapiens],cysteinyl-tRNA synthetase isoform 
c [Homo sapiens],cysteinyl-tRNA synthetase 
isoform d [Homo sapiens] 
  X X 
gi|7706497|ref|NP_057392.1| cytidine monophosphate (UMP-CMP) kinase 1, 
cytosolic [Homo sapiens] 
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  X X gi|11128019|ref|NP_061820.1| cytochrome c [Homo sapiens] 
  X   
gi|17017988|ref|NP_001853.2| cytochrome c oxidase subunit Vb precursor [Homo 
sapiens] 
  X   gi|32129199|ref|NP_149073.1| cytokine induced protein 29 kDa [Homo sapiens] 
  X X gi|50428925|ref|NP_001272.2| cytoskeleton associated protein 1 [Homo sapiens] 
X X X gi|5174539|ref|NP_005908.1| cytosolic malate dehydrogenase [Homo sapiens] 
    X 
gi|24850115|ref|NP_733746.1| cytosolic sialic acid 9-O-acetylesterase homolog 
[Homo sapiens] 
  X X 
gi|148529014|ref|NP_001914.3
| 
damage-specific DNA binding protein 1 [Homo 
sapiens] 
  X X 
gi|145386531|ref|NP_0010778
61.1|,gi|4503291|ref|NP_00134
6.1| 
D-dopachrome tautomerase [Homo sapiens] 
  X   
gi|4826686|ref|NP_004930.1| DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 [Homo 
sapiens] 
    X 
gi|50659095|ref|NP_004719.2| DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 
[Homo sapiens] 
  X   
gi|100913206|ref|NP_001348.2
| 
DEAH (Asp-Glu-Ala-His) box polypeptide 9 [Homo 
sapiens] 
  X   gi|54112429|ref|NP_212132.2| dedicator of cytokinesis 7 [Homo sapiens] 
    X 
gi|4503349|ref|NP_001366.1| deoxyribonuclease II, lysosomal precursor [Homo 
sapiens] 
  X X 
gi|4503423|ref|NP_001939.1|,g
i|70906441|ref|NP_001020419.
1| 
deoxyuridine triphosphatase isoform 2 [Homo 
sapiens],deoxyuridine triphosphatase isoform 1 
precursor [Homo sapiens] 
  X   
gi|148539846|ref|NP_001932.2
|,gi|148539848|ref|NP_077741.
2| 
desmocollin 3 isoform Dsc3a preproprotein [Homo 
sapiens],desmocollin 3 isoform Dsc3b 
preproprotein [Homo sapiens] 
  X   
gi|116534898|ref|NP_001934.2
| 
desmoglein 2 preproprotein [Homo sapiens] 
  X X 
gi|5802966|ref|NP_006861.1|,g
i|58530848|ref|NP_001011546.
1| 
destrin isoform a [Homo sapiens],destrin isoform b 
[Homo sapiens] 
  X   
gi|119395758|ref|NP_005210.3
|,gi|119395760|ref|NP_001073
280.1| 
diaphanous 1 isoform 1 [Homo 
sapiens],diaphanous 1 isoform 2 [Homo sapiens] 
  X   
gi|10140853|ref|NP_065438.1|,
gi|120433590|ref|NP_0010733
31.1|,gi|120433593|ref|NP_001
073332.1| 
diazepam binding inhibitor isoform 1 [Homo 
sapiens],diazepam binding inhibitor isoform 3 
[Homo sapiens],diazepam binding inhibitor isoform 
2 [Homo sapiens] 
  X   
gi|40548389|ref|NP_056965.3|,
gi|40548393|ref|NP_037385.2|,
gi|66346689|ref|NP_00101806
7.1| 
dickkopf homolog 3 precursor [Homo 
sapiens],dickkopf homolog 3 precursor [Homo 
sapiens],dickkopf homolog 3 precursor [Homo 
sapiens] 
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  X   
gi|91199540|ref|NP_000099.2| dihydrolipoamide dehydrogenase precursor [Homo 
sapiens] 
  X   gi|4503377|ref|NP_001377.1| dihydropyrimidinase-like 2 [Homo sapiens] 
  X   gi|4503379|ref|NP_001378.1| dihydropyrimidinase-like 3 [Homo sapiens] 
    X 
gi|18491024|ref|NP_005691.2|,
gi|86792661|ref|NP_569710.2| 
dipeptidyl peptidase III [Homo sapiens] 
  X X gi|31543380|ref|NP_009193.2| DJ-1 protein [Homo sapiens] 
    X 
gi|47132600|ref|NP_998731.1|,
gi|4758148|ref|NP_004392.1| 
DNA fragmentation factor, 45kDa, alpha 
polypeptide isoform 2 [Homo sapiens],DNA 
fragmentation factor, 45kDa, alpha polypeptide 
isoform 1 [Homo sapiens] 
  X   
gi|112293277|ref|NP_055095.2
| 
DnaJ (Hsp40) homolog, subfamily C, member 8 
[Homo sapiens] 
  X   
gi|27597059|ref|NP_056005.1| DnaJ homolog, subfamily C, member 9 [Homo 
sapiens] 
  X   
gi|62530384|ref|NP_001910.2| dodecenoyl-Coenzyme A delta isomerase 
precursor [Homo sapiens] 
  X X gi|14211889|ref|NP_115963.1| dpy-30-like protein [Homo sapiens] 
    X 
gi|18426913|ref|NP_543157.1|,
gi|18426915|ref|NP_004386.2| 
drebrin 1 isoform b [Homo sapiens],drebrin 1 
isoform a [Homo sapiens] 
    X 
gi|21361670|ref|NP_054782.2|,
gi|62198235|ref|NP_00101443
6.1| 
drebrin-like isoform a [Homo sapiens],drebrin-like 
isoform b [Homo sapiens] 
  X   
gi|33350932|ref|NP_001367.2| dynein, cytoplasmic, heavy polypeptide 1 [Homo 
sapiens] 
  X   gi|4503337|ref|NP_001354.1| dyskerin [Homo sapiens] 
  X   
gi|34577047|ref|NP_899236.1|,
gi|34577049|ref|NP_056363.2| 
dystonin isoform 1 [Homo sapiens],dystonin 
isoform 1eA precursor [Homo sapiens] 
  X X 
gi|148539835|ref|NP_004384.2
| 
dystroglycan 1 preproprotein [Homo sapiens] 
  X   
gi|86788015|ref|NP_00103443
7.1|,gi|86788132|ref|NP_00103
4438.1|,gi|9665262|ref|NP_004
096.2| 
EGF-containing fibulin-like extracellular matrix 
protein 1 precursor [Homo sapiens] 
  X   
gi|31317224|ref|NP_005702.3| EGF-like repeats and discoidin I-like domains-
containing protein 3 [Homo sapiens] 
  X   
gi|110347457|ref|NP_001400.3
| 
EGF-like-domain, multiple 3 [Homo sapiens] 
  X X gi|38201714|ref|NP_001410.2| ELAV-like 1 [Homo sapiens] 
  X   gi|4826714|ref|NP_005098.1| endonuclease G-like 1 [Homo sapiens] 
    X 
gi|5803013|ref|NP_006808.1| endoplasmic reticulum protein 29 isoform 1 
precursor [Homo sapiens] 
    X 
gi|34335272|ref|NP_006395.2| endothelial protein C receptor precursor [Homo 
sapiens] 
  X   gi|4758302|ref|NP_004441.1| enhancer of rudimentary homolog [Homo sapiens] 
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X X X gi|4503571|ref|NP_001419.1| enolase 1 [Homo sapiens] 
  X X gi|5803011|ref|NP_001966.1| enolase 2 [Homo sapiens] 
  X   gi|10864017|ref|NP_067027.1| enolase-phosphatase 1 [Homo sapiens] 
    X gi|4758280|ref|NP_004429.1| ephrin receptor EphA4 [Homo sapiens] 
  X X 
gi|5453678|ref|NP_006423.1| epididymal secretory protein E1 precursor [Homo 
sapiens] 
  X X 
gi|124494254|ref|NP_006182.2
| 
ErbB3-binding protein 1 [Homo sapiens] 
  X   
gi|4557245|ref|NP_001098.1| erythrocyte acylphosphatase 1 isoform a [Homo 
sapiens] 
  X X 
gi|33413400|ref|NP_001975.1| esterase D/formylglutathione hydrolase [Homo 
sapiens] 
  X X 
gi|4503471|ref|NP_001393.1| eukaryotic translation elongation factor 1 alpha 1 
[Homo sapiens] 
  X X 
gi|4503475|ref|NP_001949.1| eukaryotic translation elongation factor 1 alpha 2 
[Homo sapiens] 
  X X 
gi|11136628|ref|NP_066944.1|,
gi|148222882|ref|NP_0010833
45.1|,gi|4503477|ref|NP_00195
0.1|,gi|83376130|ref|NP_00103
2752.1| 
eukaryotic translation elongation factor 1 beta 2 
[Homo sapiens],hypothetical protein LOC644820 
[Homo sapiens] 
  X X 
gi|25453472|ref|NP_001951.2|,
gi|25453474|ref|NP_115754.2| 
eukaryotic translation elongation factor 1 delta 
isoform 2 [Homo sapiens],eukaryotic translation 
elongation factor 1 delta isoform 1 [Homo sapiens] 
  X X 
gi|4503481|ref|NP_001395.1| eukaryotic translation elongation factor 1 gamma 
[Homo sapiens] 
  X X 
gi|4503483|ref|NP_001952.1| eukaryotic translation elongation factor 2 [Homo 
sapiens] 
    X 
gi|4758256|ref|NP_004085.1| eukaryotic translation initiation factor 2, subunit 1 
alpha, 35kDa [Homo sapiens] 
  X   
gi|4503507|ref|NP_001406.1| eukaryotic translation initiation factor 2, subunit 3 
gamma, 52kDa [Homo sapiens] 
  X   
gi|38201619|ref|NP_004944.2|,
gi|38201621|ref|NP_886553.2|,
gi|38201623|ref|NP_937884.1|,
gi|38201625|ref|NP_937885.1|,
gi|38201627|ref|NP_937887.1| 
eukaryotic translation initiation factor 4 gamma, 1 
isoform 4 [Homo sapiens],eukaryotic translation 
initiation factor 4 gamma, 1 isoform 1 [Homo 
sapiens],eukaryotic translation initiation factor 4 
gamma, 1 isoform 1 [Homo sapiens] 
  X X 
gi|4503529|ref|NP_001407.1| eukaryotic translation initiation factor 4A isoform 1 
[Homo sapiens] 
  X X 
gi|50053795|ref|NP_001408.2| eukaryotic translation initiation factor 4B [Homo 
sapiens] 
  X X 
gi|31563374|ref|NP_852131.1|,
gi|31563378|ref|NP_852133.1|,
gi|4504771|ref|NP_002203.1| 
eukaryotic translation initiation factor 6 isoform c 
[Homo sapiens],eukaryotic translation initiation 
factor 6 isoform a [Homo sapiens] 
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  X   
gi|4885225|ref|NP_005234.1|,g
i|7669490|ref|NP_053733.1| 
Ewing sarcoma breakpoint region 1 isoform EWS 
[Homo sapiens],Ewing sarcoma breakpoint region 
1 isoform EWS-b [Homo sapiens] 
  X   gi|4507943|ref|NP_003391.1| exportin 1 [Homo sapiens] 
  X X 
gi|4758236|ref|NP_004416.1| extracellular matrix protein 1 isoform 1 precursor 
[Homo sapiens] 
    X 
gi|12707572|ref|NP_073155.1| extracellular matrix protein 1 isoform 2 precursor 
[Homo sapiens] 
  X X gi|21614499|ref|NP_003370.2| ezrin [Homo sapiens] 
  X X 
gi|5453597|ref|NP_006126.1| F-actin capping protein alpha-1 subunit [Homo 
sapiens] 
  X X 
gi|4826659|ref|NP_004921.1| F-actin capping protein beta subunit [Homo 
sapiens] 
  X X 
gi|7661714|ref|NP_055703.1|,g
i|91807125|ref|NP_001035109.
1| 
family with sequence similarity 3, member C 
precursor [Homo sapiens],family with sequence 
similarity 3, member C precursor [Homo sapiens] 
  X   
gi|14149680|ref|NP_056107.1| family with sequence similarity 62 (C2 domain 
containing), member A [Homo sapiens] 
  X X 
gi|17402900|ref|NP_003893.2| far upstream element-binding protein [Homo 
sapiens] 
  X X gi|4503685|ref|NP_001995.1| farnesyl diphosphate synthase [Homo sapiens] 
  X   gi|31377837|ref|NP_078898.2| FAST kinase domains 1 [Homo sapiens] 
  X X gi|41872631|ref|NP_004095.4| fatty acid synthase [Homo sapiens] 
    X gi|20149498|ref|NP_000137.2| ferritin, light polypeptide [Homo sapiens] 
  X   
gi|16933542|ref|NP_002017.1|,
gi|47132551|ref|NP_997640.1|,
gi|47132555|ref|NP_997643.1|,
gi|47132557|ref|NP_997647.1| 
fibronectin 1 isoform 3 preproprotein [Homo 
sapiens],fibronectin 1 isoform 2 preproprotein 
[Homo sapiens],fibronectin 1 isoform 4 
preproprotein [Homo sapiens],fibronectin 1 isoform 
1 preproprotein [Homo sapiens] 
  X X gi|34734062|ref|NP_001987.2| fibulin 1 isoform C precursor [Homo sapiens] 
  X   
gi|51873053|ref|NP_00100401
9.1|,gi|51873055|ref|NP_00198
9.2| 
fibulin 2 precursor, isoform a [Homo sapiens],fibulin 
2 precursor, isoform b [Homo sapiens] 
X X X 
gi|116063573|ref|NP_001447.2
| 
filamin A, alpha isoform 1 [Homo sapiens] 
  X X 
gi|105990514|ref|NP_001448.2
| 
filamin B, beta (actin binding protein 278) [Homo 
sapiens] 
    X 
gi|17149836|ref|NP_463460.1|,
gi|4503725|ref|NP_000792.1| 
FK506-binding protein 1A [Homo sapiens] 
  X   gi|4503727|ref|NP_002004.1| FK506-binding protein 3 [Homo sapiens] 
  X X gi|4503729|ref|NP_002005.1| FK506-binding protein 4 [Homo sapiens] 
  X   
gi|4758356|ref|NP_004102.1| flap structure-specific endonuclease 1 [Homo 
sapiens] 
  X X gi|5901956|ref|NP_009016.1| follistatin-like 1 precursor [Homo sapiens] 
  X   gi|28376619|ref|NP_064501.1| follistatin-like 5 [Homo sapiens] 
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  X X gi|4885063|ref|NP_005156.1| fructose-bisphosphate aldolase C [Homo sapiens] 
  X X gi|40068512|ref|NP_114409.2| fucosidase, alpha-L- 2, plasma [Homo sapiens] 
  X   gi|19743875|ref|NP_000134.2| fumarate hydratase precursor [Homo sapiens] 
  X   
gi|47078238|ref|NP_997657.1|,
gi|47078240|ref|NP_004118.3| 
G protein pathway suppressor 1 isoform 1 [Homo 
sapiens],G protein pathway suppressor 1 isoform 2 
[Homo sapiens] 
    X 
gi|50355941|ref|NP_940971.1|,
gi|74048357|ref|NP_065188.4|,
gi|74048403|ref|NP_00102756
7.1|,gi|74048422|ref|NP_00102
7566.1| 
G protein-coupled receptor 126 beta 1 [Homo 
sapiens],G protein-coupled receptor 126 alpha 1 
[Homo sapiens],G protein-coupled receptor 126 
beta 2 [Homo sapiens],G protein-coupled receptor 
126 alpha 2 [Homo sapiens] 
  X X 
gi|115430223|ref|NP_002297.2
| 
galectin 3 [Homo sapiens] 
  X X gi|5031863|ref|NP_005558.1| galectin 3 binding protein [Homo sapiens] 
  X   
gi|116805322|ref|NP_001449.3
| 
gamma filamin [Homo sapiens] 
  X   
gi|4503987|ref|NP_003869.1| gamma-glutamyl hydrolase precursor [Homo 
sapiens] 
  X   gi|4503971|ref|NP_001484.1| GDP dissociation inhibitor 1 [Homo sapiens] 
  X X gi|6598323|ref|NP_001485.2| GDP dissociation inhibitor 2 [Homo sapiens] 
    X gi|4504165|ref|NP_000168.1| gelsolin isoform a precursor [Homo sapiens] 
  X   
gi|38044288|ref|NP_937895.1|,
gi|4504165|ref|NP_000168.1| 
gelsolin isoform b [Homo sapiens],gelsolin isoform 
a precursor [Homo sapiens] 
  X X gi|63252913|ref|NP_001738.2| gelsolin-like capping protein [Homo sapiens] 
  X X 
gi|119393897|ref|NP_000149.2
| 
glucan (1,4-alpha-), branching enzyme 1 [Homo 
sapiens] 
    X 
gi|54607043|ref|NP_000148.2|,
gi|54607045|ref|NP_00100574
1.1|,gi|54607047|ref|NP_00100
5742.1|,gi|54607049|ref|NP_00
1005749.1|,gi|54607051|ref|NP
_001005750.1| 
glucocerebrosidase precursor [Homo sapiens] 
  X X 
gi|13027378|ref|NP_005462.1| glucosamine-6-phosphate deaminase 1 [Homo 
sapiens] 
  X X gi|18201905|ref|NP_000166.2| glucose phosphate isomerase [Homo sapiens] 
    X 
gi|108773793|ref|NP_0010358
10.1|,gi|109389365|ref|NP_000
393.4| 
glucose-6-phosphate dehydrogenase isoform b 
[Homo sapiens],glucose-6-phosphate 
dehydrogenase isoform a [Homo sapiens] 
    X gi|4885281|ref|NP_005262.1| glutamate dehydrogenase 1 [Homo sapiens] 
  X X 
gi|6912618|ref|NP_036545.1| glutaminyl-peptide cyclotransferase precursor 
[Homo sapiens] 
    X gi|4826960|ref|NP_005042.1| glutaminyl-tRNA synthetase [Homo sapiens] 
    X gi|95113651|ref|NP_006532.2| glutaredoxin 3 [Homo sapiens] 
  X   gi|50301238|ref|NP_000628.2| glutathione reductase [Homo sapiens] 
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  X   gi|4504169|ref|NP_000169.1| glutathione synthetase [Homo sapiens] 
  X X gi|4504183|ref|NP_000843.1| glutathione transferase [Homo sapiens] 
  X X gi|4758484|ref|NP_004823.1| glutathione-S-transferase omega 1 [Homo sapiens] 
  X X 
gi|7669492|ref|NP_002037.2| glyceraldehyde-3-phosphate dehydrogenase 
[Homo sapiens] 
    X gi|5032009|ref|NP_005600.1| glycogen phosphorylase [Homo sapiens] 
  X X gi|71037379|ref|NP_002854.3| glycogen phosphorylase, liver [Homo sapiens] 
    X 
gi|116805340|ref|NP_002038.2
| 
glycyl-tRNA synthetase [Homo sapiens] 
  X X gi|34850074|ref|NP_057164.2| glyoxalase domain containing 4 [Homo sapiens] 
  X X 
gi|118402586|ref|NP_006699.2
| 
glyoxalase I [Homo sapiens] 
  X   gi|4504081|ref|NP_002072.1| glypican 1 precursor [Homo sapiens] 
    X 
gi|39995109|ref|NP_000396.2| GM2 ganglioside activator precursor [Homo 
sapiens] 
    X gi|54633312|ref|NP_036333.2| golgi apparatus protein 1 [Homo sapiens] 
  X X 
gi|29550838|ref|NP_057632.2|,
gi|29550850|ref|NP_808800.1| 
golgi membrane protein 1 [Homo sapiens] 
  X X gi|4504151|ref|NP_002078.1| granulin precursor [Homo sapiens] 
  X   
gi|4504111|ref|NP_002077.1|,g
i|45359859|ref|NP_987102.1| 
growth factor receptor-bound protein 2 isoform 1 
[Homo sapiens],growth factor receptor-bound 
protein 2 isoform 2 [Homo sapiens] 
    X 
gi|58761500|ref|NP_037473.3| GTP-binding protein PTD004 isoform 1 [Homo 
sapiens] 
    X 
gi|5174447|ref|NP_006089.1| guanine nucleotide binding protein (G protein), beta 
polypeptide 2-like 1 [Homo sapiens] 
    X gi|42544159|ref|NP_006635.2| heat shock 105kD [Homo sapiens] 
  X X gi|4504523|ref|NP_002148.1| heat shock 10kDa protein 1 [Homo sapiens] 
    X gi|4504517|ref|NP_001531.1| heat shock 27kDa protein 1 [Homo sapiens] 
  X X 
gi|19923193|ref|NP_003923.2| heat shock 70kD protein binding protein [Homo 
sapiens] 
  X X 
gi|4885431|ref|NP_005337.1|,g
i|5123454|ref|NP_005336.2| 
heat shock 70kDa protein 1B [Homo sapiens],heat 
shock 70kDa protein 1A [Homo sapiens] 
  X   
gi|124256496|ref|NP_005518.3
| 
heat shock 70kDa protein 1-like [Homo sapiens] 
  X X gi|38327039|ref|NP_002145.3| heat shock 70kDa protein 4 [Homo sapiens] 
  X X gi|16507237|ref|NP_005338.1| heat shock 70kDa protein 5 [Homo sapiens] 
  X X 
gi|34419635|ref|NP_002146.2| heat shock 70kDa protein 6 (HSP70B') [Homo 
sapiens] 
X X X 
gi|5729877|ref|NP_006588.1| heat shock 70kDa protein 8 isoform 1 [Homo 
sapiens] 
  X X 
gi|24234688|ref|NP_004125.3| heat shock 70kDa protein 9 precursor [Homo 
sapiens] 
X X X gi|20149594|ref|NP_031381.2| heat shock 90kDa protein 1, beta [Homo sapiens] 
  X   gi|4557647|ref|NP_001528.1| heat shock factor binding protein 1 [Homo sapiens] 
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  X X 
gi|153792590|ref|NP_0010179
63.2|,gi|154146191|ref|NP_005
339.3| 
heat shock protein 90kDa alpha (cytosolic), class A 
member 1 isoform 1 [Homo sapiens],heat shock 
protein 90kDa alpha (cytosolic), class A member 1 
isoform 2 [Homo sapiens] 
  X   
gi|50345292|ref|NP_00100203
3.1|,gi|50345294|ref|NP_00100
2032.1|,gi|7705877|ref|NP_057
269.1| 
hematological and neurological expressed 1 
isoform 3 [Homo sapiens],hematological and 
neurological expressed 1 isoform 2 [Homo 
sapiens],hematological and neurological expressed 
1 isoform 1 [Homo sapiens] 
  X   
gi|21700763|ref|NP_653171.1| hematological and neurological expressed 1-like 
[Homo sapiens] 
  X X 
gi|126012571|ref|NP_005520.4
| 
heparan sulfate proteoglycan 2 [Homo sapiens] 
  X X 
gi|4758516|ref|NP_004485.1| hepatoma-derived growth factor (high-mobility 
group protein 1-like) [Homo sapiens] 
  X   
gi|14249158|ref|NP_116020.1|,
gi|48255931|ref|NP_00100152
0.1| 
hepatoma-derived growth factor-related protein 2 
isoform 2 [Homo sapiens],hepatoma-derived 
growth factor-related protein 2 isoform 1 [Homo 
sapiens] 
  X X 
gi|14043070|ref|NP_112420.1|,
gi|4504445|ref|NP_002127.1| 
heterogeneous nuclear ribonucleoprotein A1 
isoform b [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein A1 isoform a [Homo sapiens] 
  X X 
gi|14043072|ref|NP_112533.1| heterogeneous nuclear ribonucleoprotein A2/B1 
isoform B1 [Homo sapiens] 
  X   
gi|4504447|ref|NP_002128.1| heterogeneous nuclear ribonucleoprotein A2/B1 
isoform A2 [Homo sapiens] 
  X X 
gi|34740329|ref|NP_919223.1| heterogeneous nuclear ribonucleoprotein A3 
[Homo sapiens] 
  X X 
gi|55956919|ref|NP_112556.2|,
gi|55956921|ref|NP_004490.2| 
heterogeneous nuclear ribonucleoprotein AB 
isoform a [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein AB isoform b [Homo sapiens] 
  X X 
gi|117189975|ref|NP_112604.2
|,gi|117190174|ref|NP_004491.
2|,gi|117190192|ref|NP_00107
0910.1|,gi|117190254|ref|NP_0
01070911.1| 
heterogeneous nuclear ribonucleoprotein C isoform 
a [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein C isoform b [Homo 
sapiens],heterogeneous nuclear ribonucleoprotein 
C isoform a [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein C isoform b [H 
  X X 
gi|14110414|ref|NP_002129.2|,
gi|14110420|ref|NP_112738.1| 
heterogeneous nuclear ribonucleoprotein D isoform 
c [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein D isoform a [Homo sapiens] 
  X   
gi|14110407|ref|NP_112740.1| heterogeneous nuclear ribonucleoprotein D-like 
[Homo sapiens] 
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  X X 
gi|148470397|ref|NP_0010916
78.1|,gi|148470400|ref|NP_001
091677.1|,gi|148470402|ref|NP
_001091675.1|,gi|148470404|r
ef|NP_001091674.1|,gi|148470
406|ref|NP_001091676.1|,gi|48
26760|ref|NP_004957.1| 
heterogeneous nuclear ribonucleoprotein F [Homo 
sapiens] 
  X X 
gi|5031753|ref|NP_005511.1| heterogeneous nuclear ribonucleoprotein H1 
[Homo sapiens] 
  X   
gi|14141157|ref|NP_036339.1|,
gi|14141159|ref|NP_067676.2| 
heterogeneous nuclear ribonucleoprotein H3 
isoform a [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein H3 isoform b [Homo sapiens] 
X X X 
gi|14165435|ref|NP_112552.1|,
gi|14165437|ref|NP_112553.1|,
gi|14165439|ref|NP_002131.2| 
heterogeneous nuclear ribonucleoprotein K isoform 
b [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein K isoform a [Homo 
sapiens],heterogeneous nuclear ribonucleoprotein 
K isoform a [Homo sapiens] 
  X X 
gi|52632383|ref|NP_001524.2| heterogeneous nuclear ribonucleoprotein L isoform 
a [Homo sapiens] 
    X 
gi|52632385|ref|NP_00100533
5.1| 
heterogeneous nuclear ribonucleoprotein L isoform 
b [Homo sapiens] 
  X X 
gi|156151392|ref|NP_0010958
67.1|,gi|156151394|ref|NP_001
095868.1|,gi|156151396|ref|NP
_001095869.1|,gi|5031755|ref|
NP_005817.1| 
heterogeneous nuclear ribonucleoprotein R isoform 
4 [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein R isoform 1 [Homo 
sapiens],heterogeneous nuclear ribonucleoprotein 
R isoform 3 [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein R isoform 2 [H 
  X   
gi|14141161|ref|NP_004492.2|,
gi|74136883|ref|NP_114032.2| 
heterogeneous nuclear ribonucleoprotein U isoform 
b [Homo sapiens],heterogeneous nuclear 
ribonucleoprotein U isoform a [Homo sapiens] 
    X gi|4504371|ref|NP_000511.1| hexosaminidase A preproprotein [Homo sapiens] 
  X X gi|4504373|ref|NP_000512.1| hexosaminidase B preproprotein [Homo sapiens] 
  X X 
gi|22208967|ref|NP_665906.1|,
gi|22208971|ref|NP_665908.1|,
gi|22208977|ref|NP_665911.1| 
high mobility group AT-hook 1 isoform a [Homo 
sapiens] 
  X X gi|4504425|ref|NP_002119.1| high-mobility group box 1 [Homo sapiens] 
  X X gi|11321591|ref|NP_002120.1| high-mobility group box 2 [Homo sapiens] 
  X   gi|71143137|ref|NP_005333.2| high-mobility group box 3 [Homo sapiens] 
  X   
gi|48255933|ref|NP_004956.5| high-mobility group nucleosome binding domain 1 
[Homo sapiens] 
    X 
gi|4885413|ref|NP_005331.1| histidine triad nucleotide binding protein 1 [Homo 
sapiens] 
  X X gi|6996014|ref|NP_002100.2| histidyl-tRNA synthetase [Homo sapiens] 
  X   
gi|4504341|ref|NP_003633.1| histone acetyltransferase 1 isoform a [Homo 
sapiens] 
  X   gi|4885381|ref|NP_005313.1| histone cluster 1, H1b [Homo sapiens] 
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  X   
gi|4885375|ref|NP_005310.1|,g
i|4885377|ref|NP_005311.1|,gi|
4885379|ref|NP_005312.1| 
histone cluster 1, H1c [Homo sapiens],histone 
cluster 1, H1d [Homo sapiens],histone cluster 1, 
H1e [Homo sapiens] 
  X   
gi|25092737|ref|NP_734466.1|,
gi|4504253|ref|NP_002096.1| 
histone cluster 1, H2aa [Homo sapiens],H2A 
histone family, member X [Homo sapiens] 
    X 
gi|10645195|ref|NP_066390.1|,
gi|106775678|ref|NP_0010358
07.1|,gi|10800130|ref|NP_0664
09.1|,gi|10800132|ref|NP_0664
08.1|,gi|10800144|ref|NP_0665
44.1|,gi|15617199|ref|NP_2542
80.1|,gi|18105045|ref|NP_5421
63.1|,gi|19557656|ref|NP_0035
04.2|,gi|24638446|ref|NP_ 
histone cluster 1, H2ae [Homo sapiens],histone 
cluster 2, H2aa4 [Homo sapiens],histone cluster 1, 
H2ad [Homo sapiens],histone cluster 1, H2ag 
[Homo sapiens],histone cluster 1, H2aj [Homo 
sapiens],histone cluster 3, H2a [Homo 
sapiens],histone cluster 1, H2 
  X X 
gi|10800140|ref|NP_066406.1|,
gi|16306566|ref|NP_003518.2|,
gi|20336754|ref|NP_066402.2|,
gi|28173554|ref|NP_778225.1|,
gi|4504277|ref|NP_003519.1| 
histone cluster 1, H2bb [Homo sapiens],histone 
cluster 1, H2bo [Homo sapiens],histone cluster 1, 
H2bj [Homo sapiens],histone cluster 3, H2bb 
[Homo sapiens],histone cluster 2, H2be [Homo 
sapiens] 
  X   
gi|10800138|ref|NP_066407.1|,
gi|18105048|ref|NP_542160.1|,
gi|20336752|ref|NP_619790.1|,
gi|21166389|ref|NP_003517.2|,
gi|21396484|ref|NP_003514.2|,
gi|4504257|ref|NP_003509.1|,g
i|4504259|ref|NP_003510.1|,gi|
4504261|ref|NP_003511.1|,gi|4
504263|ref|NP_003512.1 
histone cluster 1, H2bd [Homo sapiens],histone 
cluster 1, H2bk [Homo sapiens],histone cluster 1, 
H2bd [Homo sapiens],histone cluster 1, H2bc 
[Homo sapiens],histone cluster 1, H2be [Homo 
sapiens],histone cluster 1, H2bg [Homo 
sapiens],histone cluster 1, H2 
  X   
gi|10440560|ref|NP_066298.1|,
gi|169162559|ref|XP_497711.3
|,gi|21071021|ref|NP_003521.2
|,gi|31742503|ref|NP_066403.2
|,gi|4504279|ref|NP_002098.1|,
gi|4504281|ref|NP_003520.1|,g
i|4504285|ref|NP_003522.1|,gi|
4504287|ref|NP_003523.1|,gi|4
504289|ref|NP_003524.1 
histone cluster 1, H3f [Homo 
sapiens],PREDICTED: hypothetical protein [Homo 
sapiens],histone cluster 1, H3d [Homo 
sapiens],histone cluster 2, H3c [Homo sapiens],H3 
histone, family 3A [Homo sapiens],histone cluster 
1, H3a [Homo sapiens],histone cluster 1,  
  
111 
 
q
P
S
C 
c
a
P
S
C 
P
C
C 
Protein Description 
  X X 
gi|11415030|ref|NP_068803.1|,
gi|28173560|ref|NP_778224.1|,
gi|4504301|ref|NP_003529.1|,g
i|4504303|ref|NP_003530.1|,gi|
4504305|ref|NP_003531.1|,gi|4
504307|ref|NP_003532.1|,gi|45
04309|ref|NP_003533.1|,gi|450
4311|ref|NP_003534.1|,gi|4504
313|ref|NP_003535.1|,g 
histone cluster 1, H4j [Homo sapiens],histone 
cluster 4, H4 [Homo sapiens],histone cluster 1, H4a 
[Homo sapiens],histone cluster 1, H4d [Homo 
sapiens],histone cluster 1, H4f [Homo 
sapiens],histone cluster 1, H4k [Homo 
sapiens],histone cluster 1, H4c [Homo 
  X X 
gi|18375623|ref|NP_542165.1|,
gi|4758112|ref|NP_004631.1| 
HLA-B associated transcript 1 [Homo 
sapiens],HLA-B associated transcript 1 [Homo 
sapiens] 
  X X 
gi|150456457|ref|NP_938075.2
|,gi|151301219|ref|NP_938074.
2|,gi|154759421|ref|NP_00152
7.3| 
HMT1 hnRNP methyltransferase-like 2 isoform 2 
[Homo sapiens],HMT1 hnRNP methyltransferase-
like 2 isoform 3 [Homo sapiens],HMT1 hnRNP 
methyltransferase-like 2 isoform 1 [Homo sapiens] 
  X   gi|7706322|ref|NP_057123.1| homeobox prox 1 [Homo sapiens] 
  X   
gi|94538320|ref|NP_00103551
7.1|,gi|94538322|ref|NP_00531
7.2| 
hydroxyacyl glutathione hydrolase isoform 2 [Homo 
sapiens],hydroxyacyl glutathione hydrolase isoform 
1 [Homo sapiens] 
  X   gi|27734925|ref|NP_775928.1| hypothetical protein LOC285315 [Homo sapiens] 
  X   gi|39930541|ref|NP_899064.1| hypothetical protein LOC286257 [Homo sapiens] 
  X   
gi|63055057|ref|NP_00101799
2.1| 
hypothetical protein LOC345651 [Homo sapiens] 
  X   gi|42734438|ref|NP_057707.3| hypothetical protein LOC51571 [Homo sapiens] 
  X   gi|46195792|ref|NP_060485.3| hypothetical protein LOC55086 [Homo sapiens] 
    X gi|50843837|ref|NP_060541.3| hypothetical protein LOC55701 [Homo sapiens] 
    X 
gi|51093863|ref|NP_073744.2|,
gi|79750824|ref|NP_00103061
1.1| 
hypothetical protein LOC64855 isoform 1 [Homo 
sapiens],hypothetical protein LOC64855 isoform 2 
[Homo sapiens] 
  X X gi|13129018|ref|NP_076956.1| hypothetical protein LOC79017 [Homo sapiens] 
  X X 
gi|4504483|ref|NP_000185.1| hypoxanthine phosphoribosyltransferase 1 [Homo 
sapiens] 
    X gi|5453832|ref|NP_006380.1| hypoxia up-regulated 1 precursor [Homo sapiens] 
  X   gi|4504699|ref|NP_002183.1| inhibin beta A precursor [Homo sapiens] 
    X 
gi|119964726|ref|NP_000867.2
| 
insulin-like growth factor 2 receptor precursor 
[Homo sapiens] 
  X   
gi|62243068|ref|NP_000589.2|,
gi|62243248|ref|NP_00101341
6.1| 
insulin-like growth factor binding protein 3 isoform b 
precursor [Homo sapiens],insulin-like growth factor 
binding protein 3 isoform a precursor [Homo 
sapiens] 
  X   
gi|62243290|ref|NP_001543.2| insulin-like growth factor binding protein 4 
precursor [Homo sapiens] 
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    X 
gi|11321593|ref|NP_002169.1| insulin-like growth factor binding protein 6 [Homo 
sapiens] 
  X   
gi|4504619|ref|NP_001544.1| insulin-like growth factor binding protein 7 [Homo 
sapiens] 
X     gi|88758615|ref|NP_000410.2| integrin alpha 2b preproprotein [Homo sapiens] 
  X   
gi|4758578|ref|NP_004754.1| integrin cytoplasmic domain-associated protein 1 
isoform 1 [Homo sapiens] 
    X gi|10834978|ref|NP_000575.1| interleukin 8 precursor [Homo sapiens] 
  X X 
gi|24234747|ref|NP_004506.2| interleukin enhancer binding factor 2 [Homo 
sapiens] 
  X X 
gi|24234750|ref|NP_036350.2|,
gi|24234753|ref|NP_004507.2|,
gi|24234756|ref|NP_703194.1| 
interleukin enhancer binding factor 3 isoform a 
[Homo sapiens],interleukin enhancer binding factor 
3 isoform b [Homo sapiens],interleukin enhancer 
binding factor 3 isoform c [Homo sapiens] 
  X X 
gi|4506787|ref|NP_003861.1| IQ motif containing GTPase activating protein 1 
[Homo sapiens] 
  X X 
gi|28178825|ref|NP_005887.2| isocitrate dehydrogenase 1 (NADP+), soluble 
[Homo sapiens] 
  X   
gi|40018633|ref|NP_004499.2| isopentenyl-diphosphate delta isomerase [Homo 
sapiens] 
  X   
gi|109255243|ref|NP_004178.2
| 
jumonji, AT rich interactive domain 1C [Homo 
sapiens] 
    X 
gi|4506155|ref|NP_002765.1|,g
i|61744424|ref|NP_001012982.
1| 
kallikrein-related peptidase 6 isoform A 
preproprotein [Homo sapiens],kallikrein-related 
peptidase 6 isoform A preproprotein [Homo 
sapiens] 
    X gi|4504901|ref|NP_002259.1| karyopherin alpha 4 [Homo sapiens] 
  X X gi|19923142|ref|NP_002256.2| karyopherin beta 1 [Homo sapiens] 
X X X 
gi|119395750|ref|NP_006112.3
| 
keratin 1 [Homo sapiens] 
X X X gi|40354192|ref|NP_000412.2| keratin 10 [Homo sapiens] 
  X   gi|4557699|ref|NP_000214.1| keratin 12 [Homo sapiens] 
  X X 
gi|40354195|ref|NP_954657.1|,
gi|4557888|ref|NP_000215.1| 
keratin 18 [Homo sapiens],keratin 18 [Homo 
sapiens] 
X     gi|47132620|ref|NP_000414.2| keratin 2 [Homo sapiens] 
  X X gi|45597458|ref|NP_778253.1| keratin 77 [Homo sapiens] 
  X X gi|4504919|ref|NP_002264.1| keratin 8 [Homo sapiens] 
X X X gi|55956899|ref|NP_000217.2| keratin 9 [Homo sapiens] 
  X   
gi|5730027|ref|NP_006550.1| KH domain containing, RNA binding, signal 
transduction associated 1 [Homo sapiens] 
  X X 
gi|154355000|ref|NP_003676.2
| 
KH-type splicing regulatory protein (FUSE binding 
protein 2) [Homo sapiens] 
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  X   
gi|118498356|ref|NP_0010729
89.1|,gi|118498362|ref|NP_001
072990.1|,gi|118498368|ref|NP
_004977.2|,gi|33620775|ref|NP
_891556.1| 
kinectin 1 isoform a [Homo sapiens],kinectin 1 
isoform b [Homo sapiens],kinectin 1 isoform c 
[Homo sapiens],kinectin 1 isoform a [Homo 
sapiens] 
    X 
gi|21361809|ref|NP_062556.2|,
gi|56699409|ref|NP_002130.2| 
kynurenine aminotransferase III isoform 3 [Homo 
sapiens],RNA binding motif protein, X-linked [Homo 
sapiens] 
  X   
gi|94557308|ref|NP_005318.2| L-3-hydroxyacyl-Coenzyme A dehydrogenase 
precursor [Homo sapiens] 
X X X gi|5031857|ref|NP_005557.1| lactate dehydrogenase A [Homo sapiens] 
X X   gi|4557032|ref|NP_002291.1| lactate dehydrogenase B [Homo sapiens] 
  X X gi|27436946|ref|NP_733821.1| lamin A/C isoform 1 precursor [Homo sapiens] 
  X   gi|5031875|ref|NP_005563.1| lamin A/C isoform 2 [Homo sapiens] 
    X gi|27436948|ref|NP_733822.1| lamin A/C isoform 3 [Homo sapiens] 
  X X gi|5031877|ref|NP_005564.1| lamin B1 [Homo sapiens] 
  X   gi|27436951|ref|NP_116126.2| lamin B2 [Homo sapiens] 
  X   gi|21264602|ref|NP_005551.3| laminin alpha 5 [Homo sapiens] 
    X 
gi|145309326|ref|NP_002284.3
| 
laminin, gamma 1 precursor [Homo sapiens] 
  X   
gi|4557733|ref|NP_000419.1| latent transforming growth factor beta binding 
protein 2 [Homo sapiens] 
  X   
gi|110347412|ref|NP_003564.2
|,gi|110347431|ref|NP_001036
009.1|,gi|110347437|ref|NP_00
1036010.1| 
latent transforming growth factor beta binding 
protein 4 isoform b [Homo sapiens],latent 
transforming growth factor beta binding protein 4 
isoform a [Homo sapiens],latent transforming 
growth factor beta binding protein 4 isoform c 
[Homo sapiens] 
  X   gi|21359933|ref|NP_064554.2| latexin [Homo sapiens] 
    X gi|5803023|ref|NP_006807.1| lectin, mannose-binding 2 [Homo sapiens] 
    X 
gi|56682962|ref|NP_005597.3|,
gi|56682964|ref|NP_00100853
0.1| 
legumain preproprotein [Homo sapiens] 
    X gi|40254924|ref|NP_060979.2| leucine rich repeat containing 59 [Homo sapiens] 
  X X gi|4505029|ref|NP_000886.1| leukotriene A4 hydrolase [Homo sapiens] 
  X X gi|5453710|ref|NP_006139.1| LIM and SH3 protein 1 [Homo sapiens] 
    X gi|51317399|ref|NP_000226.2| lipase A precursor [Homo sapiens] 
  X   
gi|29337281|ref|NP_076435.1| Ly-6 neurotoxin-like protein 1 isoform a [Homo 
sapiens] 
  X   
gi|4504957|ref|NP_002285.1|,g
i|7669503|ref|NP_054701.1| 
lysosomal-associated membrane protein 2 
precursor [Homo sapiens] 
  X X gi|32307144|ref|NP_000293.2| lysyl hydroxylase precursor [Homo sapiens] 
  X X gi|4505011|ref|NP_002309.1| lysyl oxidase-like 2 precursor [Homo sapiens] 
    X gi|5031815|ref|NP_005539.1| lysyl-tRNA synthetase [Homo sapiens] 
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  X X 
gi|4505185|ref|NP_002406.1| macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) [Homo sapiens] 
    X 
gi|4505087|ref|NP_002361.1|,g
i|8922331|ref|NP_060518.1| 
mago-nashi homolog [Homo sapiens],mago-nashi 
homolog B [Homo sapiens] 
    X 
gi|24797067|ref|NP_002107.3| major histocompatibility complex, class I, A 
precursor [Homo sapiens] 
  X   
gi|52630342|ref|NP_002108.4| major histocompatibility complex, class I, C 
precursor [Homo sapiens] 
X X X 
gi|67782305|ref|NP_000627.2|,
gi|67782307|ref|NP_00101963
6.1| 
manganese superoxide dismutase isoform A 
precursor [Homo sapiens] 
  X X 
gi|20127486|ref|NP_005808.2| mannose 6 phosphate receptor binding protein 1 
[Homo sapiens] 
  X   
gi|24497519|ref|NP_005898.2| mannosidase, alpha, class 1A, member 1 [Homo 
sapiens] 
  X X 
gi|51477714|ref|NP_002363.2| mannosidase, alpha, class 2A, member 1 [Homo 
sapiens] 
    X gi|13491174|ref|NP_075385.1| MARCKS-like 1 [Homo sapiens] 
  X   gi|11321565|ref|NP_002372.1| matrilin 3 precursor [Homo sapiens] 
    X 
gi|21626466|ref|NP_061322.2|,
gi|62750354|ref|NP_954659.1| 
matrin 3 [Homo sapiens] 
    X 
gi|4505215|ref|NP_002412.1| matrix metalloproteinase 1 preproprotein [Homo 
sapiens] 
  X   
gi|11342666|ref|NP_004521.1| matrix metalloproteinase 2 preproprotein [Homo 
sapiens] 
  X   gi|30520310|ref|NP_848927.1| metadherin [Homo sapiens] 
  X X 
gi|5174529|ref|NP_005902.1| methionine adenosyltransferase II, alpha [Homo 
sapiens] 
  X   
gi|11034825|ref|NP_037415.1|,
gi|33519455|ref|NP_877725.1| 
methionine adenosyltransferase II, beta isoform 1 
[Homo sapiens],methionine adenosyltransferase II, 
beta isoform 2 [Homo sapiens] 
  X   
gi|153945728|ref|NP_005900.2
| 
microtubule-associated protein 1B [Homo sapiens] 
  X X 
gi|47519639|ref|NP_002366.2| microtubule-associated protein 4 isoform 1 [Homo 
sapiens] 
  X   
gi|48375173|ref|NP_149052.1| microtubule-associated protein 6 isoform 1 [Homo 
sapiens] 
  X X 
gi|6912494|ref|NP_036457.1| microtubule-associated protein, RP/EB family, 
member 1 [Homo sapiens] 
  X   
gi|4505135|ref|NP_002382.1|,g
i|59894792|ref|NP_001012334.
1|,gi|59894796|ref|NP_001012
333.1| 
midkine [Homo sapiens] 
  X   
gi|5174557|ref|NP_005919.1| milk fat globule-EGF factor 8 protein [Homo 
sapiens] 
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    X 
gi|33356547|ref|NP_004517.2| minichromosome maintenance complex component 
2 [Homo sapiens] 
  X   
gi|6631095|ref|NP_002379.2| minichromosome maintenance complex component 
3 [Homo sapiens] 
  X X 
gi|21735621|ref|NP_005909.2| mitochondrial malate dehydrogenase precursor 
[Homo sapiens] 
  X   
gi|148747437|ref|NP_060691.2
|,gi|27735029|ref|NP_775739.1
| 
Mob4B protein [Homo sapiens],MOB1, Mps One 
Binder kinase activator-like 1A [Homo sapiens] 
  X X gi|4505257|ref|NP_002435.1| moesin [Homo sapiens] 
  X   gi|6912448|ref|NP_036418.1| mortality factor 4 like 2 [Homo sapiens] 
  X   
gi|156119615|ref|NP_008832.2
| 
myosin IXA [Homo sapiens] 
  X   
gi|29568111|ref|NP_006088.2| myosin regulatory light chain 9 isoform a [Homo 
sapiens] 
  X X 
gi|15809016|ref|NP_291024.1|,
gi|5453740|ref|NP_006462.1| 
myosin regulatory light chain MRCL2 [Homo 
sapiens],myosin regulatory light chain MRCL3 
[Homo sapiens] 
  X X 
gi|12667788|ref|NP_002464.1| myosin, heavy polypeptide 9, non-muscle [Homo 
sapiens] 
  X X 
gi|17986258|ref|NP_066299.2|,
gi|88999583|ref|NP_524147.2| 
myosin, light chain 6, alkali, smooth muscle and 
non-muscle isoform 1 [Homo sapiens],myosin, light 
chain 6, alkali, smooth muscle and non-muscle 
isoform 2 [Homo sapiens] 
X X   
gi|153070260|ref|NP_002347.5
| 
myristoylated alanine-rich protein kinase C 
substrate [Homo sapiens] 
  X   gi|11342664|ref|NP_002454.1| myxovirus resistance protein 2 [Homo sapiens] 
  X   
gi|12056473|ref|NP_061819.2| N-acetylneuraminic acid phosphate synthase 
[Homo sapiens] 
  X   gi|23510451|ref|NP_001631.3| N-acylaminoacyl-peptide hydrolase [Homo sapiens] 
    X 
gi|4505415|ref|NP_000894.1|,g
i|70995396|ref|NP_001020604.
1|,gi|70995422|ref|NP_001020
605.1| 
NAD(P)H menadione oxidoreductase 1, dioxin-
inducible isoform a [Homo sapiens],NAD(P)H 
menadione oxidoreductase 1, dioxin-inducible 
isoform b [Homo sapiens],NAD(P)H menadione 
oxidoreductase 1, dioxin-inducible isoform c [Homo 
sapiens] 
  X X 
gi|5031931|ref|NP_005585.1| nascent polypeptide-associated complex alpha 
subunit isoform b [Homo sapiens] 
  X   
gi|115527120|ref|NP_004534.2
| 
nebulin [Homo sapiens] 
  X   
gi|4502169|ref|NP_003896.1|,g
i|66363686|ref|NP_001018169.
1|,gi|66363688|ref|NP_001018
170.1| 
NEDD8 activating enzyme E1 subunit 1 isoform a 
[Homo sapiens],NEDD8 activating enzyme E1 
subunit 1 isoform b [Homo sapiens],NEDD8 
activating enzyme E1 subunit 1 isoform c [Homo 
sapiens] 
  X   
gi|47933379|ref|NP_003818.2| N-ethylmaleimide-sensitive factor attachment 
protein, alpha [Homo sapiens] 
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  X X 
gi|5453760|ref|NP_006147.1| neural precursor cell expressed, developmentally 
down-regulated 8 [Homo sapiens] 
  X   gi|4505445|ref|NP_000900.1| neuropeptide Y receptor Y1 [Homo sapiens] 
  X   gi|5453790|ref|NP_006160.1| nicotinamide N-methyltransferase [Homo sapiens] 
  X   
gi|115298674|ref|NP_002499.2
| 
nidogen 1 precursor [Homo sapiens] 
  X X 
gi|66392203|ref|NP_00101814
6.1| 
NME1-NME2 protein [Homo sapiens] 
  X X 
gi|38045913|ref|NP_937818.1|,
gi|4557797|ref|NP_000260.1| 
non-metastatic cells 1, protein (NM23A) expressed 
in isoform a [Homo sapiens],non-metastatic cells 1, 
protein (NM23A) expressed in isoform b [Homo 
sapiens] 
  X X 
gi|34932414|ref|NP_031389.3| non-POU domain containing, octamer-binding 
[Homo sapiens] 
  X X 
gi|27262628|ref|NP_002473.2|,
gi|27262634|ref|NP_751896.1| 
nuclear autoantigenic sperm protein isoform 2 
[Homo sapiens],nuclear autoantigenic sperm 
protein isoform 1 [Homo sapiens] 
  X X 
gi|56118310|ref|NP_073568.2| nuclear casein kinase and cyclin-dependent kinase 
substrate 1 [Homo sapiens] 
  X X 
gi|5729953|ref|NP_006591.1| nuclear distribution gene C homolog [Homo 
sapiens] 
  X   gi|71361682|ref|NP_006176.2| nuclear mitotic apparatus protein 1 [Homo sapiens] 
    X 
gi|114155142|ref|NP_003283.2
| 
nuclear pore complex-associated protein TPR 
[Homo sapiens] 
  X X gi|5031985|ref|NP_005787.1| nuclear transport factor 2 [Homo sapiens] 
  X X 
gi|34098946|ref|NP_004550.2| nuclease sensitive element binding protein 1 
[Homo sapiens] 
  X X gi|20070228|ref|NP_006175.2| nucleobindin 1 [Homo sapiens] 
  X X gi|4826870|ref|NP_005004.1| nucleobindin 2 [Homo sapiens] 
  X X 
gi|148596949|ref|NP_004732.2
| 
nucleolar and coiled-body phosphoprotein 1 [Homo 
sapiens] 
  X X gi|55956788|ref|NP_005372.2| nucleolin [Homo sapiens] 
  X X 
gi|10835063|ref|NP_002511.1|,
gi|40353734|ref|NP_954654.1| 
nucleophosmin 1 isoform 1 [Homo 
sapiens],nucleophosmin 1 isoform 2 [Homo 
sapiens] 
  X X 
gi|157168362|ref|NP_000261.2
| 
nucleoside phosphorylase [Homo sapiens] 
  X X 
gi|21327708|ref|NP_631946.1|,
gi|4758756|ref|NP_004528.1| 
nucleosome assembly protein 1-like 1 [Homo 
sapiens] 
  X X 
gi|5174613|ref|NP_005960.1| nucleosome assembly protein 1-like 4 [Homo 
sapiens] 
  X   gi|37594464|ref|NP_054861.2| nudix-type motif 5 [Homo sapiens] 
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  X   
gi|18860829|ref|NP_056375.1|,
gi|18860831|ref|NP_570844.1|,
gi|18860833|ref|NP_570845.1|,
gi|18860835|ref|NP_570846.1|,
gi|18860837|ref|NP_570847.1|,
gi|18860841|ref|NP_570848.1|,
gi|18860843|ref|NP_570849.1|,
gi|18860845|ref|NP_570850.1| 
optic atrophy 1 isoform 1 [Homo sapiens],optic 
atrophy 1 isoform 2 [Homo sapiens],optic atrophy 1 
isoform 3 [Homo sapiens],optic atrophy 1 isoform 4 
[Homo sapiens],optic atrophy 1 isoform 5 [Homo 
sapiens],optic atrophy 1 isoform 6 [Homo sapiens] 
  X   
gi|109148508|ref|NP_060140.2
| 
otubain 1 [Homo sapiens] 
  X   
gi|24432106|ref|NP_066997.3|,
gi|40548408|ref|NP_954675.1| 
p30 DBC protein [Homo sapiens] 
  X   
gi|20149635|ref|NP_057227.2|,
gi|29568099|ref|NP_061327.2| 
p47 protein isoform a [Homo sapiens],p47 protein 
isoform b [Homo sapiens] 
  X   
gi|20149635|ref|NP_057227.2|,
gi|33286434|ref|NP_872289.1| 
p47 protein isoform a [Homo sapiens],p47 protein 
isoform c [Homo sapiens] 
  X X gi|46276863|ref|NP_002815.3| parathymosin [Homo sapiens] 
  X   
gi|16945970|ref|NP_066967.2|,
gi|19923653|ref|NP_150091.2| 
PC4 and SFRS1 interacting protein 1 isoform 1 
[Homo sapiens],PC4 and SFRS1 interacting protein 
1 isoform 2 [Homo sapiens] 
    X gi|7657441|ref|NP_055706.1| PDGFA associated protein 1 [Homo sapiens] 
  X   
gi|11496885|ref|NP_005442.2|,
gi|47157328|ref|NP_998801.1| 
PDZ and LIM domain 7 isoform 1 [Homo 
sapiens],PDZ and LIM domain 7 isoform 4 [Homo 
sapiens] 
  X X 
gi|4506333|ref|NP_002843.1| pentraxin-related gene, rapidly induced by IL-1 beta 
[Homo sapiens] 
  X   
gi|149589008|ref|NP_000276.2
| 
peptidase D [Homo sapiens] 
  X   
gi|21070974|ref|NP_620121.1|,
gi|21070980|ref|NP_620176.1|,
gi|21070982|ref|NP_620177.1|,
gi|21070984|ref|NP_000910.2| 
peptidylglycine alpha-amidating monooxygenase 
isoform b, preproprotein [Homo 
sapiens],peptidylglycine alpha-amidating 
monooxygenase isoform c, preproprotein [Homo 
sapiens],peptidylglycine alpha-amidating 
monooxygenase isoform d, preproprotein [Homo 
sapien 
  X X gi|10863927|ref|NP_066953.1| peptidylprolyl isomerase A [Homo sapiens] 
  X X 
gi|4758950|ref|NP_000933.1| peptidylprolyl isomerase B precursor [Homo 
sapiens] 
  X   gi|4505991|ref|NP_000934.1| peptidylprolyl isomerase C [Homo sapiens] 
  X   gi|5454154|ref|NP_006338.1| peptidylprolyl isomerase H [Homo sapiens] 
  X   gi|7706339|ref|NP_057143.1| peptidylprolyl isomerase-like 1 [Homo sapiens] 
  X   
gi|109150416|ref|NP_036425.1
| 
peroxidasin homolog [Homo sapiens] 
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X X X 
gi|32455264|ref|NP_859047.1|,
gi|32455266|ref|NP_859048.1|,
gi|4505591|ref|NP_002565.1| 
peroxiredoxin 1 [Homo sapiens] 
  X X gi|32189392|ref|NP_005800.3| peroxiredoxin 2 isoform a [Homo sapiens] 
  X   
gi|32483377|ref|NP_054817.2|,
gi|5802974|ref|NP_006784.1| 
peroxiredoxin 3 isoform b [Homo 
sapiens],peroxiredoxin 3 isoform a precursor 
[Homo sapiens] 
  X X 
gi|6912238|ref|NP_036226.1| peroxiredoxin 5 precursor, isoform a [Homo 
sapiens] 
  X   
gi|32455260|ref|NP_857634.1| peroxiredoxin 5 precursor, isoform b [Homo 
sapiens] 
  X X gi|4758638|ref|NP_004896.1| peroxiredoxin 6 [Homo sapiens] 
    X 
gi|70995211|ref|NP_001389.2| peroxisomal enoyl-coenzyme A hydratase-like 
protein [Homo sapiens] 
  X X 
gi|6912594|ref|NP_036531.1| phosphatidylinositol transfer protein, beta [Homo 
sapiens] 
  X X gi|40068518|ref|NP_002622.2| phosphogluconate dehydrogenase [Homo sapiens] 
  X X gi|4505763|ref|NP_000282.1| phosphoglycerate kinase 1 [Homo sapiens] 
X X X gi|4505753|ref|NP_002620.1| phosphoglycerate mutase 1 (brain) [Homo sapiens] 
  X X 
gi|5453914|ref|NP_006218.1| phospholipid transfer protein isoform a precursor 
[Homo sapiens] 
  X X 
gi|33356541|ref|NP_872617.1| phospholipid transfer protein isoform b precursor 
[Homo sapiens] 
  X   
gi|4505705|ref|NP_003759.1| phosphoprotein enriched in astrocytes 15 [Homo 
sapiens] 
    X 
gi|119220557|ref|NP_0010729
92.1|,gi|5453539|ref|NP_00644
3.1| 
phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole 
succinocarboxamide synthetase isoform 2 [Homo 
sapiens] 
  X   
gi|31657129|ref|NP_036525.1| phosphoribosylformylglycinamidine synthase 
[Homo sapiens] 
  X X 
gi|17402893|ref|NP_478059.1| phosphoserine aminotransferase isoform 1 [Homo 
sapiens] 
    X 
gi|10863955|ref|NP_066977.1| phosphoserine aminotransferase isoform 2 [Homo 
sapiens] 
    X 
gi|153792298|ref|NP_0010084
96.2| 
piwi-like 3 [Homo sapiens] 
  X   
gi|24307907|ref|NP_006207.1| plasminogen activator inhibitor type 1, member 2 
[Homo sapiens] 
  X X gi|10835159|ref|NP_000593.1| plasminogen activator inhibitor-1 [Homo sapiens] 
  X   gi|7549809|ref|NP_005023.2| plastin 3 [Homo sapiens] 
  X   
gi|4557741|ref|NP_000421.1| platelet-activating factor acetylhydrolase, isoform 
Ib, alpha subunit [Homo sapiens] 
  X   
gi|4505585|ref|NP_002563.1| platelet-activating factor acetylhydrolase, isoform 
Ib, beta subunit 30kDa [Homo sapiens] 
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    X 
gi|9994187|ref|NP_057289.1| platelet-derived growth factor C precursor [Homo 
sapiens] 
  X   
gi|5453872|ref|NP_006198.1| platelet-derived growth factor receptor-like protein 
[Homo sapiens] 
  X X 
gi|41322908|ref|NP_958781.1|,
gi|41322910|ref|NP_958783.1|,
gi|41322912|ref|NP_958780.1|,
gi|41322914|ref|NP_958785.1|,
gi|41322916|ref|NP_958782.1|,
gi|41322919|ref|NP_958784.1|,
gi|41322923|ref|NP_958786.1|,
gi|47607492|ref|NP_000436.2| 
plectin 1 isoform 3 [Homo sapiens],plectin 1 
isoform 7 [Homo sapiens],plectin 1 isoform 2 
[Homo sapiens],plectin 1 isoform 10 [Homo 
sapiens],plectin 1 isoform 6 [Homo sapiens],plectin 
1 isoform 8 [Homo sapiens],plectin 1 isoform 11 
[Homo sapiens] 
  X   gi|19923372|ref|NP_006496.2| poliovirus receptor [Homo sapiens] 
  X X 
gi|156523968|ref|NP_001609.2
| 
poly (ADP-ribose) polymerase family, member 1 
[Homo sapiens] 
  X X 
gi|46367787|ref|NP_002559.2| poly(A) binding protein, cytoplasmic 1 [Homo 
sapiens] 
    X gi|5453854|ref|NP_006187.1| poly(rC) binding protein 1 [Homo sapiens] 
  X   
gi|14141166|ref|NP_114366.1|,
gi|14141168|ref|NP_005007.2|,
gi|148833484|ref|NP_0010920
90.1| 
poly(rC)-binding protein 2 isoform b [Homo 
sapiens],poly(rC)-binding protein 2 isoform a 
[Homo sapiens],poly(rC)-binding protein 2 isoform c 
[Homo sapiens] 
  X X 
gi|148886654|ref|NP_699197.3
| 
polydom [Homo sapiens] 
  X X 
gi|4758412|ref|NP_004472.1| polypeptide N-acetylgalactosaminyltransferase 2 
[Homo sapiens] 
  X   
gi|157502212|ref|NP_059119.2
| 
polypeptide N-acetylgalactosaminyltransferase 7 
[Homo sapiens] 
  X X 
gi|14165464|ref|NP_114367.1|,
gi|14165466|ref|NP_114368.1|,
gi|4506243|ref|NP_002810.1| 
polypyrimidine tract-binding protein 1 isoform b 
[Homo sapiens],polypyrimidine tract-binding protein 
1 isoform c [Homo sapiens],polypyrimidine tract-
binding protein 1 isoform a [Homo sapiens] 
    X 
gi|17298690|ref|NP_055096.2|,
gi|17978512|ref|NP_510965.1| 
poly-U binding splicing factor 60KDa isoform b 
[Homo sapiens],poly-U binding splicing factor 
60KDa isoform a [Homo sapiens] 
    X 
gi|169216498|ref|XP_0017329
09.1|,gi|169216723|ref|XP_001
721120.1|,gi|169217303|ref|XP
_001732908.1|,gi|4503841|ref|
NP_001460.1| 
PREDICTED: hypothetical LOC389901 [Homo 
sapiens],ATP-dependent DNA helicase II, 70 kDa 
subunit [Homo sapiens] 
  X   
gi|169167572|ref|XP_0017238
34.1|,gi|169167798|ref|XP_001
720870.1|,gi|169167889|ref|XP
_001722518.1| 
PREDICTED: hypothetical protein [Homo sapiens] 
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  X   
gi|113418707|ref|XP_0011318
59.1|,gi|113419208|ref|XP_001
126350.1|,gi|113419745|ref|XP
_001126471.1|,gi|169171467|r
ef|XP_001727085.1|,gi|503205
7|ref|NP_005611.1| 
PREDICTED: hypothetical LOC729659 [Homo 
sapiens],S100 calcium binding protein A11 [Homo 
sapiens] 
    X 
gi|113420837|ref|XP_0011266
59.1|,gi|113420848|ref|XP_001
127088.1|,gi|113431257|ref|XP
_499153.3|,gi|151101404|ref|N
P_002814.3|,gi|151101407|ref|
NP_001092755.1|,gi|16921754
8|ref|XP_001722951.1| 
PREDICTED: hypothetical protein [Homo 
sapiens],prothymosin, alpha isoform 2 [Homo 
sapiens],prothymosin, alpha isoform 1 [Homo 
sapiens] 
    X 
gi|169171852|ref|XP_0017138
92.1|,gi|17999541|ref|NP_0606
76.2| 
PREDICTED: hypothetical protein [Homo 
sapiens],vacuolar protein sorting 35 [Homo 
sapiens] 
X     
gi|113408761|ref|XP_0011339
49.1|,gi|113408763|ref|XP_001
133950.1|,gi|113412122|ref|XP
_001134262.1|,gi|113412126|r
ef|XP_001134264.1|,gi|169160
691|ref|XP_001725753.1|,gi|16
9160693|ref|XP_001725752.1|,
gi|4507645|ref|NP_000356.1| 
PREDICTED: hypothetical protein isoform 4 [Homo 
sapiens],PREDICTED: hypothetical protein isoform 
5 [Homo sapiens],PREDICTED: similar to rcTPI1 
isoform 4 [Homo sapiens],PREDICTED: similar to 
rcTPI1 isoform 6 [Homo sapiens] 
  X   
gi|169218211|ref|XP_0017195
13.1|,gi|41322908|ref|NP_9587
81.1|,gi|41322910|ref|NP_9587
83.1|,gi|41322912|ref|NP_9587
80.1|,gi|41322914|ref|NP_9587
85.1|,gi|41322916|ref|NP_9587
82.1|,gi|41322919|ref|NP_9587
84.1|,gi|41322923|ref|NP_9587
86.1|,gi|47607492|ref|NP_ 
PREDICTED: hypothetical protein, partial [Homo 
sapiens],plectin 1 isoform 3 [Homo sapiens],plectin 
1 isoform 7 [Homo sapiens],plectin 1 isoform 2 
[Homo sapiens],plectin 1 isoform 10 [Homo 
sapiens],plectin 1 isoform 6 [Homo sapiens],plectin 
1 isoform 8 [Ho 
  X X 
gi|169211725|ref|XP_944964.3
|,gi|169212081|ref|XP_001718
231.1|,gi|4506715|ref|NP_0010
22.1| 
PREDICTED: similar to 40S ribosomal protein S28 
[Homo sapiens] 
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  X X 
gi|169204113|ref|XP_0017265
74.1|,gi|169204115|ref|XP_001
726573.1|,gi|169204808|ref|XP
_001723478.1|,gi|169204810|r
ef|XP_001723479.1|,gi|169204
812|ref|XP_001723476.1|,gi|16
9205440|ref|XP_001724025.1|,
gi|169205442|ref|XP_0017240
27.1|,gi|169205444|ref|XP_001
7 
PREDICTED: similar to 40S ribosomal protein SA 
(p40) (34/67 kDa laminin receptor) (Colon 
carcinoma laminin-binding protein) (NEM/1CHD4) 
(Multidrug resistance-associated protein MGr1-Ag) 
isoform 2 [Homo sapiens 
  X X 
gi|169211223|ref|XP_0017246
24.1|,gi|4503545|ref|NP_00196
1.1| 
PREDICTED: similar to eukaryotic initiation factor 
5A [Homo sapiens],eukaryotic translation initiation 
factor 5A [Homo sapiens] 
  X   
gi|113422396|ref|XP_0011280
89.1|,gi|113422908|ref|XP_001
127657.1|,gi|169202850|ref|XP
_001718427.1|,gi|4557581|ref|
NP_001435.1| 
PREDICTED: similar to fatty acid binding protein 
homologue [Homo sapiens], PREDICTED: 
hypothetical protein [Homo sapiens],fatty acid 
binding protein 5 (psoriasis-associated) [Homo 
sapiens] 
    X 
gi|113411534|ref|XP_0011343
69.1|,gi|169213804|ref|XP_001
721116.1|,gi|49574537|ref|NP_
004474.2|,gi|89057342|ref|XP_
950829.1| 
PREDICTED: similar to Glycine cleavage system H 
protein, mitochondrial [Homo sapiens],glycine 
cleavage system protein H (aminomethyl carrier) 
[Homo sapiens] 
  X   
gi|169206597|ref|XP_0017168
26.1|,gi|4557617|ref|NP_00081
1.1| 
PREDICTED: similar to growth arrest-specific 6 
[Homo sapiens],growth arrest-specific 6 [Homo 
sapiens] 
    X 
gi|169201876|ref|XP_0017248
91.1|,gi|4503285|ref|NP_00134
5.1|,gi|45446745|ref|NP_99531
7.1|,gi|5453543|ref|NP_001344
.2| 
PREDICTED: similar to hCG2017792 [Homo 
sapiens],aldo-keto reductase family 1, member C2 
[Homo sapiens],aldo-keto reductase family 1, 
member C2 [Homo sapiens],aldo-keto reductase 
family 1, member C1 [Homo sapiens] 
  X   
gi|17471847|ref|XP_061427.1|,
gi|29294624|ref|NP_808210.1|,
gi|4759158|ref|NP_004588.1| 
PREDICTED: similar to hCG2040270 [Homo 
sapiens],small nuclear ribonucleoprotein 
polypeptide D2 [Homo sapiens] 
  X X 
gi|169206886|ref|XP_0017208
42.1|,gi|169206888|ref|XP_001
720843.1|,gi|169207175|ref|XP
_001720508.1|,gi|169207177|r
ef|XP_001720509.1|,gi|503174
9|ref|NP_005508.1|,gi|8903758
8|ref|XP_950717.1| 
PREDICTED: similar to high mobility group 
nucleosomal binding domain 2 isoform 1 [Homo 
sapiens],PREDICTED: similar to high mobility 
group nucleosomal binding domain 2 isoform 2 
[Homo sapiens],PREDICTED: similar to high 
mobility group nucleosomal binding d 
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    X 
gi|169215551|ref|XP_0017206
74.1|,gi|169215761|ref|XP_001
723241.1|,gi|169215763|ref|XP
_001723240.1|,gi|169215954|r
ef|XP_001726307.1|,gi|169215
956|ref|XP_001726306.1|,gi|45
04425|ref|NP_002119.1| 
PREDICTED: similar to high-mobility group 
(nonhistone chromosomal) protein 1-like 10 [Homo 
sapiens],PREDICTED: similar to high-mobility 
group (nonhistone chromosomal) protein 1-like 10 
isoform 2 [Homo sapiens] 
  X   
gi|113420668|ref|XP_935058.2
|,gi|113421073|ref|XP_944970.
2|,gi|71143137|ref|NP_005333.
2| 
PREDICTED: similar to high-mobility group box 3 
[Homo sapiens],high-mobility group box 3 [Homo 
sapiens] 
  X   
gi|169211543|ref|XP_0017261
75.1|,gi|5031863|ref|NP_00555
8.1| 
PREDICTED: similar to lectin, galactoside-binding, 
soluble, 3 binding protein [Homo sapiens],galectin 
3 binding protein [Homo sapiens] 
  X   
gi|113416734|ref|XP_0011310
22.1|,gi|113417218|ref|XP_001
130142.1|,gi|169168235|ref|XP
_001722613.1| 
PREDICTED: similar to mCG13783 [Homo 
sapiens] 
    X 
gi|169165045|ref|XP_0017261
02.1|,gi|169165350|ref|XP_001
722030.1|,gi|88969090|ref|XP_
946711.1| 
PREDICTED: similar to peptidyl-Pro cis trans 
isomerase [Homo sapiens] 
  X   
gi|169215435|ref|XP_0017185
59.1| 
PREDICTED: similar to peptidylprolyl isomerase A-
like [Homo sapiens] 
    X 
gi|113413200|ref|XP_934799.2
| 
PREDICTED: similar to protein expressed in 
prostate, ovary, testis, and placenta 2 [Homo 
sapiens] 
  X X 
gi|169204588|ref|XP_0017234
53.1|,gi|89035369|ref|XP_9331
68.1|,gi|89036005|ref|XP_9501
71.1| 
PREDICTED: similar to prothymosin alpha [Homo 
sapiens],PREDICTED: similar to prothymosin alpha 
isoform 1 [Homo sapiens],PREDICTED: similar to 
prothymosin alpha isoform 2 [Homo sapiens] 
  X   
gi|169214627|ref|XP_0017252
25.1|,gi|169214710|ref|XP_001
725248.1|,gi|169214941|ref|XP
_001723663.1| 
PREDICTED: similar to Putative ubiquitin-
conjugating enzyme E2 D3-like protein [Homo 
sapiens] 
    X 
gi|169216167|ref|XP_947703.2
|,gi|169216776|ref|XP_372200.
3|,gi|4506407|ref|NP_002873.1
| 
PREDICTED: similar to RanBP1 [Homo 
sapiens],RAN binding protein 1 [Homo sapiens] 
  X   
gi|113417664|ref|XP_0011278
60.1|,gi|113418285|ref|XP_001
131826.1|,gi|169169852|ref|XP
_001725212.1| 
PREDICTED: similar to rCG23287 [Homo sapiens] 
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  X   
gi|169201709|ref|XP_0017201
78.1|,gi|4507217|ref|NP_00312
4.1|,gi|89031548|ref|XP_93254
4.1|,gi|89033521|ref|XP_94320
9.1| 
PREDICTED: similar to signal recognition particle 
subunit 9 [Homo sapiens],signal recognition particle 
9kDa [Homo sapiens] 
  X   
gi|169212783|ref|XP_0017211
75.1|,gi|169212981|ref|XP_001
714051.1|,gi|169213154|ref|XP
_001714036.1| 
PREDICTED: similar to small ubiquitin-related 
modifier 2 [Homo sapiens] 
    X 
gi|169218202|ref|XP_0017244
76.1|,gi|48928058|ref|NP_0088
67.2|,gi|50400081|ref|NP_0010
02255.1|,gi|54792069|ref|NP_0
08868.3|,gi|54792071|ref|NP_0
01005849.1| 
PREDICTED: similar to SMT3B protein [Homo 
sapiens],small ubiquitin-like modifier protein 3 
[Homo sapiens],SMT3 suppressor of mif two 3 
homolog 4 [Homo sapiens],SMT3 suppressor of mif 
two 3 homolog 2 isoform a precursor [Homo 
sapiens] 
  X X 
gi|169166302|ref|XP_0017177
66.1|,gi|169166810|ref|XP_001
716969.1|,gi|169167074|ref|XP
_001717770.1| 
PREDICTED: similar to template acyivating factor-I 
alpha [Homo sapiens] 
  X   
gi|169178083|ref|XP_0017173
02.1|,gi|169179309|ref|XP_001
718968.1|,gi|169181065|ref|XP
_001725799.1|,gi|4507669|ref|
NP_003286.1|,gi|46409468|ref|
NP_997305.1| 
PREDICTED: similar to translatinally-controlled 
tumor protein [Homo sapiens] 
    X 
gi|169184561|ref|XP_0017233
99.1|,gi|169184563|ref|XP_001
723402.1|,gi|4506723|ref|NP_0
00997.1|,gi|51467774|ref|XP_4
95839.1|,gi|89031528|ref|XP_9
31621.1|,gi|89033497|ref|XP_9
48264.1|,gi|89033501|ref|XP_9
42162.1| 
PREDICTED: similar to v-fos transformation 
effector protein isoform 1 [Homo 
sapiens],PREDICTED: similar to v-fos 
transformation effector protein isoform 2 [Homo 
sapiens],ribosomal protein S3a [Homo sapiens] 
  X   
gi|169184680|ref|XP_0017143
51.1|,gi|169194808|ref|XP_001
124974.2|,gi|169194816|ref|XP
_001719067.1| 
PREDICTED: WDFY family member 4 [Homo 
sapiens],PREDICTED: similar to hCG1745555 
[Homo sapiens] 
  X   gi|12408675|ref|NP_036526.2| prefoldin subunit 2 [Homo sapiens] 
    X gi|4506355|ref|NP_002855.1| pregnancy-zone protein [Homo sapiens] 
  X   
gi|33636742|ref|NP_891988.1|,
gi|62739166|ref|NP_000926.2| 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
isoform a precursor [Homo sapiens],procollagen-
lysine, 2-oxoglutarate 5-dioxygenase 2 isoform b 
precursor [Homo sapiens] 
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    X 
gi|4505891|ref|NP_001075.1| procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 
precursor [Homo sapiens] 
X X X gi|4826898|ref|NP_005013.1| profilin 1 [Homo sapiens] 
  X X gi|4759224|ref|NP_004699.1| programmed cell death 5 [Homo sapiens] 
    X 
gi|22027538|ref|NP_037506.2| programmed cell death 6 interacting protein [Homo 
sapiens] 
    X 
gi|22202629|ref|NP_665811.1|,
gi|22202631|ref|NP_665812.1|,
gi|4757732|ref|NP_004199.1| 
programmed cell death 8 isoform 2 [Homo 
sapiens],programmed cell death 8 isoform 3 [Homo 
sapiens],programmed cell death 8 isoform 1 [Homo 
sapiens] 
  X X 
gi|33239451|ref|NP_872590.1|,
gi|4505641|ref|NP_002583.1| 
proliferating cell nuclear antigen [Homo sapiens] 
  X X 
gi|20070125|ref|NP_000909.2| prolyl 4-hydroxylase, beta subunit precursor [Homo 
sapiens] 
    X 
gi|117306169|ref|NP_955450.2
|,gi|4826940|ref|NP_005031.1| 
prolylcarboxypeptidase isoform 2 preproprotein 
[Homo sapiens],prolylcarboxypeptidase isoform 1 
preproprotein [Homo sapiens] 
    X 
gi|7019519|ref|NP_037403.1| proprotein convertase subtilisin/kexin type 1 
inhibitor precursor [Homo sapiens] 
  X   
gi|31317307|ref|NP_777596.2| proprotein convertase subtilisin/kexin type 9 
preproprotein [Homo sapiens] 
  X X 
gi|110224476|ref|NP_0010359
30.1|,gi|110224479|ref|NP_001
035931.1|,gi|11386147|ref|NP_
002769.1| 
prosaposin isoform b preproprotein [Homo 
sapiens],prosaposin isoform c preproprotein [Homo 
sapiens],prosaposin isoform a preproprotein [Homo 
sapiens] 
X X X gi|4505621|ref|NP_002558.1| prostatic binding protein [Homo sapiens] 
  X   gi|6005882|ref|NP_009104.1| protease, serine, 23 precursor [Homo sapiens] 
  X   gi|24430160|ref|NP_002797.2| proteasome 26S ATPase subunit 6 [Homo sapiens] 
    X 
gi|25777602|ref|NP_002799.3| proteasome 26S non-ATPase subunit 2 [Homo 
sapiens] 
  X   
gi|18543329|ref|NP_002804.2| proteasome 26S non-ATPase subunit 9 [Homo 
sapiens] 
  X X 
gi|5453990|ref|NP_006254.1| proteasome activator subunit 1 isoform 1 [Homo 
sapiens] 
  X   
gi|30581141|ref|NP_788955.1| proteasome activator subunit 1 isoform 2 [Homo 
sapiens] 
  X X gi|30410792|ref|NP_002809.2| proteasome activator subunit 2 [Homo sapiens] 
  X   
gi|30410794|ref|NP_005780.2|,
gi|30410796|ref|NP_789839.1| 
proteasome activator subunit 3 isoform 1 [Homo 
sapiens],proteasome activator subunit 3 isoform 2 
[Homo sapiens] 
  X X 
gi|23110935|ref|NP_683877.1|,
gi|4506179|ref|NP_002777.1| 
proteasome alpha 1 subunit isoform 1 [Homo 
sapiens],proteasome alpha 1 subunit isoform 2 
[Homo sapiens] 
  X X gi|4506181|ref|NP_002778.1| proteasome alpha 2 subunit [Homo sapiens] 
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  X X 
gi|23110939|ref|NP_687033.1|,
gi|4506183|ref|NP_002779.1| 
proteasome alpha 3 subunit isoform 2 [Homo 
sapiens],proteasome alpha 3 subunit isoform 1 
[Homo sapiens] 
  X X 
gi|156713442|ref|NP_0010961
37.1|,gi|4506185|ref|NP_00278
0.1| 
proteasome alpha 4 subunit isoform 1 [Homo 
sapiens] 
  X X gi|23110942|ref|NP_002781.2| proteasome alpha 5 subunit [Homo sapiens] 
  X X gi|23110944|ref|NP_002782.1| proteasome alpha 6 subunit [Homo sapiens] 
  X X gi|4506189|ref|NP_002783.1| proteasome alpha 7 subunit [Homo sapiens] 
  X   
gi|68303561|ref|NP_653263.2|,
gi|68303563|ref|NP_00102026
7.1|,gi|68303565|ref|NP_00102
0268.1| 
proteasome (prosome, macropain) subunit, alpha 
type, 8 isoform 1 [Homo sapiens],proteasome 
(prosome, macropain) subunit, alpha type, 8 
isoform 2 [Homo sapiens] 
  X X gi|4506193|ref|NP_002784.1| proteasome beta 1 subunit [Homo sapiens] 
  X   gi|4506195|ref|NP_002785.1| proteasome beta 2 subunit [Homo sapiens] 
  X X gi|22538465|ref|NP_002786.2| proteasome beta 3 subunit [Homo sapiens] 
  X X gi|22538467|ref|NP_002787.2| proteasome beta 4 subunit [Homo sapiens] 
  X X gi|4506201|ref|NP_002788.1| proteasome beta 5 subunit [Homo sapiens] 
  X X gi|23110925|ref|NP_002789.1| proteasome beta 6 subunit [Homo sapiens] 
  X X 
gi|4506203|ref|NP_002790.1| proteasome beta 7 subunit proprotein [Homo 
sapiens] 
  X   
gi|38679892|ref|NP_006214.2| protein (peptidyl-prolyl cis/trans isomerase) NIMA-
interacting, 4 (parvulin) [Homo sapiens] 
  X X 
gi|21361657|ref|NP_005304.3| protein disulfide isomerase-associated 3 precursor 
[Homo sapiens] 
    X 
gi|4758304|ref|NP_004902.1| protein disulfide isomerase-associated 4 [Homo 
sapiens] 
  X X 
gi|5031973|ref|NP_005733.1| protein disulfide isomerase-associated 6 [Homo 
sapiens] 
  X X 
gi|48255889|ref|NP_002734.2|,
gi|48255891|ref|NP_00100132
9.1| 
protein kinase C substrate 80K-H isoform 1 [Homo 
sapiens],protein kinase C substrate 80K-H isoform 
2 [Homo sapiens] 
  X X 
gi|4506003|ref|NP_002699.1|,g
i|4506005|ref|NP_002700.1|,gi|
4506007|ref|NP_002701.1|,gi|4
5827798|ref|NP_996756.1|,gi|4
6249376|ref|NP_996759.1|,gi|5
6790945|ref|NP_001008709.1| 
protein phosphatase 1, catalytic subunit, alpha 
isoform 1 [Homo sapiens],protein phosphatase 1, 
catalytic subunit, beta isoform 1 [Homo 
sapiens],protein phosphatase 1, catalytic subunit, 
gamma isoform [Homo sapiens] 
  X   
gi|29826282|ref|NP_817092.1|,
gi|4505999|ref|NP_002698.1| 
protein phosphatase 1G [Homo sapiens] 
    X 
gi|4506017|ref|NP_002706.1|,g
i|4758952|ref|NP_004147.1|,gi|
57222565|ref|NP_001009552.
1| 
protein phosphatase 2, catalytic subunit, alpha 
isoform [Homo sapiens],protein phosphatase 2, 
catalytic subunit, beta isoform [Homo sapiens] 
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    X 
gi|29725611|ref|NP_066954.2|,
gi|30065643|ref|NP_821067.1|,
gi|30065645|ref|NP_821068.1| 
protein phosphatase 2A, regulatory subunit B' 
isoform b [Homo sapiens],protein phosphatase 2A, 
regulatory subunit B' isoform a [Homo sapiens] 
  X   gi|4506117|ref|NP_000304.1| protein S, alpha [Homo sapiens] 
  X X 
gi|109633039|ref|NP_569707.2
|,gi|109633041|ref|NP_002831.
2| 
protein tyrosine phosphatase, receptor type, F 
isoform 2 precursor [Homo sapiens],protein 
tyrosine phosphatase, receptor type, F isoform 1 
precursor [Homo sapiens] 
  X X 
gi|4885539|ref|NP_005380.1| protein-L-isoaspartate (D-aspartate) O-
methyltransferase [Homo sapiens] 
  X   
gi|151101404|ref|NP_002814.3
|,gi|151101407|ref|NP_001092
755.1| 
prothymosin, alpha isoform 2 [Homo 
sapiens],prothymosin, alpha isoform 1 [Homo 
sapiens] 
  X   gi|9256608|ref|NP_061757.1| protocadherin beta 14 precursor [Homo sapiens] 
    X 
gi|4557831|ref|NP_000272.1| pterin-4 alpha-carbinolamine 
dehydratase/dimerization cofactor of hepatocyte 
nuclear factor 1 alpha precursor [Homo sapiens] 
  X   
gi|15826840|ref|NP_002812.2|,
gi|22902126|ref|NP_690619.1|,
gi|22902128|ref|NP_690620.1|,
gi|22902130|ref|NP_690621.1| 
PTK7 protein tyrosine kinase 7 isoform a precursor 
[Homo sapiens],PTK7 protein tyrosine kinase 7 
isoform b precursor [Homo sapiens],PTK7 protein 
tyrosine kinase 7 isoform c precursor [Homo 
sapiens],PTK7 protein tyrosine kinase 7 isoform d 
precursor [Homo  
    X gi|4505701|ref|NP_003672.1| pyridoxal kinase [Homo sapiens] 
  X X gi|11056044|ref|NP_066952.1| pyrophosphatase 1 [Homo sapiens] 
  X X gi|33286418|ref|NP_002645.3| pyruvate kinase, muscle isoform 1 [Homo sapiens] 
  X   
gi|33286420|ref|NP_872270.1|,
gi|33286422|ref|NP_872271.1| 
pyruvate kinase, muscle isoform 2 [Homo sapiens] 
  X   
gi|13325075|ref|NP_002817.2| quiescin Q6 sulfhydryl oxidase 1 isoform a [Homo 
sapiens] 
  X X 
gi|51873067|ref|NP_00100412
8.1| 
quiescin Q6 sulfhydryl oxidase 1 isoform b [Homo 
sapiens] 
  X   gi|4506467|ref|NP_002897.1| radixin [Homo sapiens] 
  X   gi|24797086|ref|NP_002262.3| RAN binding protein 5 [Homo sapiens] 
  X   gi|45331213|ref|NP_036548.1| RAN binding protein 6 [Homo sapiens] 
  X X 
gi|38327552|ref|NP_938405.1|,
gi|5031703|ref|NP_005745.1| 
Ras-GTPase-activating protein SH3-domain-
binding protein [Homo sapiens] 
  X   
gi|38505165|ref|NP_942126.1|,
gi|9845509|ref|NP_061485.1|,g
i|9845511|ref|NP_008839.2| 
ras-related C3 botulinum toxin substrate 1 isoform 
Rac1c [Homo sapiens],ras-related C3 botulinum 
toxin substrate 1 isoform Rac1b [Homo 
sapiens],ras-related C3 botulinum toxin substrate 1 
isoform Rac1 [Homo sapiens] 
  X X gi|5453555|ref|NP_006316.1| ras-related nuclear protein [Homo sapiens] 
  X X 
gi|29789090|ref|NP_061185.1| regulator of chromosome condensation 2 [Homo 
sapiens] 
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  X   gi|4506583|ref|NP_002936.1| replication protein A1, 70kDa [Homo sapiens] 
  X   gi|4506587|ref|NP_002938.1| replication protein A3, 14kDa [Homo sapiens] 
  X X gi|4506455|ref|NP_002892.1| reticulocalbin 1 precursor [Homo sapiens] 
  X   gi|4506439|ref|NP_002884.1| retinoblastoma binding protein 7 [Homo sapiens] 
  X   gi|5032027|ref|NP_005601.1| retinoblastoma binding protein 4 [Homo sapiens] 
  X X 
gi|4757768|ref|NP_004300.1| Rho GDP dissociation inhibitor (GDI) alpha [Homo 
sapiens] 
  X   
gi|58761492|ref|NP_060595.3|,
gi|74136547|ref|NP_00101172
2.2| 
Rho guanine nucleotide exchange factor (GEF) 10-
like isoform 1 [Homo sapiens],Rho guanine 
nucleotide exchange factor (GEF) 10-like isoform 2 
[Homo sapiens] 
    X gi|5231228|ref|NP_003721.2| ribonuclease T2 precursor [Homo sapiens] 
  X X 
gi|21361547|ref|NP_002930.2|,
gi|42794608|ref|NP_976318.1|,
gi|42822864|ref|NP_976322.1|,
gi|42822866|ref|NP_976323.1|,
gi|42822868|ref|NP_976321.1|,
gi|42822870|ref|NP_976320.1|,
gi|42822872|ref|NP_976317.1|,
gi|42822874|ref|NP_976319.1| 
ribonuclease/angiogenin inhibitor [Homo sapiens] 
    X 
gi|118498359|ref|NP_056474.2
| 
ribosomal L1 domain containing 1 [Homo sapiens] 
  X X gi|15431288|ref|NP_009035.3| ribosomal protein L10a [Homo sapiens] 
  X   gi|4506597|ref|NP_000967.1| ribosomal protein L12 [Homo sapiens] 
  X X 
gi|16933546|ref|NP_444505.1|,
gi|4506667|ref|NP_000993.1| 
ribosomal protein P0 [Homo sapiens] 
  X X gi|4506671|ref|NP_000995.1| ribosomal protein P2 [Homo sapiens] 
  X X gi|14277700|ref|NP_001007.2| ribosomal protein S12 [Homo sapiens] 
    X 
gi|5032051|ref|NP_005608.1|,g
i|68160915|ref|NP_001020241.
1|,gi|68160922|ref|NP_001020
242.1| 
ribosomal protein S14 [Homo sapiens] 
    X gi|4506691|ref|NP_001011.1| ribosomal protein S16 [Homo sapiens] 
    X 
gi|11968182|ref|NP_072045.1|,
gi|169168597|ref|XP_0017137
10.1| 
ribosomal protein S18 [Homo sapiens] 
    X gi|4506695|ref|NP_001013.1| ribosomal protein S19 [Homo sapiens] 
    X gi|4506697|ref|NP_001014.1| ribosomal protein S20 [Homo sapiens] 
  X X gi|4506699|ref|NP_001015.1| ribosomal protein S21 [Homo sapiens] 
  X X gi|15718687|ref|NP_000996.2| ribosomal protein S3 [Homo sapiens] 
  X   gi|13904870|ref|NP_001000.2| ribosomal protein S5 [Homo sapiens] 
    X gi|17158044|ref|NP_001001.2| ribosomal protein S6 [Homo sapiens] 
    X gi|4506741|ref|NP_001002.1| ribosomal protein S7 [Homo sapiens] 
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    X 
gi|59859885|ref|NP_00101232
1.1|,gi|9845502|ref|NP_002286
.2| 
ribosomal protein SA [Homo sapiens] 
  X   gi|5803137|ref|NP_006734.1| RNA binding motif protein 3 [Homo sapiens] 
  X   gi|4826972|ref|NP_005096.1| RNA binding motif protein 8A [Homo sapiens] 
  X X gi|56699409|ref|NP_002130.2| RNA binding motif protein, X-linked [Homo sapiens] 
    X gi|4506753|ref|NP_003698.1| RuvB-like 1 [Homo sapiens] 
    X gi|5730023|ref|NP_006657.1| RuvB-like 2 [Homo sapiens] 
  X   gi|39841073|ref|NP_060549.3| S1 RNA binding domain 1 [Homo sapiens] 
  X X gi|5032057|ref|NP_005611.1| S100 calcium binding protein A11 [Homo sapiens] 
    X 
gi|4506765|ref|NP_002952.1|,g
i|9845516|ref|NP_062427.1| 
S100 calcium-binding protein A4 [Homo sapiens] 
  X X gi|7657532|ref|NP_055439.1| S100 calcium-binding protein A6 [Homo sapiens] 
  X X 
gi|9951915|ref|NP_000678.1| S-adenosylhomocysteine hydrolase [Homo 
sapiens] 
    X gi|62243484|ref|NP_996769.2| sarcoma antigen NY-SAR-41 [Homo sapiens] 
  X   gi|38202214|ref|NP_006355.2| SEC23-related protein A [Homo sapiens] 
  X   gi|56117838|ref|NP_003003.3| secreted frizzled-related protein 1 [Homo sapiens] 
  X   
gi|11545873|ref|NP_071420.1|,
gi|78190498|ref|NP_00103002
4.1| 
secreted modular calcium-binding protein 1 isoform 
2 [Homo sapiens],secreted modular calcium-
binding protein 1 isoform 1 [Homo sapiens] 
  X   
gi|4507171|ref|NP_003109.1| secreted protein, acidic, cysteine-rich [Homo 
sapiens] 
    X gi|68160947|ref|NP_003460.2| secretogranin II precursor [Homo sapiens] 
  X   gi|24797148|ref|NP_036379.2| selenophosphate synthetase 1 [Homo sapiens] 
    X gi|5174673|ref|NP_006071.1| semaphorin 3A precursor [Homo sapiens] 
  X   gi|8922712|ref|NP_060713.1| septin 11 [Homo sapiens] 
  X   
gi|4758158|ref|NP_004395.1|,g
i|56549636|ref|NP_001008491.
1|,gi|56549638|ref|NP_001008
492.1|,gi|56549640|ref|NP_006
146.1| 
septin 2 [Homo sapiens] 
  X   
gi|116256489|ref|NP_006631.2
| 
septin 9 isoform c [Homo sapiens] 
    X gi|45935371|ref|NP_002718.2| serglycin precursor [Homo sapiens] 
  X X 
gi|50363217|ref|NP_000286.3|,
gi|50363219|ref|NP_00100223
6.1|,gi|50363221|ref|NP_00100
2235.1| 
serine (or cysteine) proteinase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 1 
[Homo sapiens] 
  X X 
gi|13489087|ref|NP_109591.1| serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 1 [Homo sapiens] 
  X X 
gi|41152086|ref|NP_004559.4| serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 6 [Homo sapiens] 
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    X 
gi|4758906|ref|NP_004146.1| serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 9 [Homo sapiens] 
    X 
gi|39725934|ref|NP_002606.3| serine (or cysteine) proteinase inhibitor, clade F 
(alpha-2 antiplasmin, pigment epithelium derived 
factor), member 1 [Homo sapiens] 
    X 
gi|32454741|ref|NP_001226.2| serine (or cysteine) proteinase inhibitor, clade H, 
member 1 precursor [Homo sapiens] 
    X 
gi|148727341|ref|NP_009109.3
| 
serine/threonine kinase receptor associated protein 
[Homo sapiens] 
    X 
gi|50659080|ref|NP_001076.2| serpin peptidase inhibitor, clade A, member 3 
precursor [Homo sapiens] 
  X X 
gi|5453886|ref|NP_006208.1| serpin peptidase inhibitor, clade I (pancpin), 
member 2 [Homo sapiens] 
  X X 
gi|66346679|ref|NP_00101807
7.1|,gi|66346681|ref|NP_00101
8078.1|,gi|66346683|ref|NP_00
1018079.1|,gi|66346685|ref|NP
_056455.3| 
SERPINE1 mRNA binding protein 1 isoform 1 
[Homo sapiens],SERPINE1 mRNA binding protein 
1 isoform 2 [Homo sapiens],SERPINE1 mRNA 
binding protein 1 isoform 3 [Homo 
sapiens],SERPINE1 mRNA binding protein 1 
isoform 4 [Homo sapiens] 
X X X 
gi|4506891|ref|NP_003002.1| SET translocation (myeloid leukemia-associated) 
[Homo sapiens] 
X X   
gi|4506925|ref|NP_003013.1| SH3 domain binding glutamic acid-rich protein like 
[Homo sapiens] 
  X X 
gi|13775198|ref|NP_112576.1| SH3 domain binding glutamic acid-rich protein like 
3 [Homo sapiens] 
    X 
gi|28416940|ref|NP_057122.2| Shwachman-Bodian-Diamond syndrome protein 
[Homo sapiens] 
    X 
gi|122937438|ref|NP_0010739
68.1|,gi|4506693|ref|NP_00101
2.1| 
similar to 40S ribosomal protein S17 [Homo 
sapiens],ribosomal protein S17 [Homo sapiens] 
  X   gi|7657234|ref|NP_055082.1| small acidic protein [Homo sapiens] 
  X   
gi|45006986|ref|NP_004748.2| small inducible cytokine subfamily E, member 1 
[Homo sapiens] 
  X X 
gi|5902102|ref|NP_008869.1| small nuclear ribonucleoprotein D1 polypeptide 
16kDa [Homo sapiens] 
  X   
gi|4759156|ref|NP_004587.1| small nuclear ribonucleoprotein polypeptide A 
[Homo sapiens] 
    X 
gi|4759160|ref|NP_004166.1| small nuclear ribonucleoprotein polypeptide D3 
[Homo sapiens] 
  X X 
gi|4507129|ref|NP_003085.1| small nuclear ribonucleoprotein polypeptide E 
[Homo sapiens] 
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  X   
gi|13027644|ref|NP_073716.1|,
gi|13027646|ref|NP_073717.1|,
gi|13027648|ref|NP_073718.1|,
gi|13027650|ref|NP_073719.1|,
gi|38150007|ref|NP_937859.1|,
gi|4507125|ref|NP_003082.1|,g
i|4507135|ref|NP_003088.1| 
small nuclear ribonucleoprotein polypeptide N 
[Homo sapiens] 
  X X 
gi|4507801|ref|NP_003343.1|,g
i|54792065|ref|NP_001005781.
1| 
SMT3 suppressor of mif two 3 homolog 1 isoform a 
precursor [Homo sapiens] 
    X 
gi|54792069|ref|NP_008868.3|,
gi|54792071|ref|NP_00100584
9.1| 
SMT3 suppressor of mif two 3 homolog 2 isoform a 
precursor [Homo sapiens],SMT3 suppressor of mif 
two 3 homolog 2 isoform b precursor [Homo 
sapiens] 
    X 
gi|55741750|ref|NP_065075.1| solute carrier family 39 (zinc transporter), member 
10 [Homo sapiens] 
  X   
gi|4759140|ref|NP_004243.1| solute carrier family 9 (sodium/hydrogen 
exchanger), isoform 3 regulator 1 [Homo sapiens] 
    X 
gi|156627571|ref|NP_003095.2
| 
sorbitol dehydrogenase [Homo sapiens] 
  X   
gi|4759164|ref|NP_004589.1| sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan 1 precursor [Homo sapiens] 
  X   
gi|154759259|ref|NP_003118.2
| 
spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 
[Homo sapiens] 
  X   
gi|112382250|ref|NP_003119.2
| 
spectrin, beta, non-erythrocytic 1 isoform 1 [Homo 
sapiens] 
  X   
gi|112382252|ref|NP_842565.2
| 
spectrin, beta, non-erythrocytic 1 isoform 2 [Homo 
sapiens] 
    X gi|63253298|ref|NP_003123.2| spermidine synthase [Homo sapiens] 
  X X gi|21264341|ref|NP_004586.2| spermine synthase [Homo sapiens] 
  X X 
gi|25777711|ref|NP_008861.2|,
gi|25777713|ref|NP_733779.1| 
S-phase kinase-associated protein 1 isoform a 
[Homo sapiens],S-phase kinase-associated protein 
1 isoform b [Homo sapiens] 
  X   
gi|42544123|ref|NP_973727.1|,
gi|42544125|ref|NP_973724.1|,
gi|42544130|ref|NP_004621.2| 
splicing factor 1 isoform 3 [Homo sapiens],splicing 
factor 1 isoform 2 [Homo sapiens],splicing factor 1 
isoform 1 [Homo sapiens] 
  X   gi|55749531|ref|NP_006833.2| splicing factor 3B subunit 2 [Homo sapiens] 
  X   
gi|54112117|ref|NP_036565.2| splicing factor 3b, subunit 1 isoform 1 [Homo 
sapiens] 
  X X gi|54112121|ref|NP_036558.3| splicing factor 3b, subunit 3 [Homo sapiens] 
  X X 
gi|4826998|ref|NP_005057.1| splicing factor proline/glutamine rich 
(polypyrimidine tract binding protein associated) 
[Homo sapiens] 
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  X X 
gi|118582269|ref|NP_0010716
34.1| 
splicing factor, arginine/serine-rich 1 isoform 2 
[Homo sapiens],splicing factor, arginine/serine-rich 
1 isoform 1 [Homo sapiens] 
  X   
gi|47271443|ref|NP_003007.2| splicing factor, arginine/serine-rich 2 [Homo 
sapiens] 
  X   
gi|32698750|ref|NP_067051.1| SR-related CTD-associated factor 1 [Homo 
sapiens] 
  X   gi|4507267|ref|NP_003705.1| stanniocalcin 2 precursor [Homo sapiens] 
    X 
gi|77404397|ref|NP_055205.2| staphylococcal nuclease domain containing 1 
[Homo sapiens] 
  X X 
gi|44890050|ref|NP_981944.1|,
gi|44890052|ref|NP_981946.1|,
gi|5031851|ref|NP_005554.1| 
stathmin 1 [Homo sapiens] 
  X   gi|4506803|ref|NP_002966.1| stem cell growth factor precursor [Homo sapiens] 
  X   
gi|41152074|ref|NP_955805.1|,
gi|41152076|ref|NP_955806.1| 
steroid-sensitive protein 1 [Homo sapiens] 
  X X gi|5454052|ref|NP_006133.1| stratifin [Homo sapiens] 
  X X 
gi|5803181|ref|NP_006810.1| stress-induced-phosphoprotein 1 (Hsp70/Hsp90-
organizing protein) [Homo sapiens] 
  X X 
gi|18699732|ref|NP_057260.2|,
gi|7706573|ref|NP_057631.1| 
stromal cell derived factor 4 precursor [Homo 
sapiens] 
  X   
gi|4507241|ref|NP_003137.1| structure specific recognition protein 1 [Homo 
sapiens] 
  X   
gi|4885649|ref|NP_005490.1| SUMO-1 activating enzyme subunit 2 [Homo 
sapiens] 
X X X 
gi|34850061|ref|NP_008960.2| superiorcervical ganglia, neural specific 10 [Homo 
sapiens] 
X X X gi|4507149|ref|NP_000445.1| superoxide dismutase 1, soluble [Homo sapiens] 
  X   
gi|21237805|ref|NP_003066.2|,
gi|21237808|ref|NP_620706.1| 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin c2 isoform a 
[Homo sapiens],SWI/SNF-related matrix-
associated actin-dependent regulator of chromatin 
c2 isoform b [Homo sapiens] 
  X X 
gi|23397427|ref|NP_006363.3| synaptotagmin binding, cytoplasmic RNA 
interacting protein [Homo sapiens] 
    X 
gi|29568086|ref|NP_002988.3|,
gi|55749480|ref|NP_00100694
7.1| 
syndecan 1 precursor [Homo sapiens] 
  X X gi|38201675|ref|NP_002990.2| syndecan 4 precursor [Homo sapiens] 
  X   
gi|55749490|ref|NP_00100706
8.1|,gi|55749504|ref|NP_00100
7069.1|,gi|56243522|ref|NP_00
5616.2| 
syntenin isoform 1 [Homo sapiens],syntenin 
isoform 2 [Homo sapiens] 
X X X gi|16753233|ref|NP_006280.2| talin 1 [Homo sapiens] 
  X X gi|57863257|ref|NP_110379.2| T-complex protein 1 isoform a [Homo sapiens] 
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  X   gi|4507491|ref|NP_003240.1| thimet oligopeptidase 1 [Homo sapiens] 
X X X gi|50592994|ref|NP_003320.2| thioredoxin [Homo sapiens] 
  X   
gi|52487191|ref|NP_055866.1| thioredoxin domain containing 4 (endoplasmic 
reticulum) [Homo sapiens] 
    X gi|5453549|ref|NP_006397.1| thioredoxin peroxidase [Homo sapiens] 
  X X 
gi|148277065|ref|NP_003321.3
|,gi|148277071|ref|NP_001087
240.1|,gi|33519426|ref|NP_877
393.1|,gi|33519428|ref|NP_877
419.1|,gi|33519430|ref|NP_877
420.1| 
thioredoxin reductase 1 isoform 1 [Homo 
sapiens],thioredoxin reductase 1 isoform 3 [Homo 
sapiens],thioredoxin reductase 1 isoform 2 [Homo 
sapiens],thioredoxin reductase 1 isoform 2 [Homo 
sapiens] 
  X X gi|4759274|ref|NP_004777.1| thioredoxin-like 1 [Homo sapiens] 
  X   gi|14249348|ref|NP_116120.1| thioredoxin-like 5 [Homo sapiens] 
  X   gi|55770864|ref|NP_005773.2| THO complex 4 [Homo sapiens] 
  X X gi|38202255|ref|NP_689508.3| threonyl-tRNA synthetase [Homo sapiens] 
  X   gi|40317626|ref|NP_003237.2| thrombospondin 1 precursor [Homo sapiens] 
  X   
gi|4507555|ref|NP_003267.1|,g
i|73760401|ref|NP_001027455.
1|,gi|73760405|ref|NP_001027
454.1| 
thymopoietin isoform alpha [Homo 
sapiens],thymopoietin isoform gamma [Homo 
sapiens],thymopoietin isoform beta [Homo sapiens] 
X X X 
gi|11056061|ref|NP_066932.1|,
gi|34013530|ref|NP_898870.1| 
thymosin, beta 4 [Homo sapiens],thymosin-like 3 
[Homo sapiens] 
  X X 
gi|4507511|ref|NP_003246.1| TIMP metallopeptidase inhibitor 2 precursor [Homo 
sapiens] 
  X X gi|21361794|ref|NP_060918.2| TIP120 protein [Homo sapiens] 
  X X 
gi|5454114|ref|NP_006278.1| tissue factor pathway inhibitor isoform a precursor 
[Homo sapiens] 
  X X 
gi|4507509|ref|NP_003245.1| tissue inhibitor of metalloproteinase 1 precursor 
[Homo sapiens] 
  X X 
gi|155722983|ref|NP_057376.2
| 
TNF receptor-associated protein 1 [Homo sapiens] 
X X X gi|5803187|ref|NP_006746.1| transaldolase 1 [Homo sapiens] 
  X   
gi|45439355|ref|NP_958845.1|,
gi|5803191|ref|NP_006747.1| 
transcription elongation factor A 1 isoform 2 [Homo 
sapiens],transcription elongation factor A 1 isoform 
1 [Homo sapiens] 
    X gi|4557871|ref|NP_001054.1| transferrin [Homo sapiens] 
    X gi|4507457|ref|NP_003225.1| transferrin receptor [Homo sapiens] 
  X   gi|63025222|ref|NP_000651.3| transforming growth factor, beta 1 [Homo sapiens] 
  X X 
gi|4507467|ref|NP_000349.1| transforming growth factor, beta-induced, 68kDa 
[Homo sapiens] 
  X X gi|4507357|ref|NP_003555.1| transgelin 2 [Homo sapiens] 
    X 
gi|39777597|ref|NP_004604.2|,
gi|39777599|ref|NP_945189.1| 
transglutaminase 2 isoform a [Homo 
sapiens],transglutaminase 2 isoform b [Homo 
sapiens] 
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  X   gi|42518068|ref|NP_006455.2| trans-golgi network protein 2 [Homo sapiens] 
X X X gi|4507521|ref|NP_001055.1| transketolase [Homo sapiens] 
  X   gi|4759270|ref|NP_004613.1| translin [Homo sapiens] 
    X gi|5174731|ref|NP_005990.1| translin-associated factor X [Homo sapiens] 
  X   
gi|57164975|ref|NP_000347.2|,
gi|57164977|ref|NP_00100865
6.1|,gi|57164979|ref|NP_00100
8657.1| 
Treacher Collins-Franceschetti syndrome 1 isoform 
b [Homo sapiens],Treacher Collins-Franceschetti 
syndrome 1 isoform a [Homo sapiens],Treacher 
Collins-Franceschetti syndrome 1 isoform c [Homo 
sapiens] 
    X 
gi|148491080|ref|NP_055903.2
| 
trinucleotide repeat containing 6B isoform 1 [Homo 
sapiens] 
X X X gi|4507645|ref|NP_000356.1| triosephosphate isomerase 1 [Homo sapiens] 
  X   
gi|5032179|ref|NP_005753.1| tripartite motif-containing 28 protein [Homo 
sapiens] 
    X 
gi|5729770|ref|NP_000382.3| tripeptidyl-peptidase I preproprotein [Homo 
sapiens] 
  X   
gi|21361320|ref|NP_006061.2|,
gi|56090139|ref|NP_00100756
6.1| 
TRK-fused [Homo sapiens],TRK-fused [Homo 
sapiens] 
  X   
gi|63252896|ref|NP_00101800
4.1|,gi|63252900|ref|NP_00101
8006.1| 
tropomyosin 1 alpha chain isoform 3 [Homo 
sapiens],tropomyosin 1 alpha chain isoform 4 
[Homo sapiens] 
  X   
gi|42476296|ref|NP_003280.2|,
gi|47519616|ref|NP_998839.1| 
tropomyosin 2 (beta) isoform 1 [Homo 
sapiens],tropomyosin 2 (beta) isoform 2 [Homo 
sapiens] 
  X X 
gi|114155144|ref|NP_0010368
16.1|,gi|24119203|ref|NP_7059
35.1| 
tropomyosin 3 isoform 4 [Homo 
sapiens],tropomyosin 3 isoform 2 [Homo sapiens] 
X X X gi|4507651|ref|NP_003281.1| tropomyosin 4 [Homo sapiens] 
  X X 
gi|47419914|ref|NP_004175.2|,
gi|47419916|ref|NP_776049.1|,
gi|47419918|ref|NP_998810.1|,
gi|47419920|ref|NP_998811.1| 
tryptophanyl-tRNA synthetase isoform a [Homo 
sapiens],tryptophanyl-tRNA synthetase isoform b 
[Homo sapiens] 
    X gi|14389309|ref|NP_116093.1| tubulin alpha 6 [Homo sapiens] 
  X   gi|17986283|ref|NP_006000.2| tubulin, alpha 1a [Homo sapiens] 
  X X gi|57013276|ref|NP_006073.2| tubulin, alpha, ubiquitous [Homo sapiens] 
  X X gi|29788785|ref|NP_821133.1| tubulin, beta [Homo sapiens] 
  X X gi|14210536|ref|NP_115914.1| tubulin, beta 6 [Homo sapiens] 
  X X gi|5174735|ref|NP_006079.1| tubulin, beta, 2 [Homo sapiens] 
  X X gi|4759212|ref|NP_004598.1| tubulin-specific chaperone a [Homo sapiens] 
    X 
gi|14790170|ref|NP_116563.1|,
gi|4507585|ref|NP_003814.1| 
tumor necrosis factor receptor superfamily, 
member 6b [Homo sapiens] 
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    X 
gi|40805860|ref|NP_003279.2|,
gi|40805862|ref|NP_955391.1|,
gi|40805864|ref|NP_955392.1|,
gi|40805866|ref|NP_955393.1|,
gi|40805868|ref|NP_955394.1|,
gi|40805870|ref|NP_955395.1| 
tumor protein D52-like 2 isoform e [Homo 
sapiens],tumor protein D52-like 2 isoform f [Homo 
sapiens],tumor protein D52-like 2 isoform a [Homo 
sapiens],tumor protein D52-like 2 isoform b [Homo 
sapiens],tumor protein D52-like 2 isoform c [Homo 
sapiens] 
  X   
gi|22538444|ref|NP_004872.2|,
gi|22538446|ref|NP_671713.1| 
tumor protein p53 inducible protein 3 [Homo 
sapiens] 
  X X 
gi|4507669|ref|NP_003286.1| tumor protein, translationally-controlled 1 [Homo 
sapiens] 
  X X gi|4507677|ref|NP_003290.1| tumor rejection antigen (gp96) 1 [Homo sapiens] 
  X   gi|6005846|ref|NP_009215.1| twinfilin-like protein [Homo sapiens] 
X X X 
gi|5803225|ref|NP_006752.1| tyrosine 3/tryptophan 5 -monooxygenase activation 
protein, epsilon polypeptide [Homo sapiens] 
  X X 
gi|4507951|ref|NP_003396.1| tyrosine 3/tryptophan 5 -monooxygenase activation 
protein, eta polypeptide [Homo sapiens] 
  X X 
gi|5803227|ref|NP_006817.1| tyrosine 3/tryptophan 5 -monooxygenase activation 
protein, theta polypeptide [Homo sapiens] 
X X X 
gi|21735625|ref|NP_663723.1|,
gi|4507953|ref|NP_003397.1| 
tyrosine 3/tryptophan 5 -monooxygenase activation 
protein, zeta polypeptide [Homo sapiens] 
  X X 
gi|21328448|ref|NP_647539.1|,
gi|4507949|ref|NP_003395.1| 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta 
polypeptide [Homo sapiens] 
  X X 
gi|21464101|ref|NP_036611.2| tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, gamma 
polypeptide [Homo sapiens] 
  X X 
gi|29568103|ref|NP_003080.2| U1 small nuclear ribonucleoprotein 70 kDa [Homo 
sapiens] 
  X X 
gi|6005926|ref|NP_009210.1|,g
i|60279268|ref|NP_001012496.
1| 
U2 (RNU2) small nuclear RNA auxiliary factor 2 
isoform a [Homo sapiens],U2 (RNU2) small nuclear 
RNA auxiliary factor 2 isoform b [Homo sapiens] 
    X 
gi|7706425|ref|NP_057284.1| U6 snRNA-associated Sm-like protein LSm8 
[Homo sapiens] 
  X   gi|16753203|ref|NP_038466.2| ubiquilin 1 isoform 1 [Homo sapiens] 
X X X 
gi|11024714|ref|NP_061828.1|,
gi|4506713|ref|NP_002945.1|,g
i|4507761|ref|NP_003324.1|,gi|
67191208|ref|NP_066289.2|,gi|
77539055|ref|NP_001029102.
1| 
ubiquitin B precursor [Homo sapiens],ubiquitin and 
ribosomal protein S27a precursor [Homo 
sapiens],ubiquitin and ribosomal protein L40 
precursor [Homo sapiens],ubiquitin C [Homo 
sapiens] 
  X   
gi|21361091|ref|NP_004172.2| ubiquitin carboxyl-terminal esterase L1 [Homo 
sapiens] 
  X   
gi|29501813|ref|NP_005650.2| ubiquitin fusion degradation 1-like isoform A [Homo 
sapiens] 
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  X X 
gi|23510338|ref|NP_003325.2|,
gi|23510340|ref|NP_695012.1| 
ubiquitin-activating enzyme E1 [Homo sapiens] 
  X X 
gi|40806164|ref|NP_068823.2|,
gi|40806167|ref|NP_954595.1|,
gi|40806190|ref|NP_954673.1|,
gi|4507795|ref|NP_003340.1|,g
i|73765546|ref|NP_001027459.
1| 
ubiquitin-conjugating enzyme E2 variant 1 isoform 
a [Homo sapiens],ubiquitin-conjugating enzyme E2 
Kua-UEV isoform 1 [Homo sapiens],ubiquitin-
conjugating enzyme E2 Kua-UEV isoform 2 [Homo 
sapiens] 
  X X 
gi|4507797|ref|NP_003341.1| ubiquitin-conjugating enzyme E2 variant 2 [Homo 
sapiens] 
  X   
gi|4885417|ref|NP_005330.1| ubiquitin-conjugating enzyme E2-25K isoform 1 
[Homo sapiens] 
  X X 
gi|35493987|ref|NP_919235.1|,
gi|35493996|ref|NP_919236.1|,
gi|35494003|ref|NP_919237.1|,
gi|4507785|ref|NP_003336.1| 
ubiquitin-conjugating enzyme E2I [Homo sapiens] 
  X X 
gi|4507789|ref|NP_003338.1| ubiquitin-conjugating enzyme E2L 3 isoform 1 
[Homo sapiens] 
  X X gi|4507793|ref|NP_003339.1| ubiquitin-conjugating enzyme E2N [Homo sapiens] 
  X   
gi|13929462|ref|NP_001488.2| UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase 1, membrane-bound form 
[Homo sapiens] 
  X X 
gi|5802984|ref|NP_006867.1| UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 1 [Homo sapiens] 
  X X 
gi|156627575|ref|NP_003106.3
| 
UDP-N-acteylglucosamine pyrophosphorylase 1 
[Homo sapiens] 
  X X 
gi|23308579|ref|NP_006592.3| unactive progesterone receptor, 23 kD [Homo 
sapiens] 
  X   gi|4507835|ref|NP_000364.1| uridine monophosphate synthase [Homo sapiens] 
  X X 
gi|4505863|ref|NP_002649.1| urokinase plasminogen activator preproprotein 
[Homo sapiens] 
  X   gi|71051616|ref|NP_000365.3| uroporphyrinogen decarboxylase [Homo sapiens] 
  X X 
gi|4506387|ref|NP_002865.1| UV excision repair protein RAD23 homolog B 
[Homo sapiens] 
  X   gi|19913428|ref|NP_001684.2| vacuolar H+ATPase B2 [Homo sapiens] 
  X X 
gi|17978519|ref|NP_004887.2| vacuolar protein sorting 26 A isoform 1 [Homo 
sapiens] 
    X 
gi|78482614|ref|NP_00103033
7.1| 
vacuolar protein sorting 26 A isoform 2 [Homo 
sapiens] 
  X X gi|6005942|ref|NP_009057.1| valosin-containing protein [Homo sapiens] 
    X 
gi|4885653|ref|NP_005420.1| vascular endothelial growth factor C preproprotein 
[Homo sapiens] 
    X 
gi|4507869|ref|NP_003361.1| vasodilator-stimulated phosphoprotein [Homo 
sapiens] 
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  X   
gi|4885153|ref|NP_005198.1| v-crk sarcoma virus CT10 oncogene homolog 
(avian)-like [Homo sapiens] 
  X X 
gi|41327710|ref|NP_005197.3|,
gi|41327712|ref|NP_058431.2| 
v-crk sarcoma virus CT10 oncogene homolog 
isoform b [Homo sapiens],v-crk sarcoma virus 
CT10 oncogene homolog isoform a [Homo sapiens] 
  X   gi|21361116|ref|NP_004376.2| versican [Homo sapiens] 
  X   gi|18379349|ref|NP_006364.2| vesicle amine transport protein 1 [Homo sapiens] 
  X   
gi|94721250|ref|NP_003565.4|,
gi|94721252|ref|NP_919415.2| 
vesicle-associated membrane protein-associated 
protein A isoform 1 [Homo sapiens],vesicle-
associated membrane protein-associated protein A 
isoform 2 [Homo sapiens] 
    X 
gi|17136078|ref|NP_003369.2| VGF nerve growth factor inducible precursor [Homo 
sapiens] 
X X X gi|62414289|ref|NP_003371.2| vimentin [Homo sapiens] 
  X X 
gi|4507877|ref|NP_003364.1|,g
i|7669550|ref|NP_054706.1| 
vinculin isoform VCL [Homo sapiens],vinculin 
isoform meta-VCL [Homo sapiens] 
    X gi|5031977|ref|NP_005737.1| visfatin precursor [Homo sapiens] 
  X X 
gi|9257257|ref|NP_059830.1| WD repeat-containing protein 1 isoform 1 [Homo 
sapiens] 
    X 
gi|53729352|ref|NP_005103.2| WD repeat-containing protein 1 isoform 2 [Homo 
sapiens] 
    X gi|13129100|ref|NP_077001.1| XTP3-transactivated protein A [Homo sapiens] 
  X   gi|11386193|ref|NP_008922.1| zinc finger protein 197 isoform 1 [Homo sapiens] 
    X 
gi|4508047|ref|NP_003452.1|,g
i|58530845|ref|NP_001010972.
1| 
zyxin [Homo sapiens],zyxin [Homo sapiens] 
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Wound Healing 
GI No DAVID Gene Name Gene Symbol 
4502101 ANNEXIN A1 ANXA1 
4502107 ANNEXIN A5 ANXA5 
22538433 CATHEPSIN B CTSB 
76563933 
CHEMOKINE (C-X-C MOTIF) LIGAND 12 (STROMAL CELL-
DERIVED FACTOR 1) 
CXCL12 
42716297 CLUSTERIN CLU 
66347875 COMPLEMENT COMPONENT 1, R SUBCOMPONENT C1R 
4503123 CONNECTIVE TISSUE GROWTH FACTOR CTGF 
47132557 FIBRONECTIN 1 FN1 
62243290 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 IGFBP4 
4505029 LEUKOTRIENE A4 HYDROLASE LTA4H 
4505185 
MACROPHAGE MIGRATION INHIBITORY FACTOR 
(GLYCOSYLATION-INHIBITING FACTOR) 
MIF 
59894792 MIDKINE (NEURITE GROWTH-PROMOTING FACTOR 2) MDK 
4758804 
(+3) 
NUCLEAR FACTOR OF ACTIVATED T-CELLS, CYTOPLASMIC, 
CALCINEURIN-DEPENDENT 3 
NFATC3 
6912238 PEROXIREDOXIN 5 PRDX5 
4505863 PLASMINOGEN ACTIVATOR, UROKINASE PLAU 
10835159 
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, 
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1 
SERPINE1 
4507149 
SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC 
LATERAL SCLEROSIS 1 (ADULT)) 
SOD1 
40317626 THROMBOSPONDIN 1 THBS1 
5454114 
TISSUE FACTOR PATHWAY INHIBITOR (LIPOPROTEIN-
ASSOCIATED COAGULATION INHIBITOR) 
TFPI 
63025222 
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATI-
ENGELMANN DISEASE) 
TGFB1 
13929462 
UDP-GAL:BETAGLCNAC BETA 1,4- 
GALACTOSYLTRANSFERASE, POLYPEPTIDE 1 
B4GALT1 
Inflammation 
GI No DAVID Gene Name Gene Symbol 
4502101 ANNEXIN A1 ANXA1 
7662238 APOPTOTIC CHROMATIN CONDENSATION INDUCER 1 ACIN1 
4757826 BETA-2-MICROGLOBULIN B2M 
10834988 
CHEMOKINE (C-X-C MOTIF) LIGAND 12 (STROMAL CELL-
DERIVED FACTOR 1) 
CXCL12 
42716297 CLUSTERIN CLU 
4502491 
COMPLEMENT COMPONENT 1, Q SUBCOMPONENT BINDING 
PROTEIN 
C1QBP 
66347875 COMPLEMENT COMPONENT 1, R SUBCOMPONENT C1R 
47132551 FIBRONECTIN 1 FN1 
18201905 GLUCOSE PHOSPHATE ISOMERASE GPI 
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4504699 
INHIBIN, BETA A (ACTIVIN A, ACTIVIN AB ALPHA 
POLYPEPTIDE) 
INHBA 
62243290 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 IGFBP4 
24234747 INTERLEUKIN ENHANCER BINDING FACTOR 2, 45KDA ILF2 
4505029 LEUKOTRIENE A4 HYDROLASE LTA4H 
4505185 
MACROPHAGE MIGRATION INHIBITORY FACTOR 
(GLYCOSYLATION-INHIBITING FACTOR) 
MIF 
4505185 
MACROPHAGE MIGRATION INHIBITORY FACTOR 
(GLYCOSYLATION-INHIBITING FACTOR) 
MIF 
12667788 MYOSIN, HEAVY POLYPEPTIDE 9, NON-MUSCLE MYH9 
4758804 
(+3) 
NUCLEAR FACTOR OF ACTIVATED T-CELLS, CYTOPLASMIC, 
CALCINEURIN-DEPENDENT 3 
NFATC3 
46276863 PARATHYMOSIN PTMS 
32455260 PEROXIREDOXIN 5 PRDX5 
30581141 
PROTEASOME (PROSOME, MACROPAIN) ACTIVATOR 
SUBUNIT 1 (PA28 ALPHA) 
PSME1 
30410792 
PROTEASOME (PROSOME, MACROPAIN) ACTIVATOR 
SUBUNIT 2 (PA28 BETA) 
PSME2 
6005846 
PTK9L PROTEIN TYROSINE KINASE 9-LIKE (A6-RELATED 
PROTEIN) 
TWF2 
4506695 RIBOSOMAL PROTEIN S19 RPS19 
4507149 
SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC 
LATERAL SCLEROSIS 1 (ADULT)) 
SOD1 
40317626 THROMBOSPONDIN 1 THBS1 
4507509 TIMP METALLOPEPTIDASE INHIBITOR 1 TIMP1 
45439355 TRANSCRIPTION ELONGATION FACTOR A (SII), 1 TCEA1 
63025222 
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATI-
ENGELMANN DISEASE) 
TGFB1 
29788785 TUBULIN, BETA TUBB 
5174735 TUBULIN, BETA 2C TUBB2C 
4507793 
UBIQUITIN-CONJUGATING ENZYME E2N (UBC13 HOMOLOG, 
YEAST) 
UBE2N 
13929462 
UDP-GAL:BETAGLCNAC BETA 1,4- 
GALACTOSYLTRANSFERASE, POLYPEPTIDE 1 
B4GALT1 
41327712 
V-CRK SARCOMA VIRUS CT10 ONCOGENE HOMOLOG 
(AVIAN) 
CRK 
Fibrosis 
GI No DAVID Gene Name Gene Symbol 
41406057 
AMYLOID BETA (A4) PRECURSOR PROTEIN (PEPTIDASE 
NEXIN-II, ALZHEIMER DISEASE) 
APP 
4757756 ANNEXIN A2 ANXA2 
4502403 BIGLYCAN BGN 
4757900 CALRETICULIN CALR 
21361116 CHONDROITIN SULFATE PROTEOGLYCAN 2 (VERSICAN) VCAN 
87196339 COLLAGEN, TYPE VI, ALPHA 1 COL6A1 
4503123 CONNECTIVE TISSUE GROWTH FACTOR CTGF 
4503117 CYSTATIN B (STEFIN B) CSTB 
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Fibrosis - continued 
4503107 
CYSTATIN C (AMYLOID ANGIOPATHY AND CEREBRAL 
HEMORRHAGE) 
CST3 
4758236 EXTRACELLULAR MATRIX PROTEIN 1 ECM1 
16933542 FIBRONECTIN 1 FN1 
34734062 FIBULIN 1 FBLN1 
5031863 
LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 3 BINDING 
PROTEIN 
LGALS3BP 
11342666 
MATRIX METALLOPEPTIDASE 2 (GELATINASE A, 72KDA 
GELATINASE, 72KDA TYPE IV COLLAGENASE) 
MMP2 
4505621 PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN 1 PEBP1 
4507171 
SECRETED PROTEIN, ACIDIC, CYSTEINE-RICH 
(OSTEONECTIN) 
SPARC 
41152086 
SERPIN PEPTIDASE INHIBITOR, CLADE B (OVALBUMIN), 
MEMBER 6 
SERPINB6 
10835159 
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, 
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1 
SERPINE1 
24307907 
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, 
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 2 
SERPINE2 
5453886 
SERPIN PEPTIDASE INHIBITOR, CLADE I (PANCPIN), 
MEMBER 2 
SERPINI2 
4759164 
SPARC/OSTEONECTIN, CWCV AND KAZAL-LIKE DOMAINS 
PROTEOGLYCAN (TESTICAN) 1 
SPOCK1 
4507511 TIMP METALLOPEPTIDASE INHIBITOR 2 TIMP2 
5454114 
TISSUE FACTOR PATHWAY INHIBITOR (LIPOPROTEIN-
ASSOCIATED COAGULATION INHIBITOR) 
TFPI 
4507467 TRANSFORMING GROWTH FACTOR, BETA-INDUCED, 68KDA TGFBI 
Proliferation 
GI No DAVID Gene Name Gene Symbol 
12025678 ACTININ, ALPHA 4 ACTN4 
66363686 AMYLOID BETA PRECURSOR PROTEIN BINDING PROTEIN 1 NAE1 
4502101 ANNEXIN A1 ANXA1 
21536466 AXL RECEPTOR TYROSINE KINASE AXL 
4757900 CALRETICULIN CALR 
5901922 CDC37 CELL DIVISION CYCLE 37 HOMOLOG (S. CEREVISIAE) CDC37 
38455427 CHAPERONIN CONTAINING TCP1, SUBUNIT 4 (DELTA) CCT4 
42716297 CLUSTERIN CLU 
4506803 C-TYPE LECTIN DOMAIN FAMILY 11, MEMBER A CLEC11A 
4503101 CYSTEINE AND GLYCINE-RICH PROTEIN 2 CSRP 
31542331 CYSTEINE-RICH, ANGIOGENIC INDUCER, 61 CYR61 
4503337 DYSKERATOSIS CONGENITA 1, DYSKERIN DKC1 
4758302 ENHANCER OF RUDIMENTARY HOMOLOG (DROSOPHILA) ERH 
19743875 FUMARATE HYDRATASE FH 
47078238 G PROTEIN PATHWAY SUPPRESSOR 1 GPS1 
4504253 H2A HISTONE FAMILY, MEMBER X H2AFX 
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Proliferation – continued 
4758516 
HEPATOMA-DERIVED GROWTH FACTOR (HIGH-MOBILITY 
GROUP PROTEIN 1-LIKE) 
HDGF 
4504699 
INHIBIN, BETA A (ACTIVIN A, ACTIVIN AB ALPHA 
POLYPEPTIDE) 
INHBA 
62243290 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4 IGFBP4 
4504619 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 IGFBP7 
24234750 INTERLEUKIN ENHANCER BINDING FACTOR 3, 90KDA ILF3 
5730027 
KH DOMAIN CONTAINING, RNA BINDING, SIGNAL 
TRANSDUCTION ASSOCIATED 1 
KHDRBS1 
4557733 
LATENT TRANSFORMING GROWTH FACTOR BETA BINDING 
PROTEIN 2 
LTBP2 
4505185 
MACROPHAGE MIGRATION INHIBITORY FACTOR 
(GLYCOSYLATION-INHIBITING FACTOR) 
MIF 
6912494 
MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY, 
MEMBER 1 
MAPRE1 
4505135 MIDKINE (NEURITE GROWTH-PROMOTING FACTOR 2) MDK 
4557797 
NON-METASTATIC CELLS 1, PROTEIN (NM23A) EXPRESSED 
IN 
NME1 
27262628 
NUCLEAR AUTOANTIGENIC SPERM PROTEIN (HISTONE-
BINDING) 
NASP 
5729953 NUCLEAR DISTRIBUTION GENE C HOMOLOG (A. NIDULANS) NUDC 
71361682 NUCLEAR MITOTIC APPARATUS PROTEIN 1 NUMA1 
10835063 
NUCLEOPHOSMIN (NUCLEOLAR PHOSPHOPROTEIN B23, 
NUMATRIN) 
NPM1 
21327708 NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 1 NAP1L1 
46276863 PARATHYMOSIN PTMS 
21070974 PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE PAM 
32455264 PEROXIREDOXIN 1 PRDX1 
33239451 PROLIFERATING CELL NUCLEAR ANTIGEN PCNA 
4506003 
PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, ALPHA 
ISOFORM 
PPP1CA 
4506005 
PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, BETA 
ISOFORM 
PPP1CB 
4506007 
PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, GAMMA 
ISOFORM 
PPP1CC 
4505999 
PROTEIN PHOSPHATASE 1G (FORMERLY 2C), MAGNESIUM-
DEPENDENT, GAMMA ISOFORM 
PPM1G 
21361399 
PROTEIN PHOSPHATASE 2 (FORMERLY 2A), REGULATORY 
SUBUNIT A (PR 65), ALPHA ISOFORM 
PPP2R1A 
13325075 QUIESCIN Q6 QSOX1 
5453555 RAN, MEMBER RAS ONCOGENE FAMILY RAN 
29789090 REGULATOR OF CHROMOSOME CONDENSATION 2 RCC2 
4506583 REPLICATION PROTEIN A1, 70KDA RPA1 
4506439 RETINOBLASTOMA BINDING PROTEIN 7 RBBP7 
5032057 S100 CALCIUM BINDING PROTEIN A11 (CALGIZZARIN) S100A11 
7657532 S100 CALCIUM BINDING PROTEIN A6 (CALCYCLIN) S100A6 
8922712 SEPTIN 11 SEPT11 
28416940 SHWACHMAN-BODIAN-DIAMOND SYNDROME SBDS 
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Proliferation - continued 
4759164 
SPARC/OSTEONECTIN, CWCV AND KAZAL-LIKE DOMAINS 
PROTEOGLYCAN (TESTICAN) 1 
SPOCK1 
44890050 STATHMIN 1/ONCOPROTEIN 18 STMN1 
5454052 STRATIFIN SFN 
6678271 TAR DNA BINDING PROTEIN TARDBP 
50592994 THIOREDOXIN TXN 
33519426 THIOREDOXIN REDUCTASE 1 TXNRD1 
4507509 TIMP METALLOPEPTIDASE INHIBITOR 1 TIMP1 
4507511 TIMP METALLOPEPTIDASE INHIBITOR 2 TIMP2 
63025222 
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATI-
ENGELMANN DISEASE) 
TGFB1 
4507467 TRANSFORMING GROWTH FACTOR, BETA-INDUCED, 68KDA TGFBI 
4507951 
TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-
MONOOXYGENASE ACTIVATION PROTEIN, ETA 
POLYPEPTIDE 
YWHAH 
5803227 
TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-
MONOOXYGENASE ACTIVATION PROTEIN, THETA 
POLYPEPTIDE 
YWHAQ 
77539055 
UBIQUITIN A-52 RESIDUE RIBOSOMAL PROTEIN FUSION 
PRODUCT 1 
UBA52 
11024714 UBIQUITIN B UBB 
21361091 
UBIQUITIN CARBOXYL-TERMINAL ESTERASE L1 (UBIQUITIN 
THIOLESTERASE) 
UCHL1 
4507797 UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 2 UBE2V2 
35493987 
UBIQUITIN-CONJUGATING ENZYME E2I (UBC9 HOMOLOG, 
YEAST) 
UBE2I 
13929462 
UDP-GAL:BETAGLCNAC BETA 1,4- 
GALACTOSYLTRANSFERASE, POLYPEPTIDE 1 
B4GALT1 
Apoptosis 
GI No DAVID Gene Name Gene Symbol 
4885049 ACTIN, ALPHA, CARDIAC MUSCLE ACTC1 
4501891 ACTININ, ALPHA 1 ACTN1 
12025678 ACTININ, ALPHA 4 ACTN4 
4502027 ALBUMIN ALB 
41406055 
AMYLOID BETA (A4) PRECURSOR PROTEIN (PEPTIDASE 
NEXIN-II, ALZHEIMER DISEASE) 
APP 
4502169 AMYLOID BETA PRECURSOR PROTEIN BINDING PROTEIN 1 NAE1 
4502101 ANNEXIN A1 ANXA1 
4502107 ANNEXIN A5 ANXA5 
5729730 APOPTOSIS INHIBITOR 5 API5 
7662238 APOPTOTIC CHROMATIN CONDENSATION INDUCER 1 ACIN1 
4757900 CALRETICULIN CALR 
22538431 CATHEPSIN B CTSB 
42716297 CLUSTERIN CLU 
5031635 COFILIN 1 (NON-MUSCLE) CFL1 
11128019 CYTOCHROME C, SOMATIC CYCS 
4503545 EUKARYOTIC TRANSLATION INITIATION FACTOR 5A EIF5A 
4504183 GLUTATHIONE S-TRANSFERASE PI GSTP1 
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Apoptosis - continued 
4504523 HEAT SHOCK 10KDA PROTEIN 1 (CHAPERONIN 10) HSPE1 
31542947 HEAT SHOCK 60KDA PROTEIN 1 (CHAPERONIN) HSPD1 
16507237 
HEAT SHOCK 70KDA PROTEIN 5 (GLUCOSE-REGULATED 
PROTEIN, 78KDA) 
HSPA5 
24234688 HEAT SHOCK 70KDA PROTEIN 9B (MORTALIN-2) HSPA9 
4507677 HEAT SHOCK PROTEIN 90KDA BETA (GRP94), MEMBER 1 HSP90B1 
4504425 HIGH-MOBILITY GROUP BOX 1 HMGB1 
4504699 
INHIBIN, BETA A (ACTIVIN A, ACTIVIN AB ALPHA 
POLYPEPTIDE) 
INHBA 
62243068 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 IGFBP3 
24432106 KIAA1967 KIAA1967 
4504981 LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 1 (GALECTIN 1) LGALS1 
4505185 
MACROPHAGE MIGRATION INHIBITORY FACTOR 
(GLYCOSYLATION-INHIBITING FACTOR) 
MIF 
38045913 
NON-METASTATIC CELLS 1, PROTEIN (NM23A) EXPRESSED 
IN 
NME1 
10835063 
NUCLEOPHOSMIN (NUCLEOLAR PHOSPHOPROTEIN B23, 
NUMATRIN) 
NPM1 
32189392 PEROXIREDOXIN 2 PRDX2 
31317307 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 PCSK9 
24430160 
PROTEASOME (PROSOME, MACROPAIN) 26S SUBUNIT, 
ATPASE, 6 
PSMC6 
21361657 PROTEIN DISULFIDE ISOMERASE FAMILY A, MEMBER 3 PDIA3 
21361399 
PROTEIN PHOSPHATASE 2 (FORMERLY 2A), REGULATORY 
SUBUNIT A (PR 65), ALPHA ISOFORM 
PPP2R1A 
4757768 RHO GDP DISSOCIATION INHIBITOR (GDI) ALPHA ARHGDIA 
56117838 SECRETED FRIZZLED-RELATED PROTEIN 1 SFRP1 
5454052 STRATIFIN SFN 
4507149 
SUPEROXIDE DISMUTASE 1, SOLUBLE (AMYOTROPHIC 
LATERAL SCLEROSIS 1 (ADULT)) 
SOD1 
67782305 SUPEROXIDE DISMUTASE 2, MITOCHONDRIAL SOD2 
4759274 THIOREDOXIN-LIKE 1 TXNL1 
63025222 
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATI-
ENGELMANN DISEASE) 
TGFB1 
29788785 TUBULIN, BETA TUBB 
5174735 TUBULIN, BETA 2C TUBB2C 
4507669 TUMOR PROTEIN, TRANSLATIONALLY-CONTROLLED 1 TPT1 
4507951 
TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-
MONOOXYGENASE ACTIVATION PROTEIN, ETA 
POLYPEPTIDE 
YWHAH 
21735625 
TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-
MONOOXYGENASE ACTIVATION PROTEIN, ZETA 
POLYPEPTIDE 
YWHAZ 
13929462 
UDP-GAL:BETAGLCNAC BETA 1,4- 
GALACTOSYLTRANSFERASE, POLYPEPTIDE 1 
B4GALT1 
6005942 VALOSIN-CONTAINING PROTEIN VCP 
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Invasion 
GI No DAVID Gene Name Gene Symbol 
4501885 ACTIN, BETA ACTB 
4501891 ACTININ, ALPHA 1 ACTN1 
12025678 ACTININ, ALPHA 4 ACTN4 
4502101 ANNEXIN A1 ANXA1 
5031571 ARP2 ACTIN-RELATED PROTEIN 2 HOMOLOG (YEAST) ACTR2 
5031573 ARP3 ACTIN-RELATED PROTEIN 3 HOMOLOG (YEAST) ACTR3 
14589889 CADHERIN 2, TYPE 1, N-CADHERIN (NEURONAL) CDH2 
5453595 
CAP, ADENYLATE CYCLASE-ASSOCIATED PROTEIN 1 
(YEAST) 
CAP1 
5453597 
CAPPING PROTEIN (ACTIN FILAMENT) MUSCLE Z-LINE, 
ALPHA 1 
CAPZA1 
5453599 
CAPPING PROTEIN (ACTIN FILAMENT) MUSCLE Z-LINE, 
ALPHA 2 
CAPZA2 
4826659 CAPPING PROTEIN (ACTIN FILAMENT) MUSCLE Z-LINE, BETA CAPZB 
7330335 CHLORIDE INTRACELLULAR CHANNEL 4 CLIC4 
4503123 CONNECTIVE TISSUE GROWTH FACTOR CTGF 
31542331 CYSTEINE-RICH, ANGIOGENIC INDUCER, 61 CYR61 
47132555 FIBRONECTIN 1 FN1 
11342666 
MATRIX METALLOPEPTIDASE 2 (GELATINASE A, 72KDA 
GELATINASE, 72KDA TYPE IV COLLAGENASE) 
MMP2 
4505257 MOESIN MSN 
12667788 MYOSIN, HEAVY POLYPEPTIDE 9, NON-MUSCLE MYH9 
55956788 NUCLEOLIN NCL 
4757768 RHO GDP DISSOCIATION INHIBITOR (GDI) ALPHA ARHGDIA 
4506695 RIBOSOMAL PROTEIN S19 RPS19 
10835159 
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, 
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1 
SERPINE1 
24307907 
SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, 
PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 2 
SERPINE2 
5453886 
SERPIN PEPTIDASE INHIBITOR, CLADE I (PANCPIN), 
MEMBER 2 
SERPINI2 
4759164 
SPARC/OSTEONECTIN, CWCV AND KAZAL-LIKE DOMAINS 
PROTEOGLYCAN (TESTICAN) 1 
SPOCK1 
16753233 TALIN 1 TLN1 
50592994 THIOREDOXIN TXN 
40317626 THROMBOSPONDIN 1 THBS1 
63025222 
TRANSFORMING GROWTH FACTOR, BETA 1 (CAMURATI-
ENGELMANN DISEASE) 
TGFB1 
63252896 TROPOMYOSIN 1 (ALPHA) TPM1 
24119203 TROPOMYOSIN 3 TPM3 
4507651 TROPOMYOSIN 4 TPM4 
29788785 TUBULIN, BETA TUBB 
5174735 TUBULIN, BETA 2C TUBB2C 
4507761 
UBIQUITIN A-52 RESIDUE RIBOSOMAL PROTEIN FUSION 
PRODUCT 1 
UBA52 
11024714 UBIQUITIN B UBB 
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Invasion - continued 
13929462 
UDP-GAL:BETAGLCNAC BETA 1,4- 
GALACTOSYLTRANSFERASE, POLYPEPTIDE 1 
B4GALT1 
41327710 
V-CRK SARCOMA VIRUS CT10 ONCOGENE HOMOLOG 
(AVIAN) 
CRK 
62414289 VIMENTIN VIM 
4507877 VINCULIN VCL 
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APPENDIX 3 
Protein Peptide 
Precusor 
m/z 
Product 
m/z 
CID  
energy 
Product 
ion Isotope 
6-phosphogluconolactonase ELPAAVAPAGPASLAR 745.920 1009.579 25.3 y11 light 
6-phosphogluconolactonase ELPAAVAPAGPASLAR 745.920 910.510 25.3 y10 light 
6-phosphogluconolactonase ELPAAVAPAGPASLAR 745.920 839.473 25.3 y9 light 
6-phosphogluconolactonase ELPAAVAPAGPASLAR 752.937 1016.596 25.3 y11 heavy 
6-phosphogluconolactonase ELPAAVAPAGPASLAR 752.937 917.528 25.3 y10 heavy 
6-phosphogluconolactonase ELPAAVAPAGPASLAR 752.937 846.491 25.3 y9 heavy 
amyloid beta A4 protein VESLEQEAANER 687.828 1146.539 23.5 y10 light 
amyloid beta A4 protein VESLEQEAANER 687.828 946.422 23.5 y8 light 
amyloid beta A4 protein VESLEQEAANER 687.828 817.380 23.5 y7 light 
amyloid beta A4 protein VESLEQEAANER 691.337 1153.556 23.5 y10 heavy 
amyloid beta A4 protein VESLEQEAANER 691.337 946.422 23.5 y8 heavy 
amyloid beta A4 protein VESLEQEAANER 691.337 817.380 23.5 y7 heavy 
annexin I GTDVNVFNTILTTR 775.912 1178.653 26.2 y10 light 
annexin I GTDVNVFNTILTTR 775.912 1064.610 26.2 y9 light 
annexin I GTDVNVFNTILTTR 775.912 965.541 26.2 y8 light 
annexin I GTDVNVFNTILTTR 779.421 1185.670 26.2 y10 heavy 
annexin I GTDVNVFNTILTTR 779.421 1071.627 26.2 y9 heavy 
annexin I GTDVNVFNTILTTR 779.421 972.559 26.2 y8 heavy 
anterior gradient 2 homolog IMFVDPSLTVR 639.350 1033.568 22.1 y9 light 
anterior gradient 2 homolog IMFVDPSLTVR 639.350 787.431 22.1 y7 light 
anterior gradient 2 homolog IMFVDPSLTVR 639.350 672.404 22.1 y6 light 
anterior gradient 2 homolog IMFVDPSLTVR 642.858 1040.585 22.1 y9 heavy 
anterior gradient 2 homolog IMFVDPSLTVR 642.858 794.448 22.1 y7 heavy 
anterior gradient 2 homolog IMFVDPSLTVR 642.858 679.421 22.1 y6 heavy 
AXL receptor tyrosine kinase 
isoform 1 TATITVLPQQPR 662.883 938.542 22.8 y8 light 
AXL receptor tyrosine kinase 
isoform 1 TATITVLPQQPR 662.883 837.494 22.8 y7 light 
AXL receptor tyrosine kinase 
isoform 1 TATITVLPQQPR 662.883 738.426 22.8 y6 light 
AXL receptor tyrosine kinase 
isoform 1 TATITVLPQQPR 666.391 945.559 22.8 y8 heavy 
AXL receptor tyrosine kinase 
isoform 1 TATITVLPQQPR 666.391 844.511 22.8 y7 heavy 
AXL receptor tyrosine kinase 
isoform 1 TATITVLPQQPR 666.391 745.443 22.8 y6 heavy 
cadherin 2; type 1 DVHEGQPLLNVK 674.865 1134.627 23.2 y10 light 
cadherin 2; type 1 DVHEGQPLLNVK 674.865 868.525 23.2 y8 light 
cadherin 2; type 1 DVHEGQPLLNVK 674.865 683.445 23.2 y6 light 
cadherin 2; type 1 DVHEGQPLLNVK 685.889 1156.675 23.2 y10 heavy 
cadherin 2; type 1 DVHEGQPLLNVK 685.889 890.574 23.2 y8 heavy 
cadherin 2; type 1 DVHEGQPLLNVK 685.889 705.494 23.2 y6 heavy 
calreticulin EQFLDGDGWTSR 705.818 1006.459 24.1 y9 light 
calreticulin EQFLDGDGWTSR 705.818 893.375 24.1 y8 light 
calreticulin EQFLDGDGWTSR 705.818 778.348 24.1 y7 light 
calreticulin EQFLDGDGWTSR 709.326 1013.476 24.1 y9 heavy 
calreticulin EQFLDGDGWTSR 709.326 893.375 24.1 y8 heavy 
calreticulin EQFLDGDGWTSR 709.326 778.348 24.1 y7 heavy 
cathepsin D FDGILGMAYPR 620.313 807.418 21.5 y7 light 
cathepsin D FDGILGMAYPR 620.313 694.334 21.5 y6 light 
cathepsin D FDGILGMAYPR 620.313 637.313 21.5 y5 light 
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Protein Peptide 
Precusor 
m/z 
Product 
m/z 
CID  
energy 
Product 
ion Isotope 
cathepsin D FDGILGMAYPR 623.822 814.435 21.5 y7 heavy 
cathepsin D FDGILGMAYPR 623.822 694.334 21.5 y6 heavy 
cathepsin D FDGILGMAYPR 623.822 637.313 21.5 y5 heavy 
cathepsin Z VGDYGSLSGR 505.749 854.400 18.1 y8 light 
cathepsin Z VGDYGSLSGR 505.749 739.373 18.1 y7 light 
cathepsin Z VGDYGSLSGR 505.749 576.310 18.1 y6 light 
cathepsin Z VGDYGSLSGR 509.257 861.417 18.1 y8 heavy 
cathepsin Z VGDYGSLSGR 509.257 746.390 18.1 y7 heavy 
cathepsin Z VGDYGSLSGR 509.257 583.327 18.1 y6 heavy 
coactosin-like 1 DDGSAVIWVTFK 669.340 1050.598 23 y9 light 
coactosin-like 1 DDGSAVIWVTFK 669.340 892.529 23 y7 light 
coactosin-like 1 DDGSAVIWVTFK 669.340 793.461 23 y6 light 
coactosin-like 1 DDGSAVIWVTFK 673.348 1058.612 23 y9 heavy 
coactosin-like 1 DDGSAVIWVTFK 673.348 900.543 23 y7 heavy 
coactosin-like 1 DDGSAVIWVTFK 673.348 801.475 23 y6 heavy 
cystatin B VHVGDEDFVHLR 711.860 1186.585 24.3 y10 light 
cystatin B VHVGDEDFVHLR 711.860 1087.517 24.3 y9 light 
cystatin B VHVGDEDFVHLR 711.860 1030.495 24.3 y8 light 
cystatin B VHVGDEDFVHLR 715.368 1193.602 24.3 y10 heavy 
cystatin B VHVGDEDFVHLR 715.368 1094.534 24.3 y9 heavy 
cystatin B VHVGDEDFVHLR 715.368 1037.512 24.3 y8 heavy 
cystatin C ALDFAVGEYNK 613.806 1042.484 21.3 y9 light 
cystatin C ALDFAVGEYNK 613.806 780.389 21.3 y7 light 
cystatin C ALDFAVGEYNK 613.806 709.352 21.3 y6 light 
cystatin C ALDFAVGEYNK 621.322 1050.498 21.3 y9 heavy 
cystatin C ALDFAVGEYNK 621.322 788.403 21.3 y7 heavy 
cystatin C ALDFAVGEYNK 621.322 717.366 21.3 y6 heavy 
cystatin M DLSPDDPQVQK 621.304 1013.490 21.5 y9 light 
cystatin M DLSPDDPQVQK 621.304 926.458 21.5 y8 light 
cystatin M DLSPDDPQVQK 621.304 829.405 21.5 y7 light 
cystatin M DLSPDDPQVQK 628.820 1021.504 21.5 y9 heavy 
cystatin M DLSPDDPQVQK 628.820 934.472 21.5 y8 heavy 
cystatin M DLSPDDPQVQK 628.820 837.419 21.5 y7 heavy 
cysteine-rich; angiogenic inducer; 
61 LPVFGMEPR 523.279 932.466 18.6 y8 light 
cysteine-rich; angiogenic inducer; 
61 LPVFGMEPR 523.279 835.413 18.6 y7 light 
cysteine-rich; angiogenic inducer; 
61 LPVFGMEPR 523.279 736.345 18.6 y6 light 
cysteine-rich; angiogenic inducer; 
61 LPVFGMEPR 526.787 932.466 18.6 y8 heavy 
cysteine-rich; angiogenic inducer; 
61 LPVFGMEPR 526.787 835.413 18.6 y7 heavy 
cysteine-rich; angiogenic inducer; 
61 LPVFGMEPR 526.787 736.345 18.6 y6 heavy 
cysteine-rich; angiogenic inducer; 
61 ELGFDASEVELTR 733.362 1019.500 24.9 y9 light 
cysteine-rich; angiogenic inducer; 
61 ELGFDASEVELTR 733.362 904.473 24.9 y8 light 
cysteine-rich; angiogenic inducer; 
61 ELGFDASEVELTR 733.362 833.436 24.9 y7 light 
cysteine-rich; angiogenic inducer; 
61 ELGFDASEVELTR 740.379 1026.518 24.9 y9 heavy 
cysteine-rich; angiogenic inducer; 
61 ELGFDASEVELTR 740.379 911.491 24.9 y8 heavy 
cysteine-rich; angiogenic inducer; 
61 ELGFDASEVELTR 740.379 840.453 24.9 y7 heavy 
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Precusor 
m/z 
Product 
m/z 
CID  
energy 
Product 
ion Isotope 
desmoglein 2 AWITAPVALR 549.327 840.530 19.4 y8 light 
desmoglein 2 AWITAPVALR 549.327 727.446 19.4 y7 light 
desmoglein 2 AWITAPVALR 549.327 555.361 19.4 y5 light 
desmoglein 2 AWITAPVALR 552.836 847.547 19.4 y8 heavy 
desmoglein 2 AWITAPVALR 552.836 734.463 19.4 y7 heavy 
desmoglein 2 AWITAPVALR 552.836 562.378 19.4 y5 heavy 
enolase 1 LAMQEFMILPVGAANFR 954.497 1057.615 31.5 y10 light 
enolase 1 LAMQEFMILPVGAANFR 954.497 944.531 31.5 y9 light 
enolase 1 LAMQEFMILPVGAANFR 954.497 831.447 31.5 y8 light 
enolase 1 LAMQEFMILPVGAANFR 961.514 1064.632 31.5 y10 heavy 
enolase 1 LAMQEFMILPVGAANFR 961.514 951.548 31.5 y9 heavy 
enolase 1 LAMQEFMILPVGAANFR 961.514 831.447 31.5 y8 heavy 
epidermal growth factor receptor 
pathway substrate  APEPQLSPGSDASEVR 820.400 1342.660 27.5 y13 light 
epidermal growth factor receptor 
pathway substrate  APEPQLSPGSDASEVR 820.400 1004.464 27.5 y10 light 
epidermal growth factor receptor 
pathway substrate  APEPQLSPGSDASEVR 820.400 917.432 27.5 y9 light 
epidermal growth factor receptor 
pathway substrate  APEPQLSPGSDASEVR 823.908 1349.677 27.5 y13 heavy 
epidermal growth factor receptor 
pathway substrate  APEPQLSPGSDASEVR 823.908 1004.464 27.5 y10 heavy 
epidermal growth factor receptor 
pathway substrate  APEPQLSPGSDASEVR 823.908 917.432 27.5 y9 heavy 
extracellular matrix protein 1 
isoform 2 EVGPPLPQEAVPLQK 801.449 1219.704 26.9 y11 light 
extracellular matrix protein 1 
isoform 2 EVGPPLPQEAVPLQK 801.449 1122.652 26.9 y10 light 
extracellular matrix protein 1 
isoform 2 EVGPPLPQEAVPLQK 801.449 1009.568 26.9 y9 light 
extracellular matrix protein 1 
isoform 2 EVGPPLPQEAVPLQK 812.473 1241.753 26.9 y11 heavy 
extracellular matrix protein 1 
isoform 2 EVGPPLPQEAVPLQK 812.473 1144.700 26.9 y10 heavy 
extracellular matrix protein 1 
isoform 2 EVGPPLPQEAVPLQK 812.473 1024.599 26.9 y9 heavy 
family with sequence similarity 
3,member C TGEVLDTK 431.729 761.404 15.9 y7 light 
family with sequence similarity 
3,member C TGEVLDTK 431.729 704.382 15.9 y6 light 
family with sequence similarity 
3,member C TGEVLDTK 431.729 575.340 15.9 y5 light 
family with sequence similarity 
3,member C TGEVLDTK 439.245 776.435 15.9 y7 heavy 
family with sequence similarity 
3,member C TGEVLDTK 439.245 719.414 15.9 y6 heavy 
family with sequence similarity 
3,member C TGEVLDTK 439.245 590.371 15.9 y5 heavy 
G protein coupled receptor. family 
C, group 5, member  AHAWPSPYK 528.767 848.430 18.8 y7 light 
G protein coupled receptor. family 
C, group 5, member  AHAWPSPYK 528.767 777.393 18.8 y6 light 
G protein coupled receptor. family 
C, group 5, member  AHAWPSPYK 528.767 591.314 18.8 y5 light 
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Protein Peptide 
Precusor 
m/z 
Product 
m/z 
CID  
energy 
Product 
ion Isotope 
G protein coupled receptor. family 
C, group 5, member  AHAWPSPYK 532.774 856.444 18.8 y7 heavy 
G protein coupled receptor. family 
C, group 5, member  AHAWPSPYK 532.774 785.407 18.8 y6 heavy 
G protein coupled receptor. family 
C, group 5, member  AHAWPSPYK 532.774 599.328 18.8 y5 heavy 
galectin 3 binding protein LADGGATNQGR 530.263 875.397 18.8 y9 light 
galectin 3 binding protein LADGGATNQGR 530.263 760.370 18.8 y8 light 
galectin 3 binding protein LADGGATNQGR 530.263 575.290 18.8 y5 light 
galectin 3 binding protein LADGGATNQGR 533.771 875.397 18.8 y9 heavy 
galectin 3 binding protein LADGGATNQGR 533.771 760.370 18.8 y8 heavy 
galectin 3 binding protein LADGGATNQGR 533.771 575.290 18.8 y5 heavy 
gelsolin-like capping protein VSDATGQMNLTK 632.814 963.493 21.9 y9 light 
gelsolin-like capping protein VSDATGQMNLTK 632.814 892.456 21.9 y8 light 
gelsolin-like capping protein VSDATGQMNLTK 632.814 791.408 21.9 y7 light 
gelsolin-like capping protein VSDATGQMNLTK 640.329 978.524 21.9 y9 heavy 
gelsolin-like capping protein VSDATGQMNLTK 640.329 907.487 21.9 y8 heavy 
gelsolin-like capping protein VSDATGQMNLTK 640.329 806.439 21.9 y7 heavy 
gelsolin-like capping protein QAALQVAEGFISR 695.378 878.473 23.8 y8 light 
gelsolin-like capping protein QAALQVAEGFISR 695.378 779.405 23.8 y7 light 
gelsolin-like capping protein QAALQVAEGFISR 695.378 708.368 23.8 y6 light 
gelsolin-like capping protein QAALQVAEGFISR 698.886 878.473 23.8 y8 heavy 
gelsolin-like capping protein QAALQVAEGFISR 698.886 779.405 23.8 y7 heavy 
gelsolin-like capping protein QAALQVAEGFISR 698.886 708.368 23.8 y6 heavy 
heat shock 10kDa protein 1 GGEIQPVSVK 507.285 770.477 18.1 y7 light 
heat shock 10kDa protein 1 GGEIQPVSVK 507.285 657.393 18.1 y6 light 
heat shock 10kDa protein 1 GGEIQPVSVK 507.285 529.334 18.1 y5 light 
heat shock 10kDa protein 1 GGEIQPVSVK 511.292 778.491 18.1 y7 heavy 
heat shock 10kDa protein 1 GGEIQPVSVK 511.292 665.407 18.1 y6 heavy 
heat shock 10kDa protein 1 GGEIQPVSVK 511.292 537.349 18.1 y5 heavy 
heat shock 10kDa protein 1 VLQATVVAVGSGSK 658.383 975.547 22.7 y11 light 
heat shock 10kDa protein 1 VLQATVVAVGSGSK 658.383 904.510 22.7 y10 light 
heat shock 10kDa protein 1 VLQATVVAVGSGSK 658.383 704.394 22.7 y8 light 
heat shock 10kDa protein 1 VLQATVVAVGSGSK 665.898 983.561 22.7 y11 heavy 
heat shock 10kDa protein 1 VLQATVVAVGSGSK 665.898 912.524 22.7 y10 heavy 
heat shock 10kDa protein 1 VLQATVVAVGSGSK 665.898 712.408 22.7 y8 heavy 
heat shock 27kDa protein 1 LATQSNEITIPVTFESR 953.499 1162.647 31.5 y10 light 
heat shock 27kDa protein 1 LATQSNEITIPVTFESR 953.499 1049.563 31.5 y9 light 
heat shock 27kDa protein 1 LATQSNEITIPVTFESR 953.499 948.515 31.5 y8 light 
heat shock 27kDa protein 1 LATQSNEITIPVTFESR 957.008 1162.647 31.5 y10 heavy 
heat shock 27kDa protein 1 LATQSNEITIPVTFESR 957.008 1049.563 31.5 y9 heavy 
heat shock 27kDa protein 1 LATQSNEITIPVTFESR 957.008 948.515 31.5 y8 heavy 
heat shock 70kDa protein 5 TFAPEEISAMVLTK 768.903 1288.682 26 y12 light 
heat shock 70kDa protein 5 TFAPEEISAMVLTK 768.903 1217.645 26 y11 light 
heat shock 70kDa protein 5 TFAPEEISAMVLTK 768.903 991.549 26 y9 light 
heat shock 70kDa protein 5 TFAPEEISAMVLTK 776.418 1303.713 26 y12 heavy 
heat shock 70kDa protein 5 TFAPEEISAMVLTK 776.418 1232.676 26 y11 heavy 
heat shock 70kDa protein 5 TFAPEEISAMVLTK 776.418 1006.581 26 y9 heavy 
heat shock 70kDa protein 8 
isoform 1 SFYPEEVSSMVLTK 808.897 1382.687 27.2 y12 light 
heat shock 70kDa protein 8 
isoform 1 SFYPEEVSSMVLTK 808.897 1219.624 27.2 y11 light 
heat shock 70kDa protein 8 
isoform 1 SFYPEEVSSMVLTK 808.897 1122.571 27.2 y10 light 
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heat shock 70kDa protein 8 
isoform 1 SFYPEEVSSMVLTK 816.413 1397.719 27.2 y12 heavy 
heat shock 70kDa protein 8 
isoform 1 SFYPEEVSSMVLTK 816.413 1234.655 27.2 y11 heavy 
heat shock 70kDa protein 8 
isoform 1 SFYPEEVSSMVLTK 816.413 1137.602 27.2 y10 heavy 
heparan sulfate proteoglycan 2 GSVYIGGAPDVATLTGGR 845.942 1171.607 28.3 y13 light 
heparan sulfate proteoglycan 2 GSVYIGGAPDVATLTGGR 845.942 1114.585 28.3 y12 light 
heparan sulfate proteoglycan 2 GSVYIGGAPDVATLTGGR 845.942 986.527 28.3 y10 light 
heparan sulfate proteoglycan 2 GSVYIGGAPDVATLTGGR 849.450 1178.624 28.3 y13 heavy 
heparan sulfate proteoglycan 2 GSVYIGGAPDVATLTGGR 849.450 1121.602 28.3 y12 heavy 
heparan sulfate proteoglycan 2 GSVYIGGAPDVATLTGGR 849.450 993.544 28.3 y10 heavy 
hepatocyte growth factor activator 
inhibitor 1 isoform 1 EGFINYLTR 556.790 926.509 19.6 y7 light 
hepatocyte growth factor activator 
inhibitor 1 isoform 1 EGFINYLTR 556.790 779.441 19.6 y6 light 
hepatocyte growth factor activator 
inhibitor 1 isoform 1 EGFINYLTR 556.790 666.357 19.6 y5 light 
hepatocyte growth factor activator 
inhibitor 1 isoform 1 EGFINYLTR 560.299 933.527 19.6 y7 heavy 
hepatocyte growth factor activator 
inhibitor 1 isoform 1 EGFINYLTR 560.299 786.458 19.6 y6 heavy 
hepatocyte growth factor activator 
inhibitor 1 isoform 1 EGFINYLTR 560.299 673.374 19.6 y5 heavy 
heterogeneous nuclear 
ribonucleoprotein D GFGFVLFK 457.760 710.424 16.6 y6 light 
heterogeneous nuclear 
ribonucleoprotein D GFGFVLFK 457.760 653.402 16.6 y5 light 
heterogeneous nuclear 
ribonucleoprotein D GFGFVLFK 457.760 506.334 16.6 y4 light 
heterogeneous nuclear 
ribonucleoprotein D GFGFVLFK 465.276 725.455 16.6 y6 heavy 
heterogeneous nuclear 
ribonucleoprotein D GFGFVLFK 465.276 668.433 16.6 y5 heavy 
heterogeneous nuclear 
ribonucleoprotein D GFGFVLFK 465.276 521.365 16.6 y4 heavy 
heterogeneous nuclear 
ribonucleoprotein D IFVGGLSPDTPEEK 744.883 1129.537 25.3 y11 light 
heterogeneous nuclear 
ribonucleoprotein D IFVGGLSPDTPEEK 744.883 902.410 25.3 y8 light 
heterogeneous nuclear 
ribonucleoprotein D IFVGGLSPDTPEEK 744.883 815.378 25.3 y7 light 
heterogeneous nuclear 
ribonucleoprotein D IFVGGLSPDTPEEK 752.398 1144.569 25.3 y11 heavy 
heterogeneous nuclear 
ribonucleoprotein D IFVGGLSPDTPEEK 752.398 910.424 25.3 y8 heavy 
heterogeneous nuclear 
ribonucleoprotein D IFVGGLSPDTPEEK 752.398 823.392 25.3 y7 heavy 
insulin-like growth factor binding 
portein 3 FLNVLSPR 473.279 685.399 17.1 y6 light 
insulin-like growth factor binding 
portein 3 FLNVLSPR 473.279 571.356 17.1 y5 light 
insulin-like growth factor binding 
portein 3 FLNVLSPR 473.279 472.288 17.1 y4 light 
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insulin-like growth factor binding 
portein 3 FLNVLSPR 480.297 692.416 17.1 y6 heavy 
insulin-like growth factor binding 
portein 3 FLNVLSPR 480.297 578.373 17.1 y5 heavy 
insulin-like growth factor binding 
portein 3 FLNVLSPR 480.297 479.305 17.1 y4 heavy 
insulin-like growth factor binding 
protein 7 TELLPGDRDNLAIQTR 604.659 791.439 25.3 y14 light 
insulin-like growth factor binding 
protein 7 TELLPGDRDNLAIQTR 604.659 734.897 25.3 y13 light 
insulin-like growth factor binding 
protein 7 TELLPGDRDNLAIQTR 604.659 678.355 25.3 y12 light 
insulin-like growth factor binding 
protein 7 TELLPGDRDNLAIQTR 611.676 801.965 25.3 y14 heavy 
insulin-like growth factor binding 
protein 7 TELLPGDRDNLAIQTR 611.676 741.914 25.3 y13 heavy 
insulin-like growth factor binding 
protein 7 TELLPGDRDNLAIQTR 611.676 681.864 25.3 y12 heavy 
kallikrein-related peptidase 10 YHQGSGPILPR 612.828 924.526 21.3 y9 light 
kallikrein-related peptidase 10 YHQGSGPILPR 612.828 796.468 21.3 y8 light 
kallikrein-related peptidase 10 YHQGSGPILPR 612.828 652.414 21.3 y6 light 
kallikrein-related peptidase 10 YHQGSGPILPR 616.336 931.543 21.3 y9 heavy 
kallikrein-related peptidase 10 YHQGSGPILPR 616.336 803.485 21.3 y8 heavy 
kallikrein-related peptidase 10 YHQGSGPILPR 616.336 659.431 21.3 y6 heavy 
kallikrein-related peptidase 6 
isoform A AVIHPDYDAASHDQDIMLLR 760.707 998.963 31.2 y17 light 
kallikrein-related peptidase 6 
isoform A AVIHPDYDAASHDQDIMLLR 760.707 930.433 31.2 y16 light 
kallikrein-related peptidase 6 
isoform A AVIHPDYDAASHDQDIMLLR 760.707 824.393 31.2 y14 light 
kallikrein-related peptidase 6 
isoform A AVIHPDYDAASHDQDIMLLR 765.386 1005.980 31.2 y17 heavy 
kallikrein-related peptidase 6 
isoform A AVIHPDYDAASHDQDIMLLR 765.386 937.450 31.2 y16 heavy 
kallikrein-related peptidase 6 
isoform A AVIHPDYDAASHDQDIMLLR 765.386 831.411 31.2 y14 heavy 
keratin 8 YEELQSLAGK 569.293 974.515 20 y9 light 
keratin 8 YEELQSLAGK 569.293 845.473 20 y8 light 
keratin 8 YEELQSLAGK 569.293 716.430 20 y7 light 
keratin 8 YEELQSLAGK 580.317 996.564 20 y9 heavy 
keratin 8 YEELQSLAGK 580.317 867.521 20 y8 heavy 
keratin 8 YEELQSLAGK 580.317 738.479 20 y7 heavy 
keratin 8 ASLEAAIADAEQR 672.841 873.442 23.1 y8 light 
keratin 8 ASLEAAIADAEQR 672.841 802.405 23.1 y7 light 
keratin 8 ASLEAAIADAEQR 672.841 689.321 23.1 y6 light 
keratin 8 ASLEAAIADAEQR 676.350 873.442 23.1 y8 heavy 
keratin 8 ASLEAAIADAEQR 676.350 802.405 23.1 y7 heavy 
keratin 8 ASLEAAIADAEQR 676.350 689.321 23.1 y6 heavy 
lamin A/C isoform 2 SGAQASSTPLSPTR 680.347 1016.537 23.3 y10 light 
lamin A/C isoform 2 SGAQASSTPLSPTR 680.347 945.500 23.3 y9 light 
lamin A/C isoform 2 SGAQASSTPLSPTR 680.347 771.436 23.3 y7 light 
lamin A/C isoform 2 SGAQASSTPLSPTR 683.855 1023.554 23.3 y10 heavy 
lamin A/C isoform 2 SGAQASSTPLSPTR 683.855 952.517 23.3 y9 heavy 
lamin A/C isoform 2 SGAQASSTPLSPTR 683.855 778.453 23.3 y7 heavy 
lamin A/C isoform 2 TALINSTGEEVAMR 746.377 1206.578 25.3 y11 light 
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lamin A/C isoform 2 TALINSTGEEVAMR 746.377 1093.494 25.3 y10 light 
lamin A/C isoform 2 TALINSTGEEVAMR 746.377 892.419 25.3 y8 light 
lamin A/C isoform 2 TALINSTGEEVAMR 749.886 1206.578 25.3 y11 heavy 
lamin A/C isoform 2 TALINSTGEEVAMR 749.886 1093.494 25.3 y10 heavy 
lamin A/C isoform 2 TALINSTGEEVAMR 749.886 892.419 25.3 y8 heavy 
lipocalin 2 WYVVGLAGNAILR 716.409 1082.668 24.4 y11 light 
lipocalin 2 WYVVGLAGNAILR 716.409 983.600 24.4 y10 light 
lipocalin 2 WYVVGLAGNAILR 716.409 884.531 24.4 y9 light 
lipocalin 2 WYVVGLAGNAILR 723.426 1096.702 24.4 y11 heavy 
lipocalin 2 WYVVGLAGNAILR 723.426 997.634 24.4 y10 heavy 
lipocalin 2 WYVVGLAGNAILR 723.426 898.566 24.4 y9 heavy 
lipocalin 2 VPLQQNFQDNQFQGK 895.945 1353.618 29.8 y11 light 
lipocalin 2 VPLQQNFQDNQFQGK 895.945 1225.560 29.8 y10 light 
lipocalin 2 VPLQQNFQDNQFQGK 895.945 1111.517 29.8 y9 light 
lipocalin 2 VPLQQNFQDNQFQGK 903.460 1361.632 29.8 y11 heavy 
lipocalin 2 VPLQQNFQDNQFQGK 903.460 1233.574 29.8 y10 heavy 
lipocalin 2 VPLQQNFQDNQFQGK 903.460 1119.531 29.8 y9 heavy 
matrix metalloproteinase 2 VDAAFNWSK 519.256 823.410 18.5 y7 light 
matrix metalloproteinase 2 VDAAFNWSK 519.256 752.373 18.5 y6 light 
matrix metalloproteinase 2 VDAAFNWSK 519.256 681.335 18.5 y5 light 
matrix metalloproteinase 2 VDAAFNWSK 523.263 831.424 18.5 y7 heavy 
matrix metalloproteinase 2 VDAAFNWSK 523.263 760.387 18.5 y6 heavy 
matrix metalloproteinase 2 VDAAFNWSK 523.263 689.350 18.5 y5 heavy 
matrix metalloproteinase 2 AFQVWSDVTPLR 709.875 973.510 24.2 y8 light 
matrix metalloproteinase 2 AFQVWSDVTPLR 709.875 486.303 24.2 y4 light 
matrix metalloproteinase 2 AFQVWSDVTPLR 709.875 385.256 24.2 y3 light 
matrix metalloproteinase 2 AFQVWSDVTPLR 713.384 980.527 24.2 y8 heavy 
matrix metalloproteinase 2 AFQVWSDVTPLR 713.384 493.321 24.2 y4 heavy 
matrix metalloproteinase 2 AFQVWSDVTPLR 713.384 392.273 24.2 y3 heavy 
matrix metalloproteinase 7 DLPHITVDR 533.288 837.458 18.9 y7 light 
matrix metalloproteinase 7 DLPHITVDR 533.288 740.405 18.9 y6 light 
matrix metalloproteinase 7 DLPHITVDR 533.288 603.346 18.9 y5 light 
matrix metalloproteinase 7 DLPHITVDR 536.797 837.458 18.9 y7 heavy 
matrix metalloproteinase 7 DLPHITVDR 536.797 740.405 18.9 y6 heavy 
matrix metalloproteinase 7 DLPHITVDR 536.797 603.346 18.9 y5 heavy 
matrix metalloproteinase 7 FFGLPITGMLNSR 726.887 988.524 24.7 y9 light 
matrix metalloproteinase 7 FFGLPITGMLNSR 726.887 891.472 24.7 y8 light 
matrix metalloproteinase 7 FFGLPITGMLNSR 726.887 778.388 24.7 y7 light 
matrix metalloproteinase 7 FFGLPITGMLNSR 733.904 995.542 24.7 y9 heavy 
matrix metalloproteinase 7 FFGLPITGMLNSR 733.904 898.489 24.7 y8 heavy 
matrix metalloproteinase 7 FFGLPITGMLNSR 733.904 785.405 24.7 y7 heavy 
mesothelin isoform 1 IQSFLGGAPTEDLK 738.391 1234.631 25.1 y12 light 
mesothelin isoform 1 IQSFLGGAPTEDLK 738.391 887.447 25.1 y9 light 
mesothelin isoform 1 IQSFLGGAPTEDLK 738.391 830.425 25.1 y8 light 
mesothelin isoform 1 IQSFLGGAPTEDLK 749.415 1256.680 25.1 y12 heavy 
mesothelin isoform 1 IQSFLGGAPTEDLK 749.415 902.478 25.1 y9 heavy 
mesothelin isoform 1 IQSFLGGAPTEDLK 749.415 845.457 25.1 y8 heavy 
mesothelin isoform 1 TDAVLPLTVAEVQK 742.422 1097.656 25.2 y10 light 
mesothelin isoform 1 TDAVLPLTVAEVQK 742.422 984.572 25.2 y9 light 
mesothelin isoform 1 TDAVLPLTVAEVQK 742.422 887.520 25.2 y8 light 
mesothelin isoform 1 TDAVLPLTVAEVQK 753.446 1119.705 25.2 y10 heavy 
mesothelin isoform 1 TDAVLPLTVAEVQK 753.446 999.604 25.2 y9 heavy 
mesothelin isoform 1 TDAVLPLTVAEVQK 753.446 902.551 25.2 y8 heavy 
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mitochondrial malate 
dehydrogenase AGAGSATLSMAYAGAR 727.856 1040.519 24.7 y10 light 
mitochondrial malate 
dehydrogenase AGAGSATLSMAYAGAR 727.856 939.472 24.7 y9 light 
mitochondrial malate 
dehydrogenase AGAGSATLSMAYAGAR 727.856 826.388 24.7 y8 light 
mitochondrial malate 
dehydrogenase AGAGSATLSMAYAGAR 731.365 1047.537 24.7 y10 heavy 
mitochondrial malate 
dehydrogenase AGAGSATLSMAYAGAR 731.365 946.489 24.7 y9 heavy 
mitochondrial malate 
dehydrogenase AGAGSATLSMAYAGAR 731.365 826.388 24.7 y8 heavy 
moesin FVIKPIDK 480.300 812.524 17.3 y7 light 
moesin FVIKPIDK 480.300 713.456 17.3 y6 light 
moesin FVIKPIDK 480.300 600.372 17.3 y5 light 
moesin FVIKPIDK 488.314 828.552 17.3 y7 heavy 
moesin FVIKPIDK 488.314 729.484 17.3 y6 heavy 
moesin FVIKPIDK 488.314 616.400 17.3 y5 heavy 
myosin, heavy polypeptide 9, non-
muscle ELEDATETADAMNR 783.341 1008.441 26.4 y9 light 
myosin, heavy polypeptide 9, non-
muscle ELEDATETADAMNR 783.341 907.394 26.4 y8 light 
myosin, heavy polypeptide 9, non-
muscle ELEDATETADAMNR 783.341 778.351 26.4 y7 light 
myosin, heavy polypeptide 9, non-
muscle ELEDATETADAMNR 786.850 1008.441 26.4 y9 heavy 
myosin, heavy polypeptide 9, non-
muscle ELEDATETADAMNR 786.850 907.394 26.4 y8 heavy 
myosin, heavy polypeptide 9, non-
muscle ELEDATETADAMNR 786.850 778.351 26.4 y7 heavy 
NME1-NME2 QHYIDLK 458.748 788.430 16.7 y6 light 
NME1-NME2 QHYIDLK 458.748 651.371 16.7 y5 light 
NME1-NME2 QHYIDLK 458.748 488.308 16.7 y4 light 
NME1-NME2 QHYIDLK 466.264 803.461 16.7 y6 heavy 
NME1-NME2 QHYIDLK 466.264 666.403 16.7 y5 heavy 
NME1-NME2 QHYIDLK 466.264 503.339 16.7 y4 heavy 
peptidylprolyl isomerase A VSFELFADK 528.274 956.472 18.8 y8 light 
peptidylprolyl isomerase A VSFELFADK 528.274 869.440 18.8 y7 light 
peptidylprolyl isomerase A VSFELFADK 528.274 722.372 18.8 y6 light 
peptidylprolyl isomerase A VSFELFADK 535.790 971.504 18.8 y8 heavy 
peptidylprolyl isomerase A VSFELFADK 535.790 884.472 18.8 y7 heavy 
peptidylprolyl isomerase A VSFELFADK 535.790 737.403 18.8 y6 heavy 
peptidylprolyl isomerase A FEDENFILK 577.790 1007.504 20.2 y8 light 
peptidylprolyl isomerase A FEDENFILK 577.790 878.462 20.2 y7 light 
peptidylprolyl isomerase A FEDENFILK 585.306 1022.536 20.2 y8 heavy 
peptidylprolyl isomerase A FEDENFILK 585.306 893.493 20.2 y7 heavy 
peptidylprolyl isomerase B VLEGMEVVR 516.281 932.487 18.4 y8 light 
peptidylprolyl isomerase B VLEGMEVVR 516.281 819.403 18.4 y7 light 
peptidylprolyl isomerase B VLEGMEVVR 516.281 690.360 18.4 y6 light 
peptidylprolyl isomerase B VLEGMEVVR 519.790 939.504 18.4 y8 heavy 
peptidylprolyl isomerase B VLEGMEVVR 519.790 819.403 18.4 y7 heavy 
peptidylprolyl isomerase B VLEGMEVVR 519.790 690.360 18.4 y6 heavy 
peptidylprolyl isomerase B TVDNFVALATGEK 682.856 1164.590 23.4 y11 light 
peptidylprolyl isomerase B TVDNFVALATGEK 682.856 788.451 23.4 y8 light 
peptidylprolyl isomerase B TVDNFVALATGEK 682.856 689.383 23.4 y7 light 
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peptidylprolyl isomerase B TVDNFVALATGEK 690.372 1179.621 23.4 y11 heavy 
peptidylprolyl isomerase B TVDNFVALATGEK 690.372 803.483 23.4 y8 heavy 
peptidylprolyl isomerase B TVDNFVALATGEK 690.372 704.414 23.4 y7 heavy 
podocalyxin-like ATFNPAQDK 496.246 920.447 17.8 y8 light 
podocalyxin-like ATFNPAQDK 496.246 819.400 17.8 y7 light 
podocalyxin-like ATFNPAQDK 496.246 672.331 17.8 y6 light 
podocalyxin-like ATFNPAQDK 500.253 928.461 17.8 y8 heavy 
podocalyxin-like ATFNPAQDK 500.253 827.414 17.8 y7 heavy 
podocalyxin-like ATFNPAQDK 500.253 680.345 17.8 y6 heavy 
podocalyxin-like precursor isoform 
1 LASVPGSQTVVVK 642.880 1100.631 22.2 y11 light 
podocalyxin-like precursor isoform 
1 LASVPGSQTVVVK 642.880 914.531 22.2 y9 light 
podocalyxin-like precursor isoform 
1 LASVPGSQTVVVK 642.880 817.478 22.2 y8 light 
podocalyxin-like precursor isoform 
1 LASVPGSQTVVVK 650.395 1108.645 22.2 y11 heavy 
podocalyxin-like precursor isoform 
1 LASVPGSQTVVVK 650.395 922.545 22.2 y9 heavy 
podocalyxin-like precursor isoform 
1 LASVPGSQTVVVK 650.395 825.492 22.2 y8 heavy 
poliovirus receptor VQLTGEPVPMAR 649.350 1070.566 22.4 y10 light 
poliovirus receptor VQLTGEPVPMAR 649.350 957.482 22.4 y9 light 
poliovirus receptor VQLTGEPVPMAR 649.350 670.370 22.4 y6 light 
poliovirus receptor VQLTGEPVPMAR 652.859 1077.583 22.4 y10 heavy 
poliovirus receptor VQLTGEPVPMAR 652.859 957.482 22.4 y9 heavy 
poliovirus receptor VQLTGEPVPMAR 652.859 670.370 22.4 y6 heavy 
poliovirus receptor-related 1 VEFLRPSFTDGTIR 546.626 993.500 23.1 y9 light 
poliovirus receptor-related 1 VEFLRPSFTDGTIR 546.626 705.380 23.1 y12 light 
poliovirus receptor-related 1 VEFLRPSFTDGTIR 546.626 575.304 23.1 y10 light 
poliovirus receptor-related 1 VEFLRPSFTDGTIR 548.965 993.500 23.1 y9 heavy 
poliovirus receptor-related 1 VEFLRPSFTDGTIR 548.965 708.889 23.1 y12 heavy 
poliovirus receptor-related 1 VEFLRPSFTDGTIR 548.965 575.304 23.1 y10 heavy 
PREDICTED: similar to epidermal 
growth factor  SQPVSQPLTYESGPDEVR 994.982 1362.654 32.8 y12 light 
PREDICTED: similar to epidermal 
growth factor  SQPVSQPLTYESGPDEVR 994.982 1265.601 32.8 y11 light 
PREDICTED: similar to epidermal 
growth factor  SQPVSQPLTYESGPDEVR 994.982 1051.469 32.8 y9 light 
PREDICTED: similar to epidermal 
growth factor  SQPVSQPLTYESGPDEVR 998.490 1369.671 32.8 y12 heavy 
PREDICTED: similar to epidermal 
growth factor  SQPVSQPLTYESGPDEVR 998.490 1272.618 32.8 y11 heavy 
PREDICTED: similar to epidermal 
growth factor  SQPVSQPLTYESGPDEVR 998.490 1051.469 32.8 y9 heavy 
SMT3A VAGQDGSVVQFK 617.825 1064.537 21.4 y10 light 
SMT3A VAGQDGSVVQFK 617.825 879.457 21.4 y8 light 
SMT3A VAGQDGSVVQFK 617.825 764.430 21.4 y7 light 
SMT3A VAGQDGSVVQFK 621.832 1072.551 21.4 y10 heavy 
SMT3A VAGQDGSVVQFK 621.832 887.471 21.4 y8 heavy 
SMT3A VAGQDGSVVQFK 621.832 772.444 21.4 y7 heavy 
profilin 1 DSLLQDGEFSMDLR 813.377 1197.520 27.3 y10 light 
profilin 1 DSLLQDGEFSMDLR 813.377 1069.462 27.3 y9 light 
profilin 1 DSLLQDGEFSMDLR 813.377 954.435 27.3 y8 light 
profilin 1 DSLLQDGEFSMDLR 823.903 1204.538 27.3 y10 heavy 
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profilin 1 DSLLQDGEFSMDLR 823.903 1076.479 27.3 y9 heavy 
profilin 1 DSLLQDGEFSMDLR 823.903 961.452 27.3 y8 heavy 
profilin 1 TFVNITPAEVGVLVGK 822.472 1296.752 27.6 y13 light 
profilin 1 TFVNITPAEVGVLVGK 822.472 1182.709 27.6 y12 light 
profilin 1 TFVNITPAEVGVLVGK 822.472 968.578 27.6 y10 light 
profilin 1 TFVNITPAEVGVLVGK 829.988 1311.784 27.6 y13 heavy 
profilin 1 TFVNITPAEVGVLVGK 829.988 1197.741 27.6 y12 heavy 
profilin 1 TFVNITPAEVGVLVGK 829.988 983.609 27.6 y10 heavy 
prolyl 4-hydroxylase, beta subunit VDATEESDLAQQYGVR 890.921 1265.612 29.6 y11 light 
prolyl 4-hydroxylase, beta subunit VDATEESDLAQQYGVR 890.921 1136.569 29.6 y10 light 
prolyl 4-hydroxylase, beta subunit VDATEESDLAQQYGVR 890.921 934.510 29.6 y8 light 
prolyl 4-hydroxylase, beta subunit VDATEESDLAQQYGVR 894.430 1272.629 29.6 y11 heavy 
prolyl 4-hydroxylase, beta subunit VDATEESDLAQQYGVR 894.430 1143.587 29.6 y10 heavy 
prolyl 4-hydroxylase, beta subunit VDATEESDLAQQYGVR 894.430 941.528 29.6 y8 heavy 
protein disulfide isomerase-
associated 3 LAPEYEAAATR 596.304 1007.479 20.8 y9 light 
protein disulfide isomerase-
associated 3 LAPEYEAAATR 596.304 910.426 20.8 y8 light 
protein disulfide isomerase-
associated 3 LAPEYEAAATR 596.304 781.384 20.8 y7 light 
protein disulfide isomerase-
associated 3 LAPEYEAAATR 599.812 1007.479 20.8 y9 heavy 
protein disulfide isomerase-
associated 3 LAPEYEAAATR 599.812 910.426 20.8 y8 heavy 
protein disulfide isomerase-
associated 3 LAPEYEAAATR 599.812 781.384 20.8 y7 heavy 
retinoic acid receptor responder 
(tazarotene induced)  AALHFFNFR 561.796 867.426 19.8 y6 light 
retinoic acid receptor responder 
(tazarotene induced)  AALHFFNFR 561.796 730.367 19.8 y5 light 
retinoic acid receptor responder 
(tazarotene induced)  AALHFFNFR 561.796 583.299 19.8 y4 light 
retinoic acid receptor responder 
(tazarotene induced)  AALHFFNFR 565.304 867.426 19.8 y6 heavy 
retinoic acid receptor responder 
(tazarotene induced)  AALHFFNFR 565.304 730.367 19.8 y5 heavy 
retinoic acid receptor responder 
(tazarotene induced)  AALHFFNFR 565.304 583.299 19.8 y4 heavy 
Rho GDP dissociation inhibitor 
alpha AEEYEFLTPVEEAPK 876.422 1259.652 29.2 y11 light 
Rho GDP dissociation inhibitor 
alpha AEEYEFLTPVEEAPK 876.422 1130.609 29.2 y10 light 
Rho GDP dissociation inhibitor 
alpha AEEYEFLTPVEEAPK 876.422 983.541 29.2 y9 light 
Rho GDP dissociation inhibitor 
alpha AEEYEFLTPVEEAPK 883.938 1274.683 29.2 y11 heavy 
Rho GDP dissociation inhibitor 
alpha AEEYEFLTPVEEAPK 883.938 1145.641 29.2 y10 heavy 
Rho GDP dissociation inhibitor 
alpha AEEYEFLTPVEEAPK 883.938 998.572 29.2 y9 heavy 
S100 calcium binding protein A11 DGYNYTLSK 530.751 888.446 18.8 y7 light 
S100 calcium binding protein A11 DGYNYTLSK 530.751 725.383 18.8 y6 light 
S100 calcium binding protein A11 DGYNYTLSK 530.751 611.340 18.8 y5 light 
S100 calcium binding protein A11 DGYNYTLSK 538.267 903.478 18.8 y7 heavy 
S100 calcium binding protein A11 DGYNYTLSK 538.267 740.414 18.8 y6 heavy 
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S100 calcium binding protein A11 DGYNYTLSK 538.267 626.371 18.8 y5 heavy 
S100 calcium binding protein A11 TEFLSFMNTELAAFTK 925.456 1359.661 30.7 y12 light 
S100 calcium binding protein A11 TEFLSFMNTELAAFTK 925.456 1272.629 30.7 y11 light 
S100 calcium binding protein A11 TEFLSFMNTELAAFTK 925.456 1125.561 30.7 y10 light 
S100 calcium binding protein A11 TEFLSFMNTELAAFTK 936.480 1374.693 30.7 y12 heavy 
S100 calcium binding protein A11 TEFLSFMNTELAAFTK 936.480 1287.661 30.7 y11 heavy 
S100 calcium binding protein A11 TEFLSFMNTELAAFTK 936.480 1140.592 30.7 y10 heavy 
S100 calcium binding protein A16 LIHEQEQQSSS 643.305 1059.434 22.2 y9 light 
S100 calcium binding protein A16 LIHEQEQQSSS 643.305 922.375 22.2 y8 light 
S100 calcium binding protein A16 LIHEQEQQSSS 643.305 793.332 22.2 y7 light 
S100 calcium binding protein A16 LIHEQEQQSSS 646.813 1059.434 22.2 y9 heavy 
S100 calcium binding protein A16 LIHEQEQQSSS 646.813 922.375 22.2 y8 heavy 
S100 calcium binding protein A16 LIHEQEQQSSS 646.813 793.332 22.2 y7 heavy 
S100 calcium-binding protein A6 LQDAEIAR 458.248 802.405 16.7 y7 light 
S100 calcium-binding protein A6 LQDAEIAR 458.248 674.347 16.7 y6 light 
S100 calcium-binding protein A6 LQDAEIAR 458.248 559.320 16.7 y5 light 
S100 calcium-binding protein A6 LQDAEIAR 461.757 802.405 16.7 y7 heavy 
S100 calcium-binding protein A6 LQDAEIAR 461.757 674.347 16.7 y6 heavy 
S100 calcium-binding protein A6 LQDAEIAR 461.757 559.320 16.7 y5 heavy 
secreted protein; acidic; cysteine 
rich RLEAGDHPVELLAR 525.958 797.488 22.3 y7 light 
secreted protein; acidic; cysteine 
rich RLEAGDHPVELLAR 525.958 601.367 22.3 y5 light 
secreted protein; acidic; cysteine 
rich RLEAGDHPVELLAR 525.958 399.248 22.3 y7 light 
secreted protein; acidic; cysteine 
rich RLEAGDHPVELLAR 532.975 811.522 22.3 y7 heavy 
secreted protein; acidic; cysteine 
rich RLEAGDHPVELLAR 532.975 615.401 22.3 y5 heavy 
secreted protein; acidic; cysteine 
rich RLEAGDHPVELLAR 532.975 406.265 22.3 y7 heavy 
solute carrier family 9 LVEPGSPAEK 513.777 814.394 18.3 y8 light 
solute carrier family 9 LVEPGSPAEK 513.777 685.352 18.3 y7 light 
solute carrier family 9 LVEPGSPAEK 513.777 588.299 18.3 y6 light 
solute carrier family 9 LVEPGSPAEK 521.293 822.408 18.3 y8 heavy 
solute carrier family 9 LVEPGSPAEK 521.293 693.366 18.3 y7 heavy 
solute carrier family 9 LVEPGSPAEK 521.293 596.313 18.3 y6 heavy 
tissue inhibitor of 
metalloproteinase 1 SEEFLIAGK 497.266 777.451 17.8 y7 light 
tissue inhibitor of 
metalloproteinase 1 SEEFLIAGK 497.266 648.408 17.8 y6 light 
tissue inhibitor of 
metalloproteinase 1 SEEFLIAGK 497.266 501.340 17.8 y5 light 
tissue inhibitor of 
metalloproteinase 1 SEEFLIAGK 504.782 792.482 17.8 y7 heavy 
tissue inhibitor of 
metalloproteinase 1 SEEFLIAGK 504.782 663.439 17.8 y6 heavy 
tissue inhibitor of 
metalloproteinase 1 SEEFLIAGK 504.782 516.371 17.8 y5 heavy 
tissue inhibitor of 
metalloproteinase 1 GFQALGDAADIR 617.315 1029.532 21.4 y10 light 
tissue inhibitor of 
metalloproteinase 1 GFQALGDAADIR 617.315 901.474 21.4 y9 light 
tissue inhibitor of 
metalloproteinase 1 GFQALGDAADIR 617.315 830.437 21.4 y8 light 
tissue inhibitor of 
metalloproteinase 1 GFQALGDAADIR 620.823 1036.550 21.4 y10 heavy 
tissue inhibitor of 
metalloproteinase 1 GFQALGDAADIR 620.823 908.491 21.4 y9 heavy 
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tissue inhibitor of 
metalloproteinase 1 GFQALGDAADIR 620.823 837.454 21.4 y8 heavy 
transcobalamin I NGENLEVR 465.736 816.421 16.9 y7 light 
transcobalamin I NGENLEVR 465.736 759.400 16.9 y6 light 
transcobalamin I NGENLEVR 465.736 630.357 16.9 y5 light 
transcobalamin I NGENLEVR 469.244 823.438 16.9 y7 heavy 
transcobalamin I NGENLEVR 469.244 766.417 16.9 y6 heavy 
transcobalamin I NGENLEVR 469.244 637.374 16.9 y5 heavy 
transforming growth factor; beta-
induced; 68kDa SPYQLVLQHSR 664.359 1240.680 22.8 y10 light 
transforming growth factor; beta-
induced; 68kDa SPYQLVLQHSR 664.359 739.421 22.8 y6 light 
transforming growth factor; beta-
induced; 68kDa SPYQLVLQHSR 664.359 640.353 22.8 y5 light 
transforming growth factor; beta-
induced; 68kDa SPYQLVLQHSR 671.377 1254.714 22.8 y10 heavy 
transforming growth factor; beta-
induced; 68kDa SPYQLVLQHSR 671.377 746.438 22.8 y6 heavy 
transforming growth factor; beta-
induced; 68kDa SPYQLVLQHSR 671.377 647.370 22.8 y5 heavy 
transgelin 2 NFSDNQLQEGK 640.299 1018.480 22.1 y9 light 
transgelin 2 NFSDNQLQEGK 640.299 931.448 22.1 y8 light 
transgelin 2 NFSDNQLQEGK 640.299 816.421 22.1 y7 light 
transgelin 2 NFSDNQLQEGK 647.815 1033.511 22.1 y9 heavy 
transgelin 2 NFSDNQLQEGK 647.815 946.479 22.1 y8 heavy 
transgelin 2 NFSDNQLQEGK 647.815 831.452 22.1 y7 heavy 
transgelin 2 DDGLFSGDPNWFPK 797.862 1194.558 26.8 y10 light 
transgelin 2 DDGLFSGDPNWFPK 797.862 1047.489 26.8 y9 light 
transgelin 2 DDGLFSGDPNWFPK 797.862 788.409 26.8 y6 light 
transgelin 2 DDGLFSGDPNWFPK 805.378 1202.572 26.8 y10 heavy 
transgelin 2 DDGLFSGDPNWFPK 805.378 1055.504 26.8 y9 heavy 
transgelin 2 DDGLFSGDPNWFPK 805.378 796.423 26.8 y6 heavy 
transketolase HQPTAIIAK 489.790 841.514 17.6 y8 light 
transketolase HQPTAIIAK 489.790 713.456 17.6 y7 light 
transketolase HQPTAIIAK 489.790 616.403 17.6 y6 light 
transketolase HQPTAIIAK 493.797 849.528 17.6 y8 heavy 
transketolase HQPTAIIAK 493.797 721.470 17.6 y7 heavy 
transketolase HQPTAIIAK 493.797 624.417 17.6 y6 heavy 
triosephosphate isomerase 1 HVFGESDELIGQK 729.865 1321.663 24.8 y12 light 
triosephosphate isomerase 1 HVFGESDELIGQK 729.865 1222.595 24.8 y11 light 
triosephosphate isomerase 1 HVFGESDELIGQK 729.865 1075.527 24.8 y10 light 
triosephosphate isomerase 1 HVFGESDELIGQK 737.380 1336.695 24.8 y12 heavy 
triosephosphate isomerase 1 HVFGESDELIGQK 737.380 1237.626 24.8 y11 heavy 
triosephosphate isomerase 1 HVFGESDELIGQK 737.380 1090.558 24.8 y10 heavy 
triosephosphate isomerase 1 TATPQQAQEVHEK 733.865 840.421 24.9 y7 light 
triosephosphate isomerase 1 TATPQQAQEVHEK 733.865 647.823 24.9 y11 light 
triosephosphate isomerase 1 TATPQQAQEVHEK 733.865 597.299 24.9 y10 light 
triosephosphate isomerase 1 TATPQQAQEVHEK 737.872 848.435 24.9 y7 heavy 
triosephosphate isomerase 1 TATPQQAQEVHEK 737.872 651.830 24.9 y11 heavy 
triosephosphate isomerase 1 TATPQQAQEVHEK 737.872 601.306 24.9 y10 heavy 
tropomyosin 3 isoform 4 IQLVEEELDR 622.330 1002.510 21.6 y8 light 
tropomyosin 3 isoform 4 IQLVEEELDR 622.330 889.426 21.6 y7 light 
tropomyosin 3 isoform 4 IQLVEEELDR 622.330 790.358 21.6 y6 light 
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tropomyosin 3 isoform 4 IQLVEEELDR 629.347 1016.545 21.6 y8 heavy 
tropomyosin 3 isoform 4 IQLVEEELDR 629.347 896.443 21.6 y7 heavy 
tropomyosin 3 isoform 4 IQLVEEELDR 629.347 797.375 21.6 y6 heavy 
tropomyosin 3 isoform 4 IQVLQQQADDAEER 821.905 1061.449 27.6 y9 light 
tropomyosin 3 isoform 4 IQVLQQQADDAEER 821.905 933.391 27.6 y8 light 
tropomyosin 3 isoform 4 IQVLQQQADDAEER 821.905 805.332 27.6 y7 light 
tropomyosin 3 isoform 4 IQVLQQQADDAEER 825.414 1061.449 27.6 y9 heavy 
tropomyosin 3 isoform 4 IQVLQQQADDAEER 825.414 933.391 27.6 y8 heavy 
tropomyosin 3 isoform 4 IQVLQQQADDAEER 825.414 805.332 27.6 y7 heavy 
tyrosine 3\ tryptophan 5 - 
monooxygenase activation protein, 
zeta SVTEQGAELSNEER 774.860 1132.523 26.2 y10 light 
tyrosine 3\ tryptophan 5 - 
monooxygenase activation protein, 
zeta SVTEQGAELSNEER 774.860 1004.464 26.2 y9 light 
tyrosine 3\ tryptophan 5 - 
monooxygenase activation protein, 
zeta SVTEQGAELSNEER 774.860 876.406 26.2 y7 light 
tyrosine 3\ tryptophan 5 - 
monooxygenase activation protein, 
zeta SVTEQGAELSNEER 778.369 1139.540 26.2 y10 heavy 
tyrosine 3\ tryptophan 5 - 
monooxygenase activation protein, 
zeta SVTEQGAELSNEER 778.369 1011.481 26.2 y9 heavy 
tyrosine 3\ tryptophan 5 - 
monooxygenase activation protein, 
zeta SVTEQGAELSNEER 778.369 883.423 26.2 y7 heavy 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta LAEQAER 408.714 703.337 15.2 y6 light 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta LAEQAER 408.714 632.300 15.2 y5 light 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta LAEQAER 408.714 503.257 15.2 y4 light 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta LAEQAER 412.223 703.337 15.2 y6 heavy 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta LAEQAER 412.223 632.300 15.2 y5 heavy 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta LAEQAER 412.223 503.257 15.2 y4 heavy 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta AVTEQGAELSNEER 766.863 1132.523 25.9 y10 light 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta AVTEQGAELSNEER 766.863 1004.464 25.9 y9 light 
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tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta AVTEQGAELSNEER 766.863 876.406 25.9 y7 light 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta AVTEQGAELSNEER 770.372 1139.540 25.9 y10 heavy 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta AVTEQGAELSNEER 770.372 1011.481 25.9 y9 heavy 
tyrosine 3\tryptophan 5-
monooxygenase activation protein, 
theta AVTEQGAELSNEER 770.372 883.423 25.9 y7 heavy 
ubiquitin carboxyl-terminal 
esterase L1 LGVAGQWR 443.748 716.384 16.2 y6 light 
ubiquitin carboxyl-terminal 
esterase L1 LGVAGQWR 443.748 617.315 16.2 y5 light 
ubiquitin carboxyl-terminal 
esterase L1 LGVAGQWR 443.748 546.278 16.2 y4 light 
ubiquitin carboxyl-terminal 
esterase L1 LGVAGQWR 447.257 716.384 16.2 y6 heavy 
ubiquitin carboxyl-terminal 
esterase L1 LGVAGQWR 447.257 617.315 16.2 y5 heavy 
ubiquitin carboxyl-terminal 
esterase L1 LGVAGQWR 447.257 546.278 16.2 y4 heavy 
villin 2 SQEQLAAELAEYTAK 826.412 1307.684 27.7 y12 light 
villin 2 SQEQLAAELAEYTAK 826.412 1179.626 27.7 y11 light 
villin 2 SQEQLAAELAEYTAK 826.412 995.504 27.7 y9 light 
villin 2 SQEQLAAELAEYTAK 837.437 1329.733 27.7 y12 heavy 
villin 2 SQEQLAAELAEYTAK 837.437 1201.674 27.7 y11 heavy 
villin 2 SQEQLAAELAEYTAK 837.437 1010.536 27.7 y9 heavy 
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